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Apathy and Impulsivity in Frontotemporal Lobar 
Degeneration 
Ian Coyle-Gilchrist 
 
Frontotemporal Lobar Degeneration (FTLD) is pathologically heterogeneous group of 
degenerative diseases of the brain.  While there are distinct and highly recognisable clinical 
syndromes associated with FTLD there is also a wider and more diverse spectrum of 
progressive changes in movement, coordination, language and behaviour.  Correlation between 
clinical syndrome and pathology is variable.  Furthermore, over the course of an individual’s 
illness their syndrome may change, or they may present with features of more than one 
syndrome at a given time.   Apathy and Impulsivity are common, distressing and disabling 
across the entire spectrum of FTLD and may be particularly prominent compared to other 
neurodegenerative diseases.   
In this thesis I outline the current classification of syndromes associated with FTLD and 
how this has undergone expansion, refinement and fragmentation over time.  Despite changes 
in nosology and advances in understanding of pathological heterogeneity, I argue that the 
clinical syndrome of FTLD is highly recognisable and has been described for centuries.   I 
suggest that a more unifying transdiagnostic approach to FTLD may provide useful insights into 
an increasingly fragmented spectrum of disease.   
Using this approach I conducted a large epidemiological study of FTLD and report 
prevalence, incidence and lifetime risk estimates.  From this cohort of recruits I then surveyed 
patients and their carers and used a range of assessments of cognition and behaviour.   I showed 
that while reports of apathy and impulsivity are common in FTLD, patient and carer based 
reports do not correlate well with each other or predict performance on a range of behavioural 
measures of decision making or goal directed cognition.  I conclude that in FTLD, apathy and 
impulsivity are overlapping and multidimensional constructs and that no single testing 
modality used in isolation represents them completely, hence a multimodal approach to their 
assessment is required. 
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Chapter One  
The Syndromes of Frontotemporal Lobar Degeneration 
1.1 Summary 
In this chapter I describe the spectrum of clinical syndromes associated with Frontotemporal 
Lobar Degeneration (FTLD).  Using a historical perspective I describe how the nosology 
associated with progressive frontotemporal syndromes has undergone expansion, refinement 
and fragmentation over time as clinical, pathological and genetic discoveries have been made.   I 
outline the current diagnostic criteria for individual syndromes and argue that a more unifying 
transdiagnostic approach to FTLD-associated syndromes may provide useful insights into an 
increasingly fragmented spectrum of disease.  I then outline how in subsequent chapters I have 
done this in the PiPPIN study of both the epidemiology of syndromes associated with FTLD and 
of neuropsychiatric aspects of FTLD, namely apathy and impulsivity. 
 
1.2  Frontotemporal Lobar Degeneration 
Frontotemporal Lobar Degeneration (FTLD) is a heterogeneous group of pathologically defined 
neurodegenerative disorders where progressive changes in language, behaviour and movement 
are accompanied by relatively selective degeneration of the frontal and temporal lobes(1), 
neuronal loss and abnormal accumulation of proteins, such as microtubule-associated protein 
Tau, Transactive response DNA-binding Protein with molecular weight 43 kDA (TDP-43) and 
Fused in Sarcoma protein (FUS)(2). The clinical syndromes associated with FTLD include 
cognitive disorders, where progressive deterioration in language and behaviour dominate the 
clinical picture (Frontotemporal dementia, FTD) and those where additional movement 
disorders such as dystonia, Parkinsonism, instability and apraxia are present (Progressive 
Supranuclear Palsy, PSP and Corticobasal Syndromes/Degeneration, CBS/CBD)(3).   
A minority of cases can be attributed to highly penetrant inherited genetic mutations 
allowing confident molecular diagnosis in the absence of pathological examination of the brain. 
However, the majority of cases are diagnosed clinically based on clinical symptoms and 
neuroimaging correlates(4).  In those cases that reach post mortem brain examination, clinico-
pathological correlates are highly variable both within the spectrum of FTLD and beyond, where 
other non-FTLD pathologies (such as Alzheimer’s Disease, AD) can mimic the clinical features of 
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FTLD(5–7).  In addition to this advances in clinical genetics, improved access to genetic testing 
and post mortem brain examination have identified patients with FTLD pathology who 
presented in an atypical fashion with clinical syndromes less typically associated with FTLD(7–
9). 
In order to facilitate accurate clinical diagnosis and a framework for research into FTLD 
(and associated clinical syndromes) a number of different clinical diagnostic criteria have been 
devised and subsequently revised(10–13).  The terminology and nosology of these disorders has 
changed several times (and continues to do so) resulting in somewhat fragmented classification 
systems based on clinical, genetic or pathological approaches with highly variable correlations 
between them(14).  Despite this the syndromes associated with FTLD share distinctive traits 
that have been recognised for centuries.   
   Behavioural changes, particularly apathy and impulsivity, are common across the entire 
spectrum of FTLD and a significant source of distress and morbidity(15,16).  While these 
symptoms are also seen in other more common conditions (such as typical AD) the prevalence 
and prominence of apathy and impulsivity in FTLD makes this an attractive cohort in which to 
study them, recognising that any insights gained within FTLD may translate to advances in a 
much wider range of disorders. Apathy and impulsivity are not however simple unitary entities 
but are complex and multifaceted constructs(17).  The causes of apathetic behaviour in one 
subject may be quite different from another.  Rather than studying these symptoms in a small 
subgroups of subjects with similar clinical phenotypes, by taking a transdiagnostic approach and 
exploring apathy/impulsivity within the entire spectrum of syndromes associated with FTLD it 
may be possible to exploit syndromic heterogeneity to facilitate exploration of the multiple 
mechanisms of common behavioural symptoms. 
1.3 Historical Descriptions of Progressive Frontotemporal Syndromes  
The first descriptions of degenerative conditions affecting frontotemporal areas are often 
attributed to Arnold Pick.  In 1892 he described a 71 year old man who presented with two 
years’ progressive deterioration in language, movement and behaviour which he attributed to ‘senile’ shrinkage of frontal and temporal lobes(18).  He also described a deterioration in 
memory and shaking of the patient’s hand that prevented writing.   At postmortem, in addition 
to meningeal thickening and oedema there was left sided cerebral atrophy, particularly of the 
temporal lobe. The main emphasis of Pick’s report was of the occurrence of language 
dysfunction in senile atrophy.  He makes the distinction between senile atrophy and cases of 
progressive paresis of the insane where he notes similar clinical features may exist.  
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Pick also makes reference to a previous report of language disruption in senile atrophy 
by William Bevan-Lewis(18,19).  Bevan-Lewis described a 52-year-old man who developed 
progressive deterioration in language and behaviour with abnormal eye movements and 
progressive paralysis who had a strong family history of behavioural disorders (two twin sisters 
were also resident in the same asylum as the patient where their paternal aunt had also cut her 
own throat).  Jerky movements of the arms, head and neck were noted prior to and during his 
admission and partial and secondary generalised seizures occurred until his death around two 
years after first seeking medical attention. At postmortem asymmetric frontal brain atrophy was 
noted extending posteriorly to involve the parietal lobe. Like Pick, Bevan-Lewis attributes his 
case to senile atrophy, which he considers distinct to Generalised Paresis of the Insane(19).   
The term Generalised Paresis of the Insane (GPI) is now reserved for cases of 
neurosyphilis. However, in the early 19th century, GPI was also used to describe a range of 
different syndromes and pathologies.  While Bevan-Lewis and Pick are careful to consider senile 
atrophy a distinct pathological process this may not have been the case in earlier literature. 
In 1846 in the Medical Times(20) there is a report of a case of generalized paresis of the 
insane with similar clinical features and brain atrophy at post mortem:  A 37-year-old woman 
who was admitted to the Salpêtrière hospital in 1834 in a ‘state of manical agitation’.   Having 
previously led ‘an exemplary and religious life’ she is described as abandoning herself to ‘dissolute and disorderly habits, and to drinking’. Her syndrome evolved over months into a ‘paralytic numbness’, which gave an ‘expression of stupidity to her countenance’.  Her language 
was affected such that her speech was slow, inarticulate, with a stuttering quality and mild 
anomia. Emotional lability was described with ‘frequent fits of passion’ but she is otherwise 
described as ‘unconscious of her state, and ‘continually sitting’. In just over a year she died.  At 
postmortem an area of acute cerebral haemorrhage was identified as the terminal event but the 
author also notes atrophy of the frontal lobes.   
The most remarkable aspect of this report is the final statement “This local atrophy of 
certain convolutions coinciding with the progression of the general paralysis and demency is of 
considerable interest”.  This case report, translated by William Costello (1800-1867) was 
attributed to Philippe Pinel (1745-1826) but it was almost certainly the work of his son Scipion 
(1795-1859).  Remarkably he makes the connection between focal brain atrophy and a 
syndrome of progressive behavioural changes and speech disturbance. 
In 1834 GPI was a relatively new diagnostic entity.  Antoine Bayle compiled descriptions 
of a number of cases and used them to support his 1822 thesis that insanity and paresis may be 
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caused by an organic lesion of the brain.  Although prior descriptions of the syndrome exist, 
Bayle’s contribution consolidated it as a distinct clinical entity(21).  Over the subsequent century 
further descriptions of GPI led to a broadening of the clinical syndrome (phenotype) and the 
associated aetiology such that by 1912 a wide range of causes of GPI had been described 
including; sexual excess, syphilis, isolation, trauma, post infectious, alcoholism, pellagra and 
inherited causes(22).  A year later, in 1913 Hideyo Noguchi and Joseph Moore demonstrated the 
presence of spirochaetes in 12 of 70 paretic brains(23).  From then on syphilis was considered 
the major underlying cause of GPI and now GPI is used exclusively to describe specific forms of 
neurosyphilis.  Prior to this whilst the prevalence of syphilis in the general population was so 
high that syphilis was a common cause of the clinical syndrome, not all those diagnosed as 
having GPI would not necessarily have been suffering from neurosyphilis and other conditions 
(including FTLD) may have been the cause.  
The progressive changes in behaviour, language and motor function are similar in Pick, 
Bevan-Lewis, and Pinel’s cases.  All three make the connection between the clinical syndrome 
and brain atrophy and in all three cases, atrophy is most marked in frontotemporal regions. It is 
difficult to make firm conclusions as to the underlying pathological aetiology of their cases on 
the basis of the limited post mortem information they provide. It seems likely that Pick and 
Bevan-Lewis’s would have had sufficient experience with GPI caused by neurosyphilis (despite 
the underlying aetiology not being established at time) to recognise that their cases were 
different.  Meningeal thickening in Pick’s case does suggest that an infectious or inflammatory 
pathology (such as neurosyphilis) may have been a factor.  The strong family history in Bevan-
Lewis’s case is suggestive of an inherited cause but not definitive.  Spontaneous intracerebral 
bleeding in Pinel’s case is unusual in a woman in her 30’s and is highly suggestive of a vascular 
pathology. Given the prevalence of syphilis at the time a syphilitic vasculopathy in the setting of 
typical features of GPI seems likely.  Frontotemporal lobar atrophy alone does not discriminate 
between a degenerative cause or neurosyphilis and has been reported in modern cases of 
microbiologically proven neurosyphilis with atrophy of frontotemporal lobes demonstrated on 
neuroimaging(24).  
1.4 Pick’s Disease, Frontotemporal Dementia and FTLD 
Alois Alzheimer demonstrated the first positive evidence of a neurodegenerative disease (as 
opposed to absence of features of an alternative aetiology) in progressive frontotemporal 
syndromes. He described microscopic inclusions (that would later be known as ‘Pick bodies’) in 
the brains of some patients with a similar syndrome to those in Pick’s reports who also had 
frontotemporal brain atrophy.  Hence the condition became known as ‘Pick’s Disease’.  
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Subsequently it became apparent that not all cases of the syndrome Pick described had the same 
histopathological changes and hence when interest in these conditions resurfaced in the 1980s 
the term ‘Frontotemporal Dementia (FTD)’ was adopted with ‘Pick’s disease’ being redefined to 
describe only those cases in which Pick bodies are present (25). 
Just as with ‘Generalised Paresis of the Insane’ and ‘Pick’s disease’, the aetiological and 
phenotypic associations of the term ‘Frontotemporal Dementia’ are evolving.  Renewed interest 
in the cognitive syndromes associated with FTLD has led to syndromic subdivisions of 
behavioural variant FTD (bvFTD), where behavioural changes are the dominant early clinical 
features and the Primary Progressive Aphasias (PPA), where language disruption 
predominates(25). The Primary Progressive Aphasias have been subject to further subdivision 
based on the particular presentation of language dysfunction(11).  While initially the emphasis 
of early work was focused on the cognitive aspects of FTD, the motor aspects alluded to in Pick 
and Bevan-Lewis’s descriptions are now being incorporated in descriptions of FTD, including the 
overlap with Motor Neuron Disease (MND) and also with extrapyramidal syndromes such as 
Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome/Degeneration (CBS/D) which 
may share the language and behavioural aspects along with additional movement disorders(26).   
Pick’s disease remains a recognised neuropathological entity but other 
neuropathological diagnoses have also been described within the brains of patients with these 
clinical syndromes.  Inclusions of various forms of hyperphosporylated Tau (including Pick’s 
disease), TDP-43, and rarer pathologies e.g. FUS, have been grouped together under the ‘umbrella’ term Frontotemporal Lobar Degeneration (FTLD)(27). It is also recognised that non-
FTLD pathology, such as AD, can produce similar clinical syndromes(7).   
While such cases may be diagnosed clinically as having an FTLD-associated syndrome 
during life (e.g. CBS or PPA), the term FTLD is usually reserved to describe particular non-AD 
forms of neurodegeneration most typically associated with FTD, PSP or CBS (i.e. as a description 
of a pathologically, rather than syndromically, defined entity).  The relationships between 
clinical phenotype and the underlying pathology are complex.   For example less than two thirds 
of cases of Corticobasal Syndrome (CBS) are related to Corticobasal Degeneration at post-
mortem (CBD, a specific neuropathological pattern of cellular changes and Tau deposition) (7)  
Conversely less than two thirds of people with CBD pathology at post mortem have CBS during 
life, the others having a clinical syndrome more commonly associated with a another form of 
FTLD(7).   
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1.5 Genetic Forms of FTLD and the Problem of Pleiotropy  
While most cases of FTLD occur sporadically a significant minority can be attributed to genetic 
mutations that are inherited in an autosomal dominant fashion (usually with high penetrance) 
allowing confidence in pathological diagnosis even in the absence of pathological examination of 
brain tissue.  However, even when a genetic mutation is identified its relevance and relationship 
to clinical syndrome is not always straightforward – a single genetic mutation may be associated 
with widely different clinical syndromes, a phenomenon known as pleiotropy.    
For example, C9ORF72, a hexanucleotide expansion that can cause FTD, MND, or both, 
within a single family was first reported in two papers in 2011(28,29).  How the same mutation 
may result in very different phenotypes even within a single pedigree is unclear.  Variability and 
instability of expansion length, other genetic and environmental modifiers or the presence of 
comorbidities/pathological processes affecting neurodegeneration and inflammation have all 
been proposed as potentially contributing to clinical phenotype (30).  Some studies suggest 
C9ORF72 may exhibit anticipation over generations(31) but this, and the penetrance of the 
mutation remains unclear(32).  
The discovery of C9ORF72 is also contributing to our understanding of the wider 
spectrum of FTLD and other disease entities previously thought separate to FTLD. Amongst 
patients with FTD (or MND) there appears to be increased rates of psychosis amongst carriers of 
C9ORF72 expansions (33).  This has led to some groups screening cohorts of patients with 
psychiatric diagnoses for C9ORF72 finding large expansions in (for example) patients diagnosed 
with schizophrenia(34).  What role C9ORF72 has in these patients is not clear but this challenges 
the distinction between neurodegenerative and psychiatric diagnoses (at least in some patients) 
and also raises the possibility that some cases of bvFTD may be missed in the early symptomatic 
stages particularly as current bvFTD criteria exclude cases where psychiatric diagnoses are 
thought more likely to account for behavioural disturbance(35).  
1.6 The FTD-Phenocopy Syndrome 
When interest in FTD resurged in the 1980s a number of people (mainly men) were diagnosed 
as having FTD but who did not develop typical brain atrophy on imaging and subsequent did not 
deteriorate in the rapid fashion of more typical FTD(36).   When this became apparent these 
patients were reclassified as ‘phenocopies’ the presumption being that they did not have FTD 
but an acute psychiatric episode or decompensation of premorbid psychosocial factors.  As these 
cases remained relatively well for a long period of time they may have been overrepresented in 
previous studies of FTD.  As a consequence the clinical research criteria for FTD were changed so 
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such cases are excluded(35). However, recently some slowly progressive cases of FTD have been 
tested and found to carry extremely large repeats in the C9ORF72 gene(37).  Only one of 16 
phenocopy patients in a very long term follow up study of the genotyped Cambridge phenocopy 
cohort had a C9ORF72 expansion(38).  It is no longer clear how such cases should be classified.  
It is conceivable that C9ORF72 may produce changes in personality long before the more florid 
appearance of clinical FTD or that progression in some cases is particularly slow but it also 
entirely possible for people carrying C9ORF72 to acquire psychiatric or behavioural disorders 
quite independently.  Also, where there is a family history of FTD, the effects of living with a 
parent with FTD on a child’s upbringing and subsequent psychological state in adulthood can 
not be completely ignored regardless of whether they have inherited the gene or not. In addition 
eleven of 7,579 (0.15%) of the UK 1958 birth cohort who do not have a clinical diagnosis of 
neurodegenerative disease were found to have large expansions in C9ORF72(39) raising the 
possibility of incomplete penetrance by this age. 
1.7 Current Classification of FTLD Associated Syndromes 
The major syndromes commonly associated with FTLD type pathology are shown in Figure 1.1.  
Not all syndromes are encompassed fully by the current consensus diagnostic criteria.  In the 
following sections I outline the main characteristics of these syndromes with reference to 
current diagnostic criteria when applicable.   
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Figure 1.1 The Clinical Syndromes Associated With Frontotemporal Lobar 
Degeneration.  FTD=Frontotemporal Dementia, FTD-MND=Frontotemporal Dementia-
Motor Neurone Disease, bvFTD=behavioural variant Frontotemporal Dementia, 
PPA=Primary Progressive Aphasia, svPPA=sematic variant Primary Progressive Aphasia, 
lvPPA=logopenic variant Primary Progressive Aphasia, navPPA=non fluent agrammatic 
variant Primary Progressive Aphasia, PSP=Progressive Supranuclear Palsy, PSP-
RS=Progressive Supranuclear Palsy with Richardson’s Syndrome, PSP-PGF=Progressive 
Supranuclear Palsy with Progressive Gait Freezing,  PSP-P= Progressive Supranuclear 
Palsy with predominant Parkinsonism, PSP-F= Progressive Supranuclear Palsy with 
predominant Frontal presentation , PSP-OM=Progressive Supranuclear Palsy with 
predominant Ocular Motor dysfunction, PSP-SL=Progressive Supranuclear Palsy with 
predominant Speech/Language disorder, PSP-CBS= Progressive Supranuclear Palsy with 
predominant Corticobasal Syndrome, PSP-PI= Progressive Supranuclear Palsy with 
predominant postural instability, PSP-PLS=Progressive Supranuclear Palsy-Primary 
Lateral Sclerosis*, PSP-C=Progressive Supranuclear Palsy-Cerebellar Ataxia*, 
CBS=Corticobasal Syndrome, CBS-PSPS=Corticobasal Syndrome-Progressive 
Supranuclear Palsy Syndrome, CBS-FBS= Corticobasal Syndrome-Frontal Behavioural-
spatial Syndrome, CBS-NAV= Corticobasal Syndrome-Nonfluent/Agrammatic Variant. 
*Not currently encompassed in current diagnostic criteria. 
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1.7.1 Subclassification of FTD by Clinical Syndrome 
Behavioural variant Frontotemporal dementia (bvFTD) is characterised by a progressive change 
in personality and/or behaviour associated with neurodegeneration of the frontal and temporal 
lobes.  Snowden et al separate bvFTD into those who present with predominantly disinhibited, 
impulsive and perseverative behaviour and those who show more apathetic and demotivated 
behavioural changes(40).  While both groups of symptoms are encompassed by the recently 
revised diagnostic criteria(10) the current criteria have not sought to define distinct subtypes on 
the basis of syndrome alone.    
Consensus criteria have recently been proposed for PPA(11).  These firstly establish a 
core set of criteria required for PPA stating that language dysfunction and aphasia should be the 
dominant clinical features and cause of day-to-day impairment.   A second set of criteria is 
proposed to separate PPA into nonfluent/agrammatic variant (navPPA, also known as 
Progressive Non Fluent Aphasia, PNFA and PPA-agrammatic) characterised by slow effortful 
speech and agrammatism, semantic variant (svPPA, also known as Semantic Dementia, SD, and 
PPA-semantic) where semantic knowledge, word and object recognition are impaired, and 
logopenic variant (lvPPA, also known as Logopenic Progressive Aphasia, LPA and logopenic 
PPA) where word retrieval and sentence repetition deficits dominate.  They recognise that it is 
not possible to sub classify every case of PPA and suggest the term PPA-unclassifiable is used.   
A fourth group of progressive speech disorder, Primary Progressive Apraxia of Speech 
(PPAOS) has been proposed(41) where the dominant problem is of a progressive disorder of the 
motor planning of speech.  Josephs et al argue that as the dominant problem in PPAOS is one of a 
progressive disorder of motor planning as opposed to an aphasia per se(42) such cases do not 
meet inclusion under the core consensus criteria for PPA and therefore PPAOS should be 
considered a distinct neurodegenerative syndrome.  While this is a convincing argument, by the 
same reasoning svPPA could be considered separate as the dominant deficit appears to be a 
disorder of concepts(43) where the patient’s processing of semantic information is selectively 
impaired.  While such deficits may be most apparent initially during speech and communication 
they are not limited to language and a patient may not, for example, recognise a spoon either 
when trying to name it or when trying to use it.   Such deficits have a profound effect on language 
and communication but by Josephs et al’s reasoning also do not necessarily meet criteria for 
PPA.  Interestingly the same group have subsequently reported that all cases of PPAOS that they 
have followed up have subsequently progressed to develop an extrapyramidal syndrome with 
features reminiscent of PSP and CBS(42). 
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FTD may occur in isolation or in association with Motor Neuron Disease (MND).  
Typically when FTD is associated with MND (FTD-MND) the cognitive syndrome is associated 
with more behavioural than language change but the particular subtype of MND varies (for 
example whether it presents initially with limb or bulbar features) (44).  
1.7.2 Subclassification of PSP Syndromes 
Progressive Supranuclear Palsy in its classic form is a predominantly axial akinetic rigid 
syndrome, with prominent postural instability, supranuclear upgaze palsy, falls and without 
tremor or responsiveness to Levodopa.  This is sometimes referred to as Steele-Richardson-
Olzewski syndrome (or PSP-Richardson’s Syndrome, PSP-RS).  Seven of the original nine cases 
described had major cognitive and behavioural problems, although for many years, PSP has been 
regarded as primarily a movement disorder.  This position is changing. 
The 1996 National Institute of Neurological Disorders and Stroke neuropathologic 
criteria for the diagnosis of PSP (NINDS-SPSP) are a set of criteria devised for the diagnosis of 
PSP-RS(45) separating possible and probable cases on the basis of the clinical features and time 
from disease onset taken to develop them.  Falls within the first year of onset were required for 
a probable diagnosis although this has subsequently been relaxed to postural instability or falls 
within three years in the subsequent NNIPPS (Neuroprotection and Natural History in Parkinson 
Plus Syndromes) criteria(13).  Marked asymmetry or features of CBS are considered mandatory 
exclusion criteria under both sets for a diagnosis of PSP.  
However, additional syndromic variants of PSP pathology were later described 
including; Pure Akinesia with Gait Freezing (PAGF, PSP-PAGF), where during the initial course of 
the illness akinesia and freezing of gait are the dominant features without necessarily those 
associated with PSP-RS; PSP-Parkinsonism (PSP-P), where features are more reminiscent of 
idiopathic Parkinson’s disease; PSP-Corticobasal Syndrome (PSP-CBS) and PSP-Progressive Non 
Fluent Aphasia (PSP-PNFA), which combine features of PSP-RS with features of CBS and navPPA 
respectively(46).  Indeed, cognitive and behavioural phenotypes make up half of the 
presentations of PSP pathology(47). 
Most recently consensus criteria (the 2017 Movement Disorder Society PSP Criteria, 
MDS-PSP(48)) have been proposed.  There are three principal features of these criteria. First, 
they introduce four levels of certainty – from definite pathology proven, to probable, possible 
and finally ‘suggestive of’. Second, they introduce clearer operational definitions for the clinical 
features and adjunctive investigations, supporting diagnosis. Third, and most importantly for my 
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work, they introduce a set of criteria for PSP associated phenotypes other than Richardson’s 
syndrome.  
The 2017 MDS-PSP criteria incorporate clinical features described amongst subjects 
with PSP with at post mortem into four clinical domains (ocular motor dysfunction, postural 
instability, akinesia and cognitive dysfunction) and describe eight clinical syndromes associated 
with PSP type pathology (Progressive Supranuclear Palsy with Richardson’s Syndrome PSP-RS, 
Progressive Supranuclear Palsy with Progressive Gait Freezing PSP-PGF, Progressive 
Supranuclear Palsy with predominant Parkinsonism PSP-P, Progressive Supranuclear Palsy with 
predominant Frontal presentation PSP-F, Progressive Supranuclear Palsy with predominant 
Ocular Motor dysfunction PSP-OM, Progressive Supranuclear Palsy with predominant 
Speech/Language disorder PSP-SL, Progressive Supranuclear Palsy with predominant 
Corticobasal Syndrome PSP-CBS, Progressive Supranuclear Palsy with predominant postural 
instability PSP-PI) each with different levels of diagnostic certainty and likely association with 
PSP type pathology.  In these criteria the concept of ‘4R-tauopathy’ is introduced whereby no 
attempt is made to distinguish between pathologically defined PSP and CBD clinically for some 
syndromes (such as PSP-SL and PSP-CBS). 
1.7.3 Subclassification of CBS Syndromes 
Corticobasal Syndrome is a term used to describe an asymmetric syndrome of progressive limb 
rigidity, akinesia and apraxia which may be accompanied by cortical sensory deficits, dystonia 
and alien limb phenomena(12).  Corticobasal Degeneration (CBD) (and the obsolete term 
Cortico-basal-ganglionic-Degeneration) were once synonymous with CBS but is increasingly 
used as a neuropathological diagnosis only - characterised by tau pathology with specific glial 
and neuronal distribution(7) – leaving CBS for the clinical disorder.  CBS/CBD are highly 
heterogeneous, with early criteria sometimes incompatible with each other. For example, 
Lang(49) vs. Kumar(50), on whether Dementia was an exclusion criterion, or was the most 
common clinical presentation.  
Like the criteria for PPA a recent set of criteria for CBS(12) has proposed a core set of 
clinical features (limb rigidity, akinesia, apraxia, cortical sensory loss myoclonus and alien limb 
phenomena) at least some of which are required for the diagnosis of either Probable CBS or 
Possible CBS.  Syndromic variants are then defined by the presence of additional features: 
Where features of navPPA are present in addition to core CBS features the term 
Nonfluent/Agrammatic variant of PPA (CBS-NAV) is used; The term Corticobasal Syndrome -
Frontal Behavioural-Spatial syndrome (CBS-FBS) defines cases where CBS features are present 
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with additional executive dysfunction, behavioural or personality changes and/or visuospatial 
deficits; Corticobasal Syndrome –Progressive Supranuclear Palsy syndrome (CBS-PSPS) is used 
to describe those case of CBS where the extrapyramidal syndrome is axial or symmetrical and 
additional features associated with PSP-RS are also present.  In addition to diagnostic criteria for 
CBS, Armstrong et al(12) include an additional set of criteria designed to classify clinical 
syndrome by probability of underlying CBD pathology.  
1.8 Role of Neuroimaging in the Classification of FTLD Associated Syndromes 
Neuroimaging is commonly used in the diagnosis of neurodegenerative conditions.  Most 
commonly it is used to exclude other pathological processes (e.g. demyelination or a space 
occupying lesion) however it has been used to subclassify FTLD associated syndromes.  
1.8.1  Role of Neuroimaging in the Classification of FTD 
Imaging has three roles in the diagnostic criteria of FTD.  Firstly, in the exclusion of other 
pathologies (such as infarcts or space-occupying lesions) that may mimic FTD.  Second, in the 
criteria for bvFTD, frontotemporal imaging changes (either atrophy, hypoperfusion or 
hypometabolism) are required in order to make a diagnosis of probable bvFTD (in addition to (i) 
meeting criteria for possible bvFTD on the basis of the clinical syndrome and (ii) exhibiting 
significant functional decline)(10).  Third amongst PPA regional atrophy, hypoperfusion or 
hypometabolism is used to classify the clinical syndromes as ‘imaging supported’ if the area 
affected is predominantly left posterior perisylvian or parietal for lvPPA, left posterior 
frontoinsular for navPPA, or anterior temporal lobe for svPPA(11).   
Prior to the current criteria FTD was often previously divided into ‘frontal’ and ‘temporal’ variants(51,52) on the basis of clinical symptoms and imaging correlates (including 
SPECT perfusion).  Frontal variant FTD implied more frontal lobe involvement and typically 
behavioural changes as the dominant clinical features.  Temporal FTD (also known as Semantic 
Dementia) was characterised by markedly asymmetric anterior temporal lobe atrophy and TDP-
43 pathology in the majority of cases.  When semantic dementia affects the left temporal lobe the 
clinical syndrome is typically of impaired semantic knowledge exhibited by fluent speech lacking 
in meaning and impaired object recognition.  This can be considered synonymous with svPPA.  
However a right temporal variant of semantic dementia exists where behavioural changes and 
prosopagnosia predominate(53).  Both forms are recognised in the current criteria for PPA but 
the emphasis is on left temporal variants where spoken communication is more clearly 
affected(11).  Right temporal variant FTD/right semantic dementia  now often meet current 
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criteria for bvFTD(10) but are likely to reflect a distinct subgroup in terms of imaging, clinical 
and pathological profiles(43). 
1.8.2 Role of Neuroimaging in the Classification of PSP 
Previous criteria for PSP include imaging only in the exclusion of other significant pathology 
(such as cerebral infarcts).  Focal frontal or temporoparietal atrophy was considered an 
exclusion criteria for PSP under the NINDS-SPSP criteria but only the term ‘Significant other 
neurological disease on CT-scan/MRI’ is used as an exclusion criteria under the NNIPPS 
criteria(13,54).  In the most recent criteria predominant midbrain atrophy or hypometabolism 
or evidence of postsynaptic striatal dopaminergic degeneration allow the addition label of 
imaging supported diagnosis(48).  This is over and above the specific but insensitive and often 
late classical radiological features like Hummingbird and Mickey-Mouse signs.  
The 2017 MDS-PSP criteria considered the use of Tau PET imaging, but for lack of 
evidence of their biomarker utility, and validity, chose not to include Tau PET.  MRI remains the 
main imaging modality in relation to PSP, while frontal and midbrain hypometabolism from 
SPECT/PET scanning are supportive.   
1.8.3 Role of Neuroimaging in the Classification of CBS 
Apart from aiding in the exclusion of other pathology mimicking CBD, brain imaging is not 
included in the current consensus criteria used in the diagnosis and classification of CBS(12). 
1.9 Genetic and Pathological Correlates of FTLD 
Not only is FTLD associated with a range of clinical syndromes but also a number of different 
histopathological findings at post mortem.  As with the clinical syndromes these have been 
subject to subdivision and classification largely based on the presence and distribution of 
inclusions of abnormal protein aggregates within the brain(27).   There a range of such proteins 
found within the brain of people with FTLD, most commonly Tau, Transactive Response 
Deoxyribonucleic acid binding Protein 43kDA (TDP-43) and Fused in Sarcoma (FUS).  The exact 
role of these proteins in the aetiology and pathophysiology of FTLD remains unclear, however 
inherited genetic mutations in genes encoding many of them that appear to be sufficient 
(although not necessary) to produce disease in an individual.   Mutations in the gene encoding 
Tau (MAPT), for example, can produce the clinical syndrome bvFTD with abnormal Tau 
deposition at post mortem(55).  
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Table 1.1 shows some of the gene mutations that have been associated with FTLD 
pathology together with the associated protein inclusions found at post mortem and commonly 
associated clinical syndromes.  While inherited mutations are common amongst some FTLD 
syndromes (especially bvFTD/MND spectrum disorders) they are less common in others (such 
as svPPA, PSP and CBS) and even the basis for exclusion under some diagnostic criteria(12,54) .  
Amongst FTD up to 30% of cases may have a autosomal dominant pattern of inheritance within 
their family with the commonest mutations, MAPT, C9ORF72 and Progranulin (GRN) accounting 
for 10-20% of all cases(56). Recently loss of function mutations in TBK-1 (encoding TANK-
binding kinase 1) has been shown to cause MND and FTD(57) and were the third commonest 
cause in a Belgian cohort (after C9ORF72 and GRN)(58).  Patients with TBK-1 mutations have 
been described as having clinical syndromes with svPPA and spinal MND, CBS with bulbar MND, 
nfv-PPA (initially with apraxia of speech) followed by behavioural changes and limb 
weakness(59).  Despite substantial advances in genetic research the majority of cases occur 
sporadically and without an identified underlying genetic cause.   
While there are firm correlations between genetic mutations and microscopic post 
mortem pathology amongst those with symptomatic disease, pathological changes amongst 
presymptomatic mutation carriers have not yet been established.  There is good evidence that 
structural brain changes followed by subtle impairments on formal neuropsychological testing 
can be identified prior to the emergence of overt symptoms amongst mutation carriers (56) but 
whether protein deposition and aggregation plays an active role in the process of 
neurodegeneration (or whether both are the consequence of some common upstream event) 
remains the subject of debate.  
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Gene Mutation Inclusions found at 
Post Mortem 
Associated Syndromes 
MAPT Tau bvFTD, bvFTD with Parkinsonism, PSP-RS 
C9ORF72 TDP-43 MND, bvFTD, FTD-MND, nfvPPA 
GRN TDP-43 bvFTD, nfvPPA, CBS 
TBK1 TDP-43 bvFTD, MND, FTD-MND, PPA, bvFTD with 
Parkinsonism, CBS 
VCP TDP-43 bvFTD, inclusion body myositis, Paget’s 
Disease of bone, MND, FTD-MND 
CHMP2b FTLD-UPS* MND, FTD-MND, bvFTD 
TARDP TDP-43 MND, FTD-MND, bvFTD 
SQSTM1 TDP-43 MND, FTD-MND, bvFTD 
DCTN1 TDP-43 Perry Syndrome, FTD, FTD-MND,  
FUS FUS MND, FTD-MND, bvFTD 
Table 1.1 Genes associated with FTLD *FTLD-UPS Frontotemporal lobar degeneration 
Ubiquitin Proteasome System.  In the brains of subjects with CHMP-2B mutations ubiquitin 
positive inclusions are found which are negative for TDP-43, FUS and Tau stains(27). 
1.10 Clinico-Pathological Correlation of FTLD Associated Syndromes 
Within the spectrum of syndromes associated with FLTD, the strength of clinicopathological 
correlation varies widely.  For example, sensitivity and specificity for PSP-RS using the NNIPPS 
criteria were 0.95 and 0.84 respectively, but only when cases with post mortem CBD were 
excluded and amongst a cohort already assessed as having likely PSP for entry into a clinical 
trial(13).  Conversely by retrospectively examining clinical records for 103 consecutive cases of 
pathologically confirmed PSP Williams et al(60) report only 54% had the clinical ‘Richardson-
Syndrome’ during life, although in this paper ‘Richardson Syndrome’ refers to a data driven 
classification of cases and is not synonymous with PSP-RS or PSP as defined by other clinical or 
research criteria.     
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Amongst cases of bvFTD, Tau and TDP-43 both producing similar behavioural 
syndromes, additional features (such as features of motor neuron disease or Steele-Richardson-
Olzewski syndrome) may help increase discriminate when they are present(14).  For CBS less 
than two thirds of cases will have CBD pathology at post mortem and conversely less than two 
thirds of those with CBD identified will meet criteria for CBS during life(7).  Amongst cases of 
PPA clinic-pathological correlations are varied.  svPPA is considered reasonably predictive of 
TDP-43 pathology;  in one series 18 of 24 cases of Semantic Dementia had ubiquitin positive 
inclusions (confirmed as TDP-43 pathology in all of 13 cases tested) at post mortem(61).   In this 
series the term ‘Semantic Dementia’ encompasses (but is not limited to) those who would 
classified as svPPA under current criteria(11).  Conversely nfvPPA (formerly PNFA) has wide 
range of pathological correlates(62).  Furthermore a significant number of patients who meet 
criteria of FTLD-associated clinical syndromes will have non FTLD-associated pathology such as 
Lewy Body or Alzheimer’s type pathology(63).  Amongst some syndromes non FTLD pathology 
may be the predominant underlying pathology (for example lvPPA(64)). 
1.11 Genotype-Phenotype Correlation 
With the caveat of incomplete penetrance, the presence of pathogenic genetic variants allow the 
diagnosis of FTLD to made in confidence in some symptomatic individuals.  Table 1.1 shows 
clinical syndromes (phenotypes) commonly associated with genetic forms of FTLD but is by no 
means exhaustive.  The range of clinical syndromes have been associated with each gene 
continues to expand.  For example on 14th October 2014 (approximately three years since the 
first publication of C9ORF72) I performed a Pubmed search for C9ORF72.  I then reviewed the 
titles and abstracts (where available online) of the papers identified for clinical syndromes that 
were proposed as associated with C9ORF72.   I identified 452 papers with a total of 53 
phenotypes (Figure 1.2).  These ranged from the spectrum of FTLD, MND, chorea, and 
Parkinsonism to more diverse conditions including multiple sclerosis(65), paraneoplastic effects 
of lung adenocarcinoma(66), and hippocampal sclerosis(67).  Since then, as of 1st January 2019, 
a further 807 papers have been published at an average rate of 194 papers per year (range 161-
201) since the start of 2015.  Despite the steady increase in published papers referencing 
C9ORF72 there are also a smaller number of papers reporting lack of associations with some 
clinical syndromes (such as DLB, idiopathic dystonia, ataxia and schizophrenia (68–71),), 
pathologically defined cohorts (such as DLB, MSA, PSP and CBD(72,73)) and geographically 
restricted cohorts of FTD/MND (such as China and Korea(74,75)).  
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Figure 1.2 Published Phenotypes Associated With C9ORF72 in the First Three Years Since 
Discovery. 
11.12 Rationale for a Transdiagnostic Approach to FTLD 
The criteria for the syndromes associated with FTLD have each emerged as the result of 
attempts to provide a common framework to facilitate uniformity in diagnosis between 
centres(11) and also to relate the clinical syndrome to underlying pathological 
processes(10,12,13,54).   They seek to define particular clinical features and group these into 
clinical syndromes.  Many use different levels of probability when relating to underlying 
pathology (e.g. possible or probable CBD(12)).   
While they define a set of clinical syndromes the current criteria do not encompass the 
entire spectrum of syndromes associated with FTLD. There is also considerable overlap between 
FTLD associated syndromes.  For example there is no clear distinction between PSP-CBS and 
CBS-PSP on the grounds of clinical presentation or on pathological descriptions.  Intermediate 
phenotypes where features of more than one of the ‘classical’ syndromes are present are 
common and an individual’s clinical syndrome may evolve and change over time(3).   While each 
set of criteria provides a useful framework for particular aspects of FTLD-associated syndromes 
they do not currently give sufficient consideration to the entire spectrum FTLD associated 
disorders.   
A more unifying transdiagnostic approach that emphasises commonalities rather than 
differences between FTLD associated syndromes(26) may provide fresh insights into FTLD, its 
clinical syndromes and their underlying neural basis.  This approach may also have the 
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advantage of capturing mixed or intermediate clinical syndromes that clearly fall within the 
spectrum of FTLD but fall between syndromes and are unclassifiable by current criteria.  
Consider (for example) a patient with severe semantic deficits but also behavioural changes.  
The behavioural changes would normally be considered exclusion criteria for a diagnosis of PPA 
but are a well-recognised feature of semantic dementia.  Another subject with progressive 
language dysfunction but features of more than one subtype of PPA, clearly should be defined as 
PPA but forcing subcategorisation beyond this seems counterintuitive. By using current criteria 
for FTLD together simultaneously, disregarding those exclusion criteria for one syndrome which 
are inclusion criteria for others and not forcing subcategorisation where the syndrome sits 
within FTLD but between syndromic labels, it may be possible to capture a more representative 
cohort of subjects with FTLD. 
While the clinical syndromes associated with frontotemporal dysfunction have been 
recognised for centuries, over time the clinical syndromes associated with individual diagnostic 
entities such as GPI or Pick’s disease have been subject to progressive expansion and subsequent 
refinement as further discoveries as to their underlying pathology are made.  More recently as 
genetic and histopathological advances have been made the syndromes associated with 
pathologically defined disease entities such as FTLD has been subject to similar phenotypic 
expansion.   In line with advances in our understanding of these conditions the terminology used 
to describe these conditions has also changed and will undoubtedly continue to do so.   
In both the clinical and research settings continuously evolving knowledge and nosology 
presents particular challenges.  A clinician may be faced with a patient with a genetically defined 
illness and uncertainty with regard to their prognosis and what clinical consequences of their 
genetic diagnosis may be.  More commonly a patient may present with clinical features of a 
syndrome associated with FTLD and uncertainty as to the underlying pathological process, 
prognosis, or when to test for genetic changes.  As trials of disease modifying treatments are 
beginning to emerge the question of who to recruit for trials aimed at particular pathological 
processes is a particular challenge to researchers.  Restricting trials to only those subjects with a 
genetic or pathologically defined illness risks restricting trials to a narrow subset of patients 
who may not be truly representative of the disease as a whole.  Such restrictions also make 
recruitment to such studies challenging given the rarity of FTLD.    
Taking a broader more inclusive approach however will lead to inclusion of multiple 
pathological processes and substantially reduce the power of a particular study to evaluate 
therapies aimed at particular pathologies.  For other researchers investigating the syndromic 
consequences of FTLD (such as particular behavioural or cognitive syndromes) the underlying 
 19 
pathology may be less important.   The structural and functional brain changes caused by FTLD 
may be more relevant to our understanding of the neural mechanisms responsible for particular 
symptoms than the underlying pathology causing neurodegeneration.  Better understanding of 
these processes may lead to better symptomatic therapies independent of the underlying 
pathological diagnosis and is the basis on which almost all currently licensed treatments for 
neurodegenerative disease in the U.K. exist. 
Irrespective of pathology frontotemporal dysfunction leads to significant 
symptomatology, cognitive and behavioural changes and associated morbidity, which are in 
themselves, attractive targets for therapeutic interventions.  While FTLD, and its associated 
syndromes, may be subdivided in a number of different ways, clinically and symptomatically 
they present as spectrum of disorders of language, behaviour and motor function which while 
diverse are also highly recognisable, sharing very particular problems and morbidity.  
Dissociating pathological subtypes on the basis of clinical features and current criteria is 
imprecise and fragments this group of disorders, leading to a potential underestimation of their 
impact as a whole and also limiting our ability to explore the features that are common between 
syndromes.  As such I argue it remains valid and useful to consider these conditions together.  
While there are clear advantages to a transdiagnostic approach, FTLD (and its associated 
clinical syndromes) are heterogeneous.  There remain important genetic, pathological and 
syndromic differences between patients, which have important clinical and scientific 
implications. For example patients with bvFTD and some forms of TDP-43 are at greater risk of 
developing MND or of passing a C9ORF72 genetic mutation onto subsequent generations than 
those with PSP-RS.  A potential treatment targeting Tau would be easier to evaluate in PSP-RS 
than in PPA or CBS where Alzheimer’s and TDP-43 type pathologies are also commonly found.  A 
transdiagnostic approach is not simply ‘lumping’ all patients together but accepts that each 
method of ‘splitting’ FTLD also has its own limitations.  Clinicopathological correlations are 
variable, clinical syndromes evolve and vary over time, gene penetrance varies and pleitropy 
increasingly recognised, mixed pathology is common in all neurodegenerative disease.  A 
transdiagnostic approach neither lumps nor splits FTLD but simultaneously recognises the 
importance of both individual differences and commonalities between patients and also that our 
current criteria and understanding of these conditions is incomplete and imperfect.   
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1.13 Conclusions and Thesis Outline 
In this chapter I outlined the spectrum of clinical syndromes associated with FTLD.  Using a 
historical perspective I first described how syndromes associated with disruption of 
frontotemporal function have been described over centuries.  I then discussed how as our 
understanding of underlying pathology associated with these syndromes has developed, the 
nosology we use to described them has evolved to reflect initial phenotypic expansion and 
subsequent refinement.  Next I discussed the current concept of FTLD as a heterogeneous group 
of disorders defined by a range of neuropathological findings and associated with a wide 
spectrum of clinical syndromes.  I then discussed the diagnostic criteria and recognised 
syndromes associated with FTLD and how they have been developed to serve multiple 
functions; to provide a framework to describe clinical features and to predict disease 
progression, prognosis and underlying pathology. These criteria are not comprehensive and do 
not encompass the entire spectrum of clinical syndromes associated with FTLD.  There is also 
overlap between criteria, clinicopathological correlation is variable and non-FTLD type 
pathology may also present with clinical syndromes that meet current criteria.  I have argued 
that while FTLD is a diverse and heterogeneous group of disorders there is merit in considering 
these conditions together as a spectrum of syndromes associated with Frontotemporal Lobar 
Degeneration both in terms of exploring the impact of these conditions and in the study of 
particular syndromic aspects.   
In the subsequent chapters I will present the results of the PiPPIN study (Pick’s disease 
and Progressive supranuclear palsy Prevalence and INcidence) of both the epidemiology of 
syndromes associated with FTLD and of some neuropsychiatric aspects of FTLD (namely apathy 
and impulsivity). I will demonstrate how this transdiagnostic approach can provide useful data 
and insights into the impact of FTLD and the underlying neuropsychological basis of common 
and disabling neuropsychiatric symptoms in dementia. 
The diagnostic criteria are heuristic, and with limitations. The criteria used in the 
diagnosis of FTLD associated syndromes had been recently updated before the PiPPIN study and 
my PhD began.  However the criteria remain fragmented and each limited to a particular subset 
of clinical syndromes.  There was also considerable overlap between them (for example a patient 
may meet criteria for navPPA and CBS-NAV simultaneously).  Similarly over the course of an 
individual’s illness as their disease progresses they may acquire additional clinical features and 
move between clinical syndromes (such as a patient meeting criteria for bvFTD and 
subsequently developing the movement disorder required for a clinical diagnosis of PSP-RS).  
Some patients may fall between criteria, meeting neither by strict application but clearly having 
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a clinical syndrome most likely associated with FTLD type pathology (such as a patient with 
profound semantic deficits who also has behavioural impairments precluding a diagnosis of 
PPA). 
For these reasons there was a need to revisit the epidemiology of FTLD associated 
syndromes using the updated criteria and an inclusive approach whereby transitional and 
intermediate clinical phenotypes are counted, but only once.  I did this in the PiPPIN study, a 
comprehensive clinical study of the epidemiology of FTLD associated syndromes using multiple 
sources of referral to recruit all clinical syndromes, transitional and intermediate cases, without 
age restrictions.  From the cohort I recruited I then went on to focus on a major transdiagnostic 
problem, apathy and impulsivity, symptoms which are particularly prominent, common, 
distressing and disabling across the entire spectrum of FTLD associated syndromes and relevant 
to a far wider, range of neurological disorders.  Despite their importance apathy and impulsivity 
remain poorly understood.  Rather than single one-dimensional syndromes they appear to be 
multidimensional and frequently coexist in disease states.  Similarly methods used in their 
assessment vary widely.   It was not clear whether apathy and impulsivity in FTLD associated 
clinical syndromes represents disruption of a single common cognitive process or multiple 
different processes.  Neither was it clear which of these are of clinical relevance and the best 
methods by which to assess and measure them.  Before we can move to clinical trials of 
symptomatic therapies aimed at treating these important symptoms we need to better 
understand their cognitive and neural correlates and how best to assess them.  With this in 
mind, as part of the PiPPIN study I used a variety of methods to assess apathetic and impulsive 
symptomatology from a range of perspectives.  I demonstrate that apathetic and impulsive 
syndromes are common in FLTD, multidimensional and that a multimodal approach to their 
assessment is required. 
In Chapter Two I first review previous epidemiological studies of FTLD associated 
syndromes and discuss some of the methodological differences between them that limit 
comparisons between studies, syndromes and cohorts.  Many of these studies used older criteria 
and are limited to particular syndromes within the spectrum of FTLD. I argue that a more 
inclusive transdiagnostic approach may give a better and more representative estimate of the 
true epidemiology of FTLD associated syndromes whereby transitional and borderline cases 
moving between clinical syndromes are included but only counted once.  I then discuss the 
methods used to recruit subjects to the PiPPIN study recruiting from multiple sources subjects 
with FTLD associated syndromes resident within the counties of Norfolk and Cambridgeshire in 
the UK without restriction to a particular age group or subset of clinical syndromes.  Using 
current criteria for FTLD associated syndromes applied simultaneously so that subjects with 
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clinical features of one FTLD associated syndrome are not excluded from the study because they 
also have features of another, but are only counted once.  While using this approach does not 
dramatically change previous epidemiological estimates of the Prevalence or Incidence of FTLD, 
by doing so I am able to present such estimates in a more robust fashion and in a manner that 
will allow easier comparison between similar cohorts in the future. 
In Chapter Three, I discuss neuropsychiatric symptoms in dementia with a particular 
emphasis on apathy and impulsivity which I discuss in terms of disruption of goal directed 
cognition and behaviour.  I hypothesise that apathetic and impulsive states within the 
syndromes associated with FTLD are due to dissociable neural and psychological mechanisms 
and that different apathetic and impulsive states may in some instances coexist and correlate 
with each other.  First, using informant reports (mainly from a spouse or carer) of patients with 
FTLD associated syndromes in the PiPPIN study I show that neuropsychiatric symptoms, 
including apathy and impulsivity are commonly reported in FTLD.  Second using a range of 
questionnaires and paper and pencil tests, I demonstrate that despite impairments across a 
range of cognitive domains, subjects with FTLD are able to give meaningful insights into their 
own cognitive and emotional states.   I show that, consistent with the reports of their carers, 
when compared to a similarly aged group of healthy volunteers, subjects with FTLD associated 
syndromes report increased negative emotional feelings, more symptoms of apathy, depression 
and decreased motivation and hedonic tone.  Finally I suggest that the underlying 
neuropsychological basis of these patient and carer reports is complex and multifaceted. 
In Chapter Four, I discuss the limitations of a questionnaire based approach and suggest 
a number of ways that these might be overcome by using more objective behavioural 
assessments of goal directed cognition and behaviour.  Across a number of different tasks aimed 
at assessing aspects of decision-making and reflection impulsivity, perception and 
responsiveness to reward, and response inhibition, patients with FTLD associated syndromes 
performed differently to healthy older controls; their responses are typically slower and less 
accurate.  While subjects with FTLD remain responsive to reward and are able to detect and 
adapt their responses to changes in perceived reward, they do so differently to healthy older 
controls. I suggest that neural and cognitive mechanisms responsible for these changes in 
performance on tasks may also contribute to the observed increase in both apathetic and 
impulsive behaviour observed by carers in this patient group. 
In Chapter Five, I take a multidimensional approach to apathy and impulsivity.  First by 
performing multiple Principal Component Analyses on different versions of the Apathy 
Evaluation Scale (AES) I show the resulting extracted components vary depending on the person 
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completing the AES (the subject, an informant who knows them well, or a clinician) and the 
subject of the AES (a subject with FTLD, a healthy older controls, or both combined).  I then 
show that while some extracted components can be related back to previous descriptions of the 
component structure of the AES, others appear more related to the manner in which items in the 
AES are presented. Also, while both subject and informant versions of the AES correlated with 
clinician based assessments, they do not correlate significantly with each other supporting the 
hypothesis that the results of questionnaire based assessments vary depending on who is asked, 
and how they are asked.  Next I quantify discrepancies between subject and informant reporting 
of symptoms and show that some, but not all, of these correlate with subject cognition and 
mood. 
I then examine the relationship between performance on behavioural tasks and whether 
subjects are considered apathetic, impulsive, or not by their carers.  I show no significant 
differences between these groups.   By performing another Principal Component Analysis, this 
time combining subject, informant, and clinician questionnaire based assessments with the 
results of behavioural testing; I show that different testing modalities load onto different 
extracted components with very little overlap.  These extracted components show significant 
(but different) correlations with ratings of mood, cognition and discrepancy scores between 
subject and informant reports.  Taken together these results support a multidimensional 
approach to apathy and impulsivity where different testing modalities and sources of 
information each contribute to the assessment of these symptoms but none in isolation give a 
true reflection of these complex multidimensional symptoms. 
Finally, in Chapter Six, I review these results together and reflect on how using this 
transdiagnostic approach to the syndromes associated with FTLD has provided robust support 
for epidemiological estimates of these syndromes even in light of the continued evolution of the 
classification and associated nosology that I have discussed in this first chapter.  I suggest these 
results provide insights into the nature of decision-making and the manner in which it is 
disrupted in FTLD which leads to disabling and distressing neuropsychiatric symptoms.  I also 
discuss the limitations of this study and future directions that might overcome some of these and 
in turn lead to therapeutic trials that ultimately translate to effective symptomatic therapies for 
apathy and impulsivity, improving the lives of not only those affected by FTLD but potentially a 
far wider range of neuropsychiatric disorders.  
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Chapter Two  
The Epidemiology of Frontotemporal Lobar Degeneration 
and the PiPPIN Study 
2.1 Summary 
In this chapter I discuss the epidemiology of syndromes associated with FTLD and the principles 
underlying systematic epidemiological study of neurodegenerative diseases.  I review previous 
epidemiological studies of FTLD and associated syndromes and outline the methods of the 
PiPPIN study (Pick’s disease and Progressive Supranuclear palsy Prevalence and INcidence 
study) a novel epidemiological study of FTLD associated syndromes in the English counties of 
Norfolk and Cambridgeshire (population 1.69 million).  Using multisource referral over two 
years and clinical revalidation using current diagnostic criteria, I aimed to identify every 
diagnosed or suspected case of FTLD resident in these two counties secondary.  A subgroup of 
47 subjects were screened for known genetic causes of dementia.  
Using this approach I calculated age and sex standardized prevalence and incidence rates 
of FTLD associated syndromes as 10.84/100,000 persons and 1.61/100,000 person-years 
respectively.  Mortality amongst those with FTLD associated syndromes was 1.56/100,000 
person-years.  The lifetime risk of a diagnosis of FTLD is 1 in 742.  Prevalence rates were similar 
between individual syndromes (Progressive Supranuclear Palsy, Corticobasal Syndrome, 
Behavioural Variant Frontotemporal Dementia and Primary Progressive Aphasia) as was mean 
survival from symptom onset however time to reach a diagnosis varied between syndromes.  
Peak prevalence was between 65-79 years and the prevalence in the over 65s more than double 
that amongst 45-64 year olds.  14.9% of those screened had a possible genetic cause of their 
dementia identified. 
 
2.2 Introduction 
The diverse clinical syndromes associated with FTLD discussed in Chapter One are often 
described as a common cause of young-onset dementia(76,77,78).  While such statistics appear 
commonly in the literature and media seeking to raise the profile of FTLD, estimates of the true 
epidemiology of FTLD vary widely.  This is largely due to methodological variations between 
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studies and changes to the understanding of FTLD and the criteria by which FTLD (and its 
associated clinical syndromes) has been defined(77).   
Some studies have suggested FTD is the commonest form of young onset dementia, or 
second commonest after Alzheimer’s disease(76,79), others suggest it is the third (behind 
Alzheimer’s and vascular dementia)(80).  Such simple, memorable and provocative statistics 
may be effective in promoting a particular cause or raising awareness; whether FTD is the first, 
second or third commonest cause of dementia is less relevant than the fact that it is an 
important cause of young onset dementia and as such may have a disproportionate socio-
economic effect compared to other diseases in more elderly cohorts.  Despite this, young onset 
dementia of any cause is rare.  By emphasising the relatively high prevalence of FTLD amongst 
younger cohorts of people with dementia there is the risk of simultaneously underrepresenting 
FTLD amongst the elderly, and reducing awareness or correct diagnosis of FTLD associated 
disorders among older patients.   
Beyond contextualising or raising the public profile of a particular disease, 
epidemiological research serves several other important purposes.  Firstly, accurate 
epidemiological research is essential for estimating the burden of disease, for priority setting, 
resource allocation and public health planning(81).  Secondly, studies of prevalence and 
incidence between different cohorts have the potential to provide insights into causation or the 
natural history of disease by identifying variation between populations(81). In order to do this 
epidemiological research needs to be accurate, with robust methodology and importantly allow 
comparison between studies of different cohorts.  While there have been a number of previous 
studies of syndromes associated with FTLD several methodological aspects limit their usefulness 
when considering the epidemiology of FTLD associated syndromes as a whole.    
In these next sections I first review the previous literature on the epidemiology of FTLD 
and discuss methodological differences between them.  I then discuss the rationale for a new 
study of the epidemiology of FTLD associated syndromes using current diagnostic criteria and a 
reproducible and standardised approach to epidemiological estimates that allows comparison 
between different populations and the calculation of lifetime risk, a more easily understood 
statistic that reflects the impact of a disease and takes account of onset at any age.    
2.3 Previous Epidemiological Studies of FTLD Associated Syndromes 
Tables 2.1.1-2.2.2 summarise previous epidemiological studies of FTLD associated syndromes.  
While there have been a number of previous studies several frequent methodological issues 
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limit their usefulness when considering the wider spectrum of FTLD and its associated 
syndromes.   
Firstly, as I discussed in Chapter One, the diagnostic criteria have each been revised 
significantly in recent years(10–13) with changes in their specificity and sensitivity(10).  Most 
previous epidemiological studies of, for example, FTD, used consensus criteria published in 1994 
and updated in 1998(82,83) these have since been revised in light of further understanding of 
the pathology and clinical phenotypes of bvFTD and subjected to pathological validation(35).    
Second most studies have restricted themselves to particular subgroups of FTLD 
associated syndromes (such as bvFTD, PSP etc.).  Intermediate phenotypes of uncertain 
nosological status lay outside former diagnostic categories, e.g. the overlap between PSP and 
CBS (CBS-PSP)(12,84). Patients may also evolve from one syndrome to another(46,85). As a 
consequence, the sum of former prevalence estimates of single disorders might not accurately 
reflect the prevalence of the syndromes when considered together.   
In addition most studies of CBS/PSP have identified patients based on their movement 
disorder (for example by screening records for ‘Parkinsonism’ or screening incident Parkinson’s 
cohorts), some have explicitly excluded those subjects with dementia (e.g. (86)).  
Finally, previous studies used widely varying methods, age-ranges and standardisation 
hindering comparisons across studies(77).   For these reasons there remains a need for further 
epidemiological study of the syndromes associated with FTLD considered together and taking 
account of revised diagnostic criteria. 
Key principles in epidemiological research are that the entity under investigation (for 
example FTLD associated syndromes) and the population in which it is studied are both clearly 
defined.  In addition to this the methods for identification of the entity should be sufficient to 
accurately identify a meaningful proportion of cases but also practical for the research to be 
conducted effectively.  For example, where screening for a condition is not time consuming, 
expensive or invasive it will be possible to screen a much larger population than when case 
identification requires more involved procedures.  While it may be possible to investigate the 
epidemiology of more common conditions within a small population, rarer conditions will 
require a larger population to reach the same level of accuracy.  Population based studies of 
FTLD and its associated syndromes are particularly challenging.  As the frequency of disease is 
low, the population at risk large and diagnosis requires expert proficiency(87).  Previous studies 
have investigated the epidemiology (specifically the incidence and prevalence) of FTLD 
associated syndromes individually but differences exist between studies of the same syndrome.  
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For example one study in Japan estimated the prevalence of FTD at 2 per 100,000 while another 
in Italy estimated the prevalence fifteen times higher at 30 per 100,000(88,89).  Such differences 
might allude to important aetiological aspects of FTLD (such as environmental or genetic 
factors) but differences between the methods used in these studies limit comparison between 
them.   
The Japanese study focussed on young onset dementia (i.e. onset less than 65 years) and 
subsequently evaluated for FTLD as a potential cause.  Subjects were only included if age at 
onset and age at census date were less than 65, they were identified via postal survey over a 
short period of time (although they do also appear to have identified some cases from local 
services).  In contrast the Italian study focussed specifically on FTLD screening through a large 
database for cases identified over a period of around 10 years.  They used different criteria for 
inclusion that also includes syndromes associated with PSP and CBD within the definition of 
FTLD.  Second the Italian study identified subjects through a registry held for over 10 years.  
Subjects were included based on age of onset and survival to the census day and hence represent 
a cumulative prevalence of young onset dementia.  While the Japanese study recruits from the 
Ibaraki Prefecture, one of the most highly developed, urban areas of Japan with close links to 
several similar immediately adjacent Prefectures, the Italian study recruited from 
Vallecamonica, a large valley in Northern Italy that was relatively isolated until the second 
World War and at the time of the study had only a single neurology unit(89).   Hence the 
dramatically different results may reflect differences in the studies entry criteria, sources of 
subject identification or alternatively reflect a true difference between the rates of FTLD 
amongst the two populations studied.  The differences may indicate important genetic or 
environmental risk factors for developing FTLD or differences in service provision, rates of 
diagnosis or survival for patients with FTLD in the two areas, all of which could have important 
implications for our understanding of FTLD, its diagnosis and treatment.  Alternatively the 
differences may simply reflect methodological differences between the two studies.  
While it is not possible to standardise methods for all epidemiological research, in order for 
epidemiological studies to be comparable specific aspects must be clearly defined namely: 
1. The population under study 
2. The definition of disease under study 
3. The definition of a prevalent, or incident case 
4. The methods used to identify these cases 
   
 
 
Reference Sample 
Population 
Age 
range 
Syndromes 
Studied 
Case 
identification 
Age at 
onset 
M:F Cases Criteria for 
confirmation 
Standardisation Prevalence 
per 100,000 
Ratnavalli 
2002(76) 
Cambridgeshire, 
UK 72,815  
45-
64 
FTD, PPA Regional centre 
with coded 
records, contact 
with regional 
specialist 
services 
52.8 14:3 11 
 
(3 CBS 
cases 6.9 
(2.9-
16.1) no 
cases of 
PSP) 
1994 Lund 
Manchester and ‘local’ criteria, 
specialist 
review either 
by clinical or 
research team 
None 15.1 (8.4-
27.0) 
Feldman 
2003(90) 
Canada.  
Individuals 
referred to 
specialist 
dementia clinics 
in Canada over 
19 months  
<70 FTD National 
cohort; cross 
section of 
subjects 
NR NR 36 FTD, 
16 
mixed 
FTD/AD 
1994 Lund 
Manchester 
criteria, clinical 
assessment 
NA 12.1% of 670 
cases of 
dementia 
Harvey 
2003(80) 
3 Boroughs of 
London, UK 
117,236 
 
45-
64 
FTD 
 
Hospital coding, 
case reporting, 
regional 
network coded 
records 
57 NR 18 1994 Lund 
Manchester 
criteria, Clinical 
record review 
Subset 
reviewed in 
person 
None 15.4 (9.1-
24.3) 
Rosso 
2003(79) 
Zuid-Holland, 
Netherlands 
2,043,949 
30-
79 
FTD Regional 
network coded 
records, postal 
survey 
58 1:1 55 1994 Lund 
Manchester 
crieria  
None 2.7 (2.1-3.5) 
 
 
Ikejima 
2009(88) 
Ibaraki, Japan 
852,889 
45-
64 
FTD Regional 
network coded 
records, postal 
survey 
60 1.5:1 17 1994 Lund 
Manchester 
criteria.  Case 
reporting. 
Adjusted for 
response rate. 
2.0 (1.3-3.2) 
 
Table 2.1.1 Prevalence Studies of Syndromes Associated with Frontotemporal Lobar Degeneration. Note the restricted age-ranges and 
variation in case identification methods.   
   
 
 
Reference Sample 
Population 
Age 
range 
Syndromes 
Studied 
Case 
identification 
Age at 
onset 
M:F Cases Criteria for 
confirmation 
Standardisation Prevalence 
per 100,000 
Borroni 
2010(91) 
Brescia, Italy 
531,249 
>45 FTD, PPA Regional 
network, 
surveillance 
registry over 8 
years with 
census day 
point 
prevalence. 
65.6 1:1.2 213 1998 Neary 
Criteria and  
McKhann 
criteria. Clinical 
case review. 
None.  95% CI 
using Poisson 
distribution.   
40 (35-45) 
Bernardi 
2012(92) 
Community of 
Biv. Reggio 
Calabria, Italy, 
509 
>50 FTD Active case 
ascertainment 
by invitation of 
all residents to 
dementia 
screening. 
75.9 1:3 18 1998 Neary 
Criteria and  
McKhann 
criteria. 
Clinician case 
review 
None 3.5% of 
population 
Borroni 
2011(93) 
Brescia, Italy 
322,334 
45-
65 at 
onset 
FTD, PPA Regional 
network, 
surveillance 
registry over 8 
years  
59.0 24:23 94 1998 Neary 
Criteria and  
McKhann 
criteria. Clinical 
case review. 
None.  95% CI 
using Poisson 
distribution.   
29.6 (23.7-
35.6) 
Gilberti 
2012(89) 
Vallecamonica, 
Italy 119,647 
45-
65 at 
onset 
FTD, PPA Regional centre, 
surveillance 
registry over 9 
years. 
66.1 
 
1:2 42 1998 Neary 
Criteria and  
McKhann 
criteria. 
Clinician case 
review 
None.  95% CI 
using Poisson 
distribution.   
35 (26-46) 
Wada-Isoe 
2012(94) 
Tottori 
Prefecture, 
Japan 587,772 
None FTD, PPA Survey of 
Regional 
Centres 
NR NR 66 1998 Neary, 
2011 
Rascovsky, 
clinician review 
of some cases 
None. 11.2 (8.5-
14.)) 
 
Table 2.1.2 Prevalence Studies of Syndromes Associated with Frontotemporal Lobar Degeneration   
   
 
 
Reference Sample 
Population 
Age 
range 
Syndromes 
Studied 
Case 
identification 
Age at 
onset 
M:F Cases Criteria for 
confirmation 
Standardisation Prevalence 
per 100,000 
Luukkainen 
2015(95) 
Nothern 
Ostrobothnia, 
Finland 107,516 
45-
65 
FTD, PPA Regional centre 
registry over 5 
years 
61.7  22 1998 Neary and 
Rascovsky 
2011/Gorno-
Tempini 2011 
(applied 
retrospectively) 
 20.5 
Incidience  
over 5 
years5.54 
(1.9-11.3) 
Nath 
2001(96) 
UK National 
study 
59,236,500 
None PSP-RS Passive case 
identification: 
case reporting,  
charity 
registries UK 
mortality 
reporting 
66  91:96 577  PSP-RS defined 
by NINDS-SPSP  
None.  1 (0.9-1.1) 
Nath 
2001(96) 
North of 
England 
Regional study 
2,589,240 
None PSP-RS Case referral, 
correspondence 
review  from 14 
months, 
survey,database 
screening 
69 60:47 80 PSP-RS defined 
by NINDS-SPSP 
(Litvan), 
reviewed 
clinical records 
and personally 
examined 
where possible 
Age to 1994 
European 
standard 
population  
2.4 (1.9-3) 
Nath 
2001(96) 
Participating 
General 
Practices in 
Newcastle Upon 
Tyne 
259,998 
None PSP-RS Screening of GP 
records for 
features 
relating to 
Parkinsonism  
67 31:49 17 Screened 
patients invited 
for assessment 
in person 
Age to 1994 
European 
standard 
population 
5 (2.5-7.5) 
Golbe 
1988(97) 
New Jersey USA, 
799,022 
None PSP-RS Survey of local 
services 
NR NR 50 Local criteria, 
clinical 
examination 
None 1.39 
 
Table 2.1.3 Prevalence Studies of Syndromes Associated with Frontotemporal Lobar Degeneration   
   
 
Reference Sample 
Population 
Age 
range 
Syndromes 
Studied 
Case 
identification 
Age at 
onset 
M:F Cases Criteria for 
confirmation 
Standardisation Prevalence 
per 100,000 
De Rijk 
1997(98) 
Europe 17,205 
subjects from 5 
studies 
>65 Parkinsonism 
with 
associated 
features (e.g. 
PSP, MSA) 
Door to door 
screening of 
older 
population for 
Parkinsonism 
NR NR NR Clinician 
review 
Age 
standardised 
23 (1% of 
Parkinsonism) 
Wermuth 
1997(99) 
Faroe Islands 
43,709 
None PSP-RS GP, Hospital 
and Nursing 
Home survey, 
Pharmacy PD 
drugs search 
database search 
NR NR 2 NR None 4.6 
Chiò 
1998(100) 
Cossato, Italy 
61,830 
None PSP-RS Postal survey of 
GP, clinical 
records search, 
pharmacy 
flagging of PD 
medication  
NR NR 2 Clinician 
review 
None 3.2 
Schrag 
1999(86) 
London and 
Kent UK 
121 608 
None PSP-RS Screened GP 
records for 
terms related to 
Parkinsonism, 
MSA or PSP.  
Followed by 
notes review 
and clinical 
reevaluation 
Note excluded 
those with 
preceding 
dementia 
   5 probable 1 
possible PSP 
Age to 
European 
standard 
population 
6.4 (2.3 -10.6) 
Trenkwalder 
1995(101)  
Two Bavarian 
villages, 
Germany 
>65 PSP-RS Door to Door 
assessment of 
1190 people 
aged >65 years 
NA NA NA No cases 
identified 
NA NA 
 
Table 2.1.4 Prevalence Studies of Syndromes Associated with Frontotemporal Lobar Degeneration 
   
 
Reference Sample 
Population 
Age 
range 
Syndromes 
Studied 
Case 
identification 
Age at 
onset 
M:F Cases Criteria for 
confirmation 
Standardisation Prevalence 
per 100,000 
Takigawa 
2016(102) 
Yonago city, 
Japan 139683  
None PSP-RS, PSP-
P, PSP-PAGF 
6 Yearly 
surveys of local 
databases and 
clinical 
referrals to 
regional centre 
72.5 12:13 25 NINDS-SPSP 
criteria with 
local criteria for 
PAGF and PSP-
P, clinical 
review of 
suspected cases 
Sex and age 
adjustment to 
Japanese 
population 
17.26 (17.03-
17.48) 
Kawashima 
2004(103) 
Yonago, Japan 
137,420 
 PSP-RS Survey, visiting 
nursing homes, 
medical records 
search 
74.0 2:1 8 NINDS-SPSP None 5.82 (1.78-
9.86) 
 
Table 2.1.5 Prevalence Studies of Syndromes Associated with Frontotemporal Lobar Degeneration 
  
   
 
Reference Sample 
Population 
Age 
range 
Syndromes 
Studied 
Case 
identification 
Age 
at 
onset 
M:F Cases Criteria for 
confirmation 
Standardisation Incidence per 
100,000 
person years 
Mercy 
2008(104) 
Cambridgeshire, 
UK  
75,600  
45-64 
years at 
diagnosis 
FTD Referrals to 
tertiary centre, 
tertiary centre 
records 
(including 
prevalence 
study) over 6 
years 
NR 9:7 16 1998 Neary 
criteria but 
explicitly also 
report SD and 
PNFA 
 
None  3.5 (2.0-5.7) 
Separately 
report of 5 
incident 
cases of 
Parkinsonian 
disorders 
(PD, DLB, 
PSP,CBS, 
MSA) 
 
Knopman 
2004(105) 
Rochester 
Minnesota 
40-69 FTD+PPA Database 
review and 
medical 
records review 
over 4 years 
48 0:4 4 1998 Neary,  
McKhann 
criteria.  
Clinical case 
review. 
None 4.1 (1.1-10.4) 
Luukkainen 
2015(95) 
Nothern 
Ostrobothnia, 
Finland 107,516 
45-65 FTD, PPA Regional centre 
registry over 5 
years 
61.7 NR 29 1998 Neary and 
Rascovsky 
2011/Gorno-
Tempini 2011 
(applied 
retrospectively) 
None .54 (1.9-11.3) 
Garre-Olmo 
2010(106) 
Girona, Spain 30-64 FTD+SD Clinical 
dementia 
registry over 3 
years 
NR NR 14 Clinical 
diagnosis 
None 1.3 (0.7-2.2) 
Linder 
2010(107) 
Umea region 
Sweden 141,950 
None PSP, CBD Incident cases 
of 
Parkinsonism 
over 4 years 
75.8 1:1 6  
(0 CBD) 
NINDS-SPSP Age to Swedish 
Population 
1.2 (0.4-2.6) 
 
Table 2.2.1 Incidence Studies of Syndromes Associated with Frontotemporal Lobar Degeneration   
   
 
 
Reference Sample 
Population 
Age 
range 
Syndromes 
Studied 
Case 
identification 
Age at 
onset 
M:F Cases Criteria for 
confirmation 
Standardisation Incidence per 
100,000 
person years 
Winter 
2010(108) 
District of 
Moscow 
1,237,900 
None PSP, CBS Incident 
Parkinsonism 
cases Over 2.5 
years 
PSP 
67.5, 
CBS 
61 
3:2 (PSP) 
1 woman 
with CBS 
5 PSP, 1 
CBS 
NINDS-SPSP 
(PSP), Lang 
1994 (CBS) 
Age to general 
population 
PSP 0.14 
(0.08-0.21) 
CBS 0.02 
(0.01-0.12) 
Savica 
2013(109) 
Olmstead 
County 
Minnesota US 
approx. 
141,000 
None PSP, CBS Records linkage 
search for 
incident 
Parkinsonism 
from Rochester 
Epidemiology 
Project over 15 
years 
NR CBS 1:3 
PSP 5:3 
20 
tauopathies 
(16 PSP, 4 
CBS) 
 
Specialist 
records review, 
Maraganore 
criteria 1992 
(CBS) 
Collins1995 
criteria (PSP) 
None Tauopathies 
1.1 
PSP 0.9 
CBS 0.2 
Bower 
1997(110)  
Olmstead 
County 
Minnesota 
1976-1990 
50-
99 
PSP-RS Medical 
records linking 
from 1976-
1990 
72.5 9:7 16 Clinician 
record review 
using Collins 
(1995) criteria 
None 5.3  
Schrag 
1999(86) 
London and 
Kent UK 
121 608 
None PSP-RS Screened GP 
records for 
terms related 
to 
Parkinsonism, 
MSA or PSP.   
NR 1:1 5 probable 
1 possible 
PSP 
Notes review 
and clinical 
reevaluation 
None. Indirect 
calculation 
based on 
reported 
survival of 5.6 
years  
1.21  
 
Table 2.2.2 Incidence Studies of Syndromes Associated with Frontotemporal Lobar Degeneration
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2.3.1 Populations Under Study 
In order to estimate either prevalence or incidence the total size of the population under study 
must be known. In the developed world reasonable estimates may be obtained from government 
census data but such data may be less reliable in the developing world.  For geographically 
restricted studies, boundaries of the area under study should be clearly defined.  In the United 
Kingdom census data with estimates of population size and demographics are freely available 
for the mid point of each year based on national census data.  This is divided into Local 
Authority, Middle and Lower Super Output Areas.  Groups of adjacent Local Authorities form 
Counties.  The boundaries of these areas are subject periodic revision and are also freely 
available.  While most changes to boundaries are relatively minor there is still potential for 
inaccuracy if the population estimates are not used with the correct geographic boundaries.  A 
particular potential error is use of UK postcodes alone to identify case location by county as 
these are subject to change separately.  For example the postcode prefix NR usually denotes 
residence within the County of Norfolk but also encompasses areas of the adjacent county of 
Suffolk. 
The size of the population under study is important.  Insufficient population size may 
lead to inaccurate estimates (particularly for rare diseases) while screen an excessively large 
population for a common condition is wasteful.  If a smaller sample population is used to 
approximate the epidemiology of a much larger population then care should be taken to ensure 
that the sample size is sufficient and that the sample is representative of the larger population.  
The choice of geographic region may also influence epidemiological research.  While identifying 
how the incidence and prevalence of disease changes between groups (where for example 
genetic or environmental factors may also vary and speak to the underlying disease aetiology) is 
a fundamental aim of epidemiological research, regional differences in healthcare organisation 
and social factors may also affect case identification (for example by variation in referral 
pathways and access to diagnostic services) or distribution (for example for more debilitating 
conditions the distribution of regional residential or nursing care facilities may lead to 
concentration of cases in particular areas). 
Most studies of FTLD restrict the population under study to specific age groups.  This 
focuses study resources on those assumed to be at highest risk but also to inflates the final 
estimate and hinders comparison between studies.  While unrestricted age boundaries has the 
advantage of allowing easy comparison between studies the variety between demographics of 
different populations may be a confounding factor.  Areas with an older population may be 
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expected to have a higher prevalence of age related disorders (including neurodegenerative 
diseases) than areas with a younger population.  Similarly differences in sex distribution or 
other demographic variation may affect epidemiological estimates of some conditions.  In order 
to address such issues many studies now standardise their results to a ‘standard’ population.  
Two standard populations are commonly used, the European Standard Population (which was 
revised in 2013) and the US Standard Population.  The lack of a single standard population 
accepted by all groups remains a barrier to comparison between studies (particularly between 
the US and Europe). 
2.3.2 Definitions of Disease Under Study 
The evolution and terminology used to describe FTLD and its associated syndromes is discussed 
in Chapter One.  A disease entity can be described by a range of factors; histopathological 
features, clinical symptoms and signs or by the results of investigations such as imaging or 
genetic tests.  For research purposes most diseases are defined by a set of clinical criteria.  While 
specific criteria are particularly important for research into disease pathology or trials of 
diseases modifying therapy, for epidemiological research overly specific criteria (at the expense 
of sensitivity) will lead to an underestimation of the frequency of disease.  Furthermore, when 
considering syndromes associated with FTLD, a range of different pathological processes 
produce overlapping clinical syndromes.  Specific criteria aimed at identifying a particular 
pathology will underestimate the frequency of the syndromic spectrum and may require a 
different approach. 
2.3.3 Incident Cases 
The incidence of a disease is the number of new occurrences of that disease within a given 
population and time.  A known time of onset is therefore necessary to define an incident case.   
For neurodegenerative conditions this is problematic as symptomatic onset is insidious without 
a clear starting point; the symptomatic onset of disease may be predated by years of subclinical 
structural or functional brain changes and cognitive changes may be demonstrable on formal 
neuropyschometry years before disease becomes symptomatically evident(56).  An alternative 
approach is to use the time of diagnosis.  The advantage of this method is that it provides a 
definitive point in time. In less heterogeneous disorders it may also be reasonable to assume 
that the point at diagnosis is a reasonable estimate of the time at which symptoms had reached a 
particular level of severity (sufficient to allow diagnosis) but not far beyond (assuming rapid and 
uniform access to diagnostic services).  When considering FTLD associated syndromes there are 
disadvantages to either method.  As with other conditions, time of onset is difficult to clearly 
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define but also may vary between syndromes.  While a predominantly language or movement 
disorder may have a point where normal function is clearly interrupted (a hand becomes clumsy 
or words are first mispronounced) the distinction between normality and symptomatic disease 
is less clear for behavioural changes.  Time of diagnosis is also problematic with many patients 
acquiring several diagnostic labels over the course of their symptomatic disease both as they see 
different specialists with varying levels of expertise and also as their progressive disorders 
change over time.  Someone with Tau pathology may, for example, present with a dysexecutive, 
apathetic syndrome and be diagnosed with depression before developing an expressive 
language disorder, acquiring a label of PPA or PPAOS, then developing additional extrapyramidal 
features typical of CBS.  bvFTD may commonly be initially diagnosed as depression or 
Alzheimer’s type dementia before the diagnosis is made.  Even after the ‘correct’ diagnosis of 
bvFTD, a proportion of subjects will subsequently develop features of PSP-RS(111).  More 
commonly PSP-RS is initially diagnosed as idiopathic Parkinson’s disease and only when initial 
dopaminergic therapy proves ineffective is the diagnosis revised.    
While time of onset has been used for some studies the majority of incident studies have 
used time of diagnosis.  While this is a pragmatic solution when addressing an individual 
syndrome when considering multiple FTLD associated syndromes, transitional and intermediate 
clinical phenotypes it is unclear whether one particular definition of incidence is sufficient for all 
syndromes.   
2.3.4 Prevalent Cases 
Prevalence is usually defined as the proportion of individuals within a defined population with a 
particular condition at a specified time.  Point prevalence is the proportion of cases at a single 
point in time.  A prevalent case should therefore, by definition be alive, with the disease under 
study and resident within the catchment area at the time of prevalence estimation (‘census 
date’).   
Most studies run over a particular time frame during which subjects will be identified by 
the study team but some will also develop symptoms, be diagnosed clinically, and migrate to and 
from the area in which the population under study resides, move between age groups and die.  
To avoid confounding estimates of prevalence it is necessary to confirm that prevalent cases 
identified are alive, within the population under study (by both geographical and age 
boundaries) and meet the definition of a prevalent case (e.g. having symptomatic disease, 
meeting research diagnostic criteria or having a formal diagnosis).   
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The methods by which prevalent cases are identified can greatly influence prevalence 
estimates.  For example two Italian studies from Brescia(91) and Vallemonica(92) report cases 
identified over eight and ten years respectively.  Both studies ensured patients were alive and 
resident within the catchment area on the census date (and hence report point prevalence) but 
by a longer period of effective recruitment and case ascertainment have a greater potential to 
identify cases.  It is also possible that some cases initially meeting criteria for inclusion will 
develop further diagnostic features that would (if re-examined) preclude them from inclusion in 
a particular study especially where the study is restricted to particular subtypes of FTLD 
associated syndromes (for example a case of bvFTD that develops features of PSP, or 
alternatively a CBS that develops more florid features of Dementia with Lewy Bodies).  Hence 
differences in the period of case ascertainment and the definition of a prevalent case may at least 
partially explain differences in reported prevalence.  
2.3.5 Case Identification 
The methods used for case identification will affect the results of any epidemiological study.  
Where it is appropriate to use a small sample population, or identification of the disease entity is 
simple and non invasive it may be possible to test every individual within the sample population.  
When identification of the disease is more involved an alternative is to use a two step approach; 
screening all of the population with a relatively quick and sensitive screening, followed by more 
specific confirmation testing in those screened as positive by screening.   
Studies of individual FTLD associated syndromes have used several approaches to 
identify cases for example: case referrals to a specialist centre (e.g. (104)), screening of medical 
records for relevant diagnosis (e.g. (102)), screening of medical records for associated 
keywords(e.g. (86)), disease registries (e.g.(96)), door to door assessment (e.g.(98)). 
Because the syndromes associated with FTLD occur infrequently within a large at risk 
population a large sample size is required.  Screening tests for dementia mainly focus on 
memory and are insensitive for FTD(112).  In addition to this, heterogeneity amongst the 
syndromes associated with FTLD are such that a test that is sensitive to (for example) the 
predominantly language disorders may well be insensitive for those cases where movement 
disorders or behavioural change dominate the clinical picture.  Other potential biomarkers of 
FTLD such as structural or functional neuroimaging or cerebrospinal fluid analysis are time 
consuming, insensitive and invasive and hence not appropriate for screening purposes.   
Healthcare record systems are a potentially useful method of case identification.  
Electronic clinical coding, billing and discharge records have been used to identify cases.  
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However for less common conditions such as FTLD associated syndromes their accuracy 
remains untested.  Misreporting and under reporting is common(113).  Also, in the U.K., access 
to healthcare records is restricted by data protection legislation to preserve patient 
confidentially. 
With a few exceptions (such as Bernardi (92) who used door-to-door screening within 
set age boundaries) most epidemiological studies of FTLD studies of FTLD associated syndromes 
have required a suspected diagnosis of either FTLD or another neurodegenerative condition (e.g. 
Parkinson’s disease) or documented clinical features that strongly imply such a diagnosis (e.g. 
treatment with dopaminergic therapy, a clinical label of ‘dementia’ or ‘parkinsonism’).  In the 
U.K. the diagnosis of such disorders is almost exclusively made in secondary care.  Even for 
comparatively common neurodegenerative conditions, such as Parkinson’s disease, specialist 
review is recommended prior to a formal diagnosis.   For FTLD associated syndromes it is 
extremely unlikely that the diagnosis would be made exclusively in the primary care setting. 
Nath et al’s study(96) demonstrates how differences in the approach used to identify 
cases changes epidemiological estimates.  In order to identify the prevalence of PSP in the UK 
they sought to identify cases of PSP nationally (from a population of 60m), regionally (from a 
subpopulation of 2.58m of the national study) and at a community level (from a subpopulation 
of 260,000 of the regional study).  Case identification at the national level was by passive 
reporting from specialists with an interest in movement disorders and the British Neurological 
Surveillance Unit (a national register of neurologists who are asked to report cases of rare 
neurological disease on a monthly basis), mortality data from the Office of National Statistics (all 
patients where PSP was included on the death certificate).  The regional study included case 
reporting from local specialists but also regional database review and screening of unselected 
correspondence from all neurologists, geriatricians and GPs who agreed to participate.  The 
community study screened GP records for key words associated with PSP or Parkinsonism and 
then review for features of PSP.  Where possible patients were seen in person or case records 
reviewed for diagnostic validation.  Crude prevalence rates increased as the population size 
decreased (from 1.0/100,000 for the national population of 29m and 6.5/100,000 for 
community population of 129,000) demonstrating that epidemiological estimates are influenced 
by methods of case ascertainment and also that more involved active case ascertainment has the 
potential to identify a greater number of cases than more passive referral methods. 
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2.4 Rationale for a New Study of FTLD Associated Syndromes: The PiPPIN Study. 
Previous studies of the epidemiology of FTLD associated syndromes have considered syndromes 
individually but not the entire spectrum of syndromes associated with FTLD.  For each study the ‘disease under study’ has been defined with reference to clinical diagnostic criteria for individual 
or subgroups of syndromes associated with FTLD.  This raises a number of issues.  Firstly the 
clinical criteria used to diagnose FTLD associated syndromes have been subject to revision over 
recent years(11–13,35) reflecting advances in our understanding of the underlying pathology 
and expansion of recognised phenotypic associations.  Second, patients may move between 
clinical syndromes as their condition progresses and the associated syndrome evolves(85).  For 
example, a patient with Tau pathology may initially present with subtle cognitive or behavioural 
changes before developing a more marked language disorder, sufficient for a diagnosis of PPA, 
then later acquiring a movement disorder sufficient for a diagnosis of CBS or PSP.  Such a patient 
may at some stages of their condition meet criteria for several FTLD associated diagnoses, or 
non-at-all.  Such transitional and intermediate cases should be included in studies of the 
epidemiology of FTLD but illustrate that when considering the entire spectrum of FTLD 
associated syndromes the sum of prevalence/incidence estimates for individual syndromes may 
overestimate the true extent of some syndromes (by counting some overlap cases more than 
once) and underestimate others (by disregarding intermediate cases that fall between criteria).  
Finally different epidemiological studies of FTLD associated syndromes used different methods.  
As discussed earlier this may have significant effects on the resulting epidemiological estimates.  
Methodological limitations are, to some extent, unavoidable but are particularly problematic 
when attempting to compare between studies and make an assessment relative prevalence of 
particular FTLD associated syndromes difficult.   
Dementia and other neurodegenerative diseases are amongst the greatest health and 
social challenges in the developed world(114).  Key to addressing these challenges are accurate 
and up to date epidemiological estimates that reflect the true spectrum of disease and the 
manner in which it presents.  Over the last few decades our understanding of FTLD has evolved.  
While prior studies of the epidemiology of FTLD have demonstrated that it is an important cause 
of dementia and disability, methodological limitations restrict comparability between studies 
and our ability to estimate the true impact and spread of FTLD associated syndromes.  There is a 
clear need for further epidemiological studies of FTLD associated syndromes that takes account 
of the revised criteria, uses a standardised population and takes an inclusive and transdiagnostic 
approach to the syndromes associated with FTLD that takes account of intermediate and 
transitional syndromes.   
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I devised and conducted a new study of FTLD associated syndromes entitled PiPPIN 
(Pick’s disease and Progressive supranuclear palsy Prevalence and INcidence).  Over two years I 
aimed to collect a representative cohort of patients with FTLD associated syndromes and in view 
of the limitations of previous epidemiological studies of individual syndromes associated with 
FTLD I aimed to simultaneously address these firstly by considering all major FTLD associated 
syndromes together and without particular age restrictions and secondly by using the recently 
revised diagnostic criteria with additional consideration of intermediate clinical syndromes.   
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2.5 Methods 
2.5.1 Ethical Approval and Consent 
The PiPPIN study was approved by the Cambridge 2 Research Ethics Committee.  Referring local 
services were required to record consent for case notification, and those patients who 
underwent assessment within the study (including notes review) provided additional written 
informed consent. Where patients lack capacity to consent, I gauged their willingness to 
consider research participation at a level compatible with their cognitive abilities, but also 
consulted an appropriate nominated person.  This consultee is usually the spouse, but may 
include a holder of Lasting Power of Attorney, IMCA, an appropriate next of kin or nominated 
consultee as outlined in the Mental Capacity Act (2005).  
2.5.2 Study Population 
The catchment area included the counties of Cambridgeshire and Norfolk in the East of England.  
I used geographic boundaries as defined by the Office for National Statistics (ONS) which is 
freely available online.  Boundaries used were as per 2011 census boundaries(115).  The 
counties contain three cities, Cambridge, Peterborough and Norwich, two of which contain 
tertiary referral centres (Addenbrooke’s hospital in Cambridge and the Norfolk and Norwich 
University Hospital in Norwich).  Peterborough has a large secondary care Hospital, and two 
other medium sized district general hospitals (the Queen Elizabeth Hospital and James Paget 
University Hospital) are situated in Norfolk.  Additional smaller healthcare units are situated in 
the area and several mental health trusts, residential and nursing care homes. 
Demographic data for both counties are available from the ONS.  The 2013 UK Office for 
National Statistics mid-year estimates(115) were used as the denominator for estimates of 
prevalence, incidence and mortality.   The combined population of the catchment area was 1.69 
million.  This area is further subdivided into 13 local authority districts with populations of 
85,398-188,373(115).   
2.5.3 Definition of Disease Under Study 
The disease entity under study was FTLD associated syndromes.  Specifically bvFTD, PSP, CBS, 
PPA.  These were as defined by the contemporary diagnostic criteria for bvFTD(10), PPA 
syndromes(11), PSP(13) and CBS(12), noting that the PSP criteria changed soon after PiPPIN.  
In order to be inclusive of all cases within the spectrum of FTLD-associated disorders, 
special consideration is required when applying the criteria to cases that lie at a boundary 
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between two categories, or who present with an overlap of clinical features.  For example, a 
hypothetical patient may present with an atypical semantic variant of PPA, with their principal 
complaint being the language disorder, and typical in respect of the language examination but 
with predominant behavioural disturbance under observation. Such a patient may lie outside of 
the svPPA criteria(11) but also not meet bvFTD criteria in view of the level of semantic deficits 
and absence of other bvFTD features. Excluding such a patient would underestimate prevalence 
of the aggregated FTLD-associated syndromes.   
Conversely, another patient might meet criteria for CBS-NAV(12) but also nfvPPA(11). 
Such a patient should clearly only be counted once when estimating the aggregated 
epidemiology of FTLD-associated syndromes, even if they might be counted twice in separate 
studies of PPA and CBS.  I did not consider exclusion criteria for one particular syndrome 
absolute where they would be considered inclusion criteria for another FTLD associated 
syndrome.  For example behavioural disturbance did not automatically result in an otherwise 
typical case of svPPA being excluded.  However exclusion criteria that do not form inclusion 
criteria for other FTLD associated syndromes (for example biomarkers strongly predictive of 
Alzheimer’s disease) remained as exclusion criteria for this study.  Where I refer to individual 
syndromes within the spectrum of FTLD I refer to the dominant clinical syndrome at the time of 
assessment.  Where there was diagnostic ambiguity a second clinician (my supervisor Professor 
Rowe) reviewed the case and a consensus was reached, based on the major syndromic features 
and with the principle that each subject counts only once.    
2.5.4 Prevalent Cases 
In line with most previous studies I defined prevalence as point prevalence such that a prevalent 
case was defined as: A subject alive and resident within the catchment area on 1st January 2014 
with a diagnosis of neurodegenerative disease and with a FTLD associated syndrome. 
The date 1st January 2014 was used as it was the midpoint of the two years that the study 
ran for.  Place of residence was defined as the subject’s home address.  Postcodes were checked 
against the ONS boundary data to ensure that the subject was resident within the catchment 
area. 
2.5.5. Incident Cases 
Incident cases were defined as those subjects with an FTLD associated syndromes who were 
diagnosed with a neurodegenerative disease between 1st 2013 and December 31st 2014.  In 
order to maximise case referral I encouraged clinicians to refer cases who did not have a formal 
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diagnosis of an FTLD associated syndrome (but where it was a considered a possibility). The 
date of diagnosis was defined as that date at which a neurodegenerative disorder was first 
considered as a likely cause of the patient’s symptoms by a clinician experienced in their 
diagnosis (this was a Neurologist, Psychiatrist, Geriatrician or Registrar working within these 
specialities).  I also recorded the date at which a specific FTLD-associated diagnosis was first 
considered and the date which the earliest symptom of dementia was noted by the patient or 
carers.  From these I was able to calculate age at onset, diagnosis and FTLD-associated diagnosis.   
2.5.6 Methods for Case Identification 
I sought to identify all prevalent and incident cases between January 1st 2013 and December 31st 
2014.  A major source of recruitment were specialist regional services for FTLD associated 
syndromes and the regional memory clinic namely: 
1. The Cambridge Memory Clinic. This is a specialist clinic for disorders of memory, 
cognition and dementia.  Held weekly in Addenbrooke’s Hospital in Cambridge.   
2. The Cambridge Early Dementia Clinic.  Despite its name this is a clinic set up primarily 
for the diagnosis, treatment and follow up of atypical dementia occurring in all age 
groups but with a particular focus on FTD.  It is the only specialist clinic of it’s kind in 
East Anglia.  Approximately two clinics are held each month at Addenbrooke’s hospital in 
Cambridge. 
3. The Cambridge Disorders of Movement and Cognition Clinic.  This is a specialist clinic 
for the diagnosis, treatment and follow up of neurodegenerative movement disorders, 
particularly PSP and CBS.  Approximately two clinics are held each month at 
Addenbrooke’s hospital in Cambridge. 
All three clinics receive referrals from primary, secondary and tertiary care services for 
dementia, Parkinson’s disease and related disorders, MND, adult neurology, medicine for the 
elderly, adult- and old-age psychiatry; memory clinics; and regional community based specialist 
nurses for Parkinson’s disease, Young Onset Dementia and Dementia.  These potential referral 
sources were additionally contacted in person, letter and email before and during the study.  
Case notification was encouraged even for cases who were not referred to the specialist clinics.   
All three clinics routinely ask for consent to collect and store patient details for research 
purposes.  They have detailed databases of patients seen over many years for either clinical or 
research purposes (including prior epidemiological estimates of FTD and young onset 
dementia(76)). To identify people who were alive but no longer under regular follow-up I 
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searched these databases for all cases with a relevant diagnosis seen between 2003 and 2013.  I 
then confirmed survival and residence in the catchment area by clinical records.  
I also accepted direct referrals from clinical research networks including the National 
Institute for Health Research Clinical Research Network Dementias and Neurodegeneration 
Speciality and the West Anglia Clinical Research Network. I also assessed patients notified by 
self-referral. 
To raise and maintain awareness of PiPPIN and promote case notification of patients 
with a diagnosed or suspected FTLD associated syndrome, I made frequent presentations to 
relevant national and regional conferences, meetings, research groups, support groups and 
charities. It was emphasised that travel to Cambridge was not a prerequisite to inclusion in the 
study, nor was participation in more in depth research.  
To encourage self referral I placed adverts in local newspapers for the PiPPIN study, was 
interviewed for a national newspaper (that placed a link to the PiPPIN study on its website) and 
sent letters of invitation to all members of the local and national charities (including the UK FTD 
support group and the PSP Association) resident within the PiPPIN area. 
After the two-year recruitment period I continued to recruit for a further four month 
period (until 31st April 2015) to allow for late case notification of patients who were alive and 
had a relevant diagnosis between 1st 2013 and December 31st 2014.  The definitions of prevalent 
and incident cases still applied. 
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2.5.7 Case confirmation 
For all patients who were willing to be reviewed by the PiPPIN study team applied the revised 
diagnostic criteria, based on clinical interview, physical examination and review of relevant tests 
including brain imaging.  I personally reviewed the majority of cases, those who were not seen 
by me were seen by Professor Rowe.  These assessments included: 
(i) Semi-structured interview of subject and carer for clinical history and demographic data.  
(ii) Structured patient and carer assessment of relevant symptoms and severity.  
(iii) Structured assessment of speech, language and cognition;  
(iv) Neurological examination  
(v) Results of investigations during clinical diagnosis were accessed from the patient’s medical 
records including neuropsychological assessments, neuroimaging and genetic testing.   
(vi) Genetic screening for 17 known genetic causes of FTLD and non-FTLD dementia(116). 
(vii) MRI of the brain 
(viii) Detailed multimodal assessment of decision making and behaviour  
I did not expect that all participants could complete all steps.  I took a pragmatic approach 
and where physical or cognitive disability limited the assessment possible I took a pragmatic 
approach restricting assessments to those the participant could reasonably undertake and 
prioritising diagnostic validation.  For cases that were unable or unwilling to be assessed in 
person I accessed existing medical records. 
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2.5.8 Epidemiological Estimates 
Incidence per 100,000 person-years was calculated using the formula: 𝑖𝑎𝑃 100,000 
Where i=number of incident cases, P=total population under study, a =number of years cases 
identified over (for the PiPPIN study a=2.0). 
  Crude prevalence per 100,000 persons was calculated using the formula: 𝑝𝑃 100,000 
Where p= number of prevalent cases, P=total population 
To identify any regional differences in case identification, I also calculated crude 
prevalence rates for each local authority.   
To allow comparison with other studies I also calculated standardised rates were 
calculated using the Revised European Standard Population 2013 (ESP2013).  This is a 
hypothetical population that assumes equal age structure between sexes.  It was recently revised 
to account for changes in the age structure of European member states since the 1970s.   
 
 
Age Population Age Population 
<1 1,000 50-54 7,000 
01-04 4,000 55-59 6,500 
05-09 5,500 60-64 6,000 
10-14 5,500 65-69 5,500 
15-19 5,500 70-74 5,000 
20-24 6,000 75-79 4,000 
25-29 6,000 80-84 2,500 
30-34 6,500 85-89 1,500 
35-39 7,000 90-94 800 
40-44 7,000 95+ 200 
45-49 7,000     
    Total 100,000 
 
Table 2.3 The 2013 European Standard Population  
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Standardisation is performed using the following formula ∑𝑎𝑖𝐴𝑖∑𝐴𝑖  
Where ai=observed frequency of cases (prevalence, incidence or mortality) within age/sex range 
I, and Ai=standard population in age/sex group i. 
Confidence intervals for standardisation were generated using the formula: 
1.96 ± 𝑟√Σ𝑛𝑖  
Where r=standardised rate and ni=number of observed cases in age/sex group i. 
2.5.9 Lifetime Risk 
While prevalence and incidence figures, expressed per 100,000 persons or person-years are 
useful for comparison between groups and diseases, it can be difficult to appreciate how they 
relate to an individual’s risk or a real world perspective.  Because of this alternative calculations 
are commonly used in literature especially that aimed at the general public or which seeks to 
raise awareness or the profile of a particular disease group.  A commonly used figure is lifetime 
risk the probability of an individual developing a disease or condition during their life, adjusted 
for the risk of dying from other causes first.  This has been used effectively in cancer(117), 
dementia(118) and MND(119).   
I calculated age- and sex-standardised lifetime risk using the current probability 
method(120,121). Note that unlike population estimates ONS mortality rates are reported in 
ten-year age bands (with the exception of the oldest age band and the 0-5 year youngest age 
band) so I combined adjacent five-year age bands from the ONS population estimates, and 
observed prevalence and death rates from my data to form corresponding ten year age bands.  
First, for each ten year age band the number of incident cases and cases of FTLD who had died 
over the two years the study ran were divided by two to give average yearly FTLD associated 
incident and mortality cases within the catchment area.  Males and female cases were calculated 
separately before standardising to the ESP2013 to give age and sex standardised rates.  The ONS 
mortality figures for each age band were also standardised to the ESP2013.   
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Next I calculated the current probability of being diagnosed with FTLD (adjusting for the 
risk of dying of other causes) for each age band using a life table approach(122,123).  First the 
probability of dying, p(Di), is calculated for each age band, i, is calculated: 
𝑝(𝐷𝑖) = 2𝑌𝑖−1𝑀𝑖−1𝑃𝑖−12 + 𝑌𝑖−1𝑀𝑖−1𝑃𝑖−1  
Where Mi=all cause deaths in age band I; Pi=total population in age band I; Yi=years in age band i 
Then the percentage alive at each age band, Ni, is calculated: 𝑁𝑖 = 𝑁𝑖−1 − (𝑁𝑖−1. 𝑝(𝐷𝑖)) 
Where N0=100 
Next the age specific incidence Ai and person-years in the age band Bi: 
𝐴𝑖 = 𝐼𝑖𝑃𝑖 
𝐵𝑖 = 𝑌𝑖(𝑁𝑖 +𝑁𝑖+1)/2 
Where Ii=FTLD incident cases in age band i 
Allowing the current probability, Ci, to be calculated for the age band: 𝐶𝑖 = 𝐴𝑖. 𝐵𝑖 
This method assumes equally sized age bands.  Special consideration is required for the 
youngest and oldest age bands.  ONS Mortality data reports deaths in the first 5 years of life 
separately leading to a smaller age band of five years for i0.  The oldest age group, i9, begins at 85 
years and has no upper limit. 
To account for these I adjusted the formula for B0  and B9: 
𝐵0 = (5𝑁𝑜 + 10𝑁1)3  
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𝐵9 = 𝑁9(𝑀9𝑃9 ) 
The lifetime risk, R, for a diagnosis of FTLD can be calculated as a percentage: 
𝑅 =∑𝐶𝑖𝑖=9𝑖=0  
Which can be expressed as a particular risk (i.e. 1 out of every X people) by the inverse of R. 
 
2.6 Results 
Two hundred and thirty four patients were assessed: 176 from specialist clinical services, 52 
from clinical and research databases and six subjects were referred directly to the study team 
and not seen in a clinical service at the study centre.  Thirty patients were rejected after review 
(15 with non FTLD associated diagnoses, 14 out of catchment area and 1 with onset after the 
recruitment window).  The non FTLD diagnoses were; phenocopy syndrome (3), AD (2), Bipolar 
disorder (1), Obsessive Compulsive Disorder (1), Parkinson’s Disease (1), Parkinson’s Disease 
Dementia (1), Dementia with Lewy Bodies (1), Dystonia (1), Stroke (1), Multi Systems Atrophy 
(1).  The two hundred and four remaining cases of FTLD-associated syndromes were identified 
in the catchment area over the study period of which 167 (81.7%) were seen in person by the 
study team.  Clinical records of consultant neurologist or psychiatrist assessments were 
available in all of the remaining cases and detailed information sufficient to apply the diagnostic 
criteria available for 200 (90%) cases.  Two patients with PSP and two with FTD-MND had only 
limited information. 
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2.6.1 Demographics and Symptom Profile 
Table 2.4 shows the age, clinical features and years since symptom onset at assessment date. 
Dominant Clinical 
Syndrome 
All bvFTD PSP CBS nfvPPA svPPA PPA 
(Other) 
Total cases 200 42 48 48 28 23 11 
M:F 93:107 19:23 29:19 17:31 11:17 12:11 5:6 
Mean Age at assessment (SD) 69.4 
(8.7) 
63.7 
(7.9) 
72.6 
(7.8) 
70.8 
(8.5) 
70.6 
(9.8) 
66.7 
(6.7) 
72.6 
(7.8) 
Mean years from onset to 
assessment (SD) 
4.3 
(2.9) 
4.4 
(3.0) 
4.7 
(3.5) 
4.4 
(2.7) 
3.7 
 (2.5) 
4.4 
(2.7) 
4.2  
(2.3) 
Behavioural changes (%) 158 
(79) 
42 
(100.0) 
40 
(83.3) 
36 
(75.0) 
13 
(46.4) 
22 
(95.7) 
5  
(45.5) 
Apathy (%) 107 
(53.5) 
34 
(81.0) 
29 
(60.4) 
25 
(52.1) 
7  
(25.0) 
9 
(39.1) 
3  
(27.3) 
Impulsivity/Disinhibition (%) 92 
(46.0) 
37 
(88.1) 
24 
(50.0) 
14 
(29.2) 
6  
(21.4) 
10 
(43.5) 
1  
(9.1) 
Language impairment (%) 138 
(69.0) 
31 
(73.8) 
13 
(27.1) 
32 
(66.7) 
28 
(100.0) 
23 
(100.0) 
11 
(100.0) 
Impaired naming/Semantic 
knowledge (%) 
82 
(41.0) 
24 
(57.1) 
3 
(6.3) 
10 
(20.8) 
12 
(42.9) 
23 
(100.0) 
10 
(90.9) 
Agrammatism/Impaired 
comprehension of 
syntactically complex 
sentences (%) 
86 
(43.0) 
14 
(33.3) 
9 
(18.8) 
25 
(52.1) 
24 
(85.7) 
5 
(21.7) 
9  
(81.8) 
Expressive errors 
(phonological errors, apraxia 
of speech, impaired sentence 
repetition) (%) 
75 
(37.5) 
9  
(21.4) 
9 
(18.8) 
23 
(47.9) 
24 
(85.7) 
1  
(4.3) 
9  
(81.8) 
Akinesia (%) 110 
(55.0) 
27 
(64.3) 
43 
(89.6) 
30 
(62.5) 
5  
(17.9) 
3 
(13.0) 
2  
(18.2) 
Rigidity (%) 85 
(42.5) 
9  
(21.4) 
41 
(85.4) 
33 
(68.8) 
1  
(3.6) 
0  
(0.0) 
1  
(9.1) 
Dystonia (%) 58 
(29.0) 
4  
(9.5) 
28 
(58.3) 
26 
(54.2) 
0  
(0.0) 
0  
(0.0) 
0  
(0.0) 
Apraxia (%) 108 
(54.0) 
12 
(28.6) 
25 
(52.1) 
45 
(93.8) 
16 
(57.1) 
2  
(8.7) 
8  
(72.7) 
Cortical sensory loss (%) 43 
(21.5) 
1  
(2.4) 
12 
(25.0) 
27 
(56.3) 
2  
(7.1) 
0  
(0.0) 
1  
(9.1) 
Slowed vertical 
saccades/Supranuclear gaze 
paresis (%) 
76 
(38.0) 
3  
(7.1) 
47 
(97.9) 
22 
(45.8) 
2  
(7.1) 
0  
(0.0) 
2  
(18.2) 
Postural instability/falls (%) 89 
(44.5) 
7  
(16.7) 
47 
(97.9) 
32 
(66.7) 
2  
(7.1) 
0  
(0.0) 
1  
(9.1) 
Features of Motor Neuron 
Disease (%) 
9 
(4.5) 
8  
(19.0) 
0  
(0.0) 
1  
(2.1) 
0  
(0.0) 
0  
(0.0) 
0  
(0.0) 
Myoclonus (%) 44 
(22.0) 
6  
(14.3) 
4  
(8.3) 
26 
(54.2) 
5  
(17.9) 
0  
(0.0) 
3  
(27.3) 
 
Table 2.4.  Clinical features by dominant clinical syndrome at the time of detailed clinical 
assessment for 200 of 204 cases identified during the PiPPIN study.  Assignment to each 
syndrome was made on the basis of the primary aspect(s) of the disorder at presentation; 
additional features may develop overtime and are indicated at the time of PiPPIN participation 
to indicate the deficits in prevalent cases, not limited to incident cases.   
   52 
2.6.2 Prevalence  
One hundred and eighty two cases were alive on 1st January 2014 (89 men, 93 women) giving a 
crude prevalence of 10.77/100,000, The European-standardised prevalence (95% confidence 
intervals) were: men 10.93/100,000 (8.66-13.20), women 10.76/100,000 (8.57-12.95) and sex-
standardised 10.84 (9.27-12.42).   
 Figure 2.1 shows crude prevalence rates by local authority boundaries, age of diagnosis 
and syndrome.  Prevalence rates by local authority ranged from 4.09-21.7/100,000 and did not 
appear to be affected by proximity to the major urban centres (marked by asterisks) or the study 
centre. 
 The youngest case was 41 years at diagnosis.   The ESP2013 age- and sex-standardised 
prevalence for the age range 40-64 was 13.05 (10.01-16.08) and 33.20 (27.02-39.37) for those 
over 65 years.  
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Figure 2.1 The Prevalence of Frontotemporal Lobar Degeneration Associated Syndromes. 
A Shows the prevalence by local authorities within Norfolk and Cambridgeshire, *denote the two 
tertiary referral centres. Contains National Statistics and Ordinance survey Data © Crown 
copyright and database right (2013). B Shows prevalence by age band.  C Shows prevalence of 
individual syndromes by age band and D shows the distribution of syndromes amongst 
prevalent cases.  
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2.6.3 Incidence and Lifetime Risk 
Fifty-three Incident cases were identified (24 men, 29 women) over 3,381,228 person-years 
giving crude and standardised incidence rates of 1.57 and 1.61 (1.14-1.99) per 100,000 person-
years respectively.  Figure 2.2 shows the crude incidence rates by age at onset and 
neurodegenerative diagnosis across all syndromes by age group. The lifetime risk (standardised 
for age and sex) was 1-in-742. 
 
 
Figure 2.2 The Incidence of FTLD Associated Syndromes.   A. The incidence of 
Frontotemporal Lobar Degeneration associated syndromes by age of onset (black bars) and by 
age at diagnosis (white). B. The distribution of incident cases by clinical syndrome.  
2.6.4 Survival 
Dates of birth, symptom onset, neurodegenerative and FTLD-associated syndrome diagnoses 
were available for 193 (95%) cases. Missing data were substituted by the mean within 
syndrome.  Fifty-four cases (23 men, 31 women) died during the assessment period giving an 
age-adjusted all-cause mortality amongst those with FTLD of 1.57 (1.15-1.99) per 100,000 
person-years.  As of 31st April 2015, 6 further cases have died.  Figure 2.3 shows the mean length 
of symptomatic disease split by time prior to a neurodegenerative diagnosis, FTLD diagnosis and 
death for all 60 cases that have died.  
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Figure 2.3 The Survival With FTLD Associated Syndromes. Mean duration from 
the onset of symptoms to the diagnosis of a neurodegenerative disorder (dark grey); 
to the specific diagnosis of a FTLD associated syndrome (white); and to death (light 
grey) for all 60 cases who have died since the start of the PiPPIN study. Inserted 
figures indicate the mean duration of each phase for each syndrome (years). 
2.6.5 Genetic Screening 
Forty-seven subjects (23%) underwent genetic screening (5 svPPA, 11 nfvPPA, 4 PPA(Other), 17 
bvFTD, 3 CBS, 1 PSP).  Seven (14.9%) subjects carried a relevant mutation (Table 2.5). 
	
0
3
6
9
12
bvFTD PSP CBS nfvPPA svPPA All
4.7
9.15.3
4.6
2.9
4.5
0.7
0.1
0.2
0.41.8
0.2
2.51.43.52.22.23.7
Y
e
a
rs
    
Mutation Clinical 
Syndrome 
Age at 
Onset 
Age at 
Diagnosis 
Age at PiPPIN 
Assessment 
Presenting Clinical Features Additional Features at PiPPIN 
Assessment 
PGRN 
c.385_388 
delAGTC 
navPPA 55 57 60 Progressive speech disturbance, word substitutions, impaired 
repetition, phonological errors, impaired comprehension of 
complex tasks, orobuccal apraxia.  MRI: Marked left frontotemporal 
atrophy. 
Rigid fixed routine, inappropriate 
giggling, jargon aphasia with 
phonological errors 
MAPT 
c.-46G>A 
 
lvPPA  69 71 72 
 
Progressive speech difficulty, non fluent stuttering speech, 
phonological errors, length dependent impaired repetition.  
MRI: Global atrophy worst left temporo-parietally. 
Mild episodic memory, visuospatial 
deficits, mild limb dyspraxia, myoclonus 
TARDBP 
c.1147A>G 
 
bvFTD 49 56 58 
 
Insidiously progressive behavioural change, apathy, reduced 
empathy, fixed daily routine.  
MRI: Bilateral anterior temporal atrophy. 
Semantic deficits, weakness and wasting 
of leg and paraspinal muscles, EMG 
confirmation of MND  
MAPT 
c.1007A>G 
svPPA 62 63 67 
 
Isolated difficulty reading and understanding meaning of words.    
MRI: Bilateral anterior temporal atrophy worst on left. 
Behavioural changes, disinhibition, 
apathy, fixed routine and loss of empathy 
C9ORF72 
 
bvFTD 57 57 60 
 
Dysexecutive, apathetic syndrome, social withdrawal reduced 
empathy.   
MRI: global atrophy, worst frontally 
Marked apathy, mute, mobile but with 
falls, no signs of motor neuron disease. 
TREM2 
c.140G>A 
CBS-NAV 61 63 N/A* Word finding and articulatory impairments. Agrammatic non fluent 
speech, equivocal apraxia visuospatial impairment, mild 
asymmetric bradykinesia, 
MRI: biparietal atrophy, worst on right, right temporal atrophy 
*Marked behavioural disturbance, 
aggression, dyskinesia, dystonia, 
grasping behaviour, supranuclear gaze 
palsy, myoclonus. 
C9ORF72 
 
bvFTD 64 65 N/A* Prominent behavioural change, disinhibition, dysexecutive 
cognitive profile.   
MRI: Within normal limits. 
*Extrapyramidal syndrome (attributable 
to medication), falls. Normal DAT scan.  
MRI: Mild generalized atrophy  
 
Table 2.5  Clinical and imaging features of the seven subjects with an identified relevant mutation.  *These two subjects were not re assessed 
in person as part of the PiPPIN study.  The clinical features are based on their clinical records subsequent to first presentation.  PGRN-Progranulin, 
MAPT-Microtubule Associated Protein Tau, TARDBP –Transactive response DNA binding protein, C9ORF72 –Chromosome 9 Open Reading Frame 
72, TREM2-Triggering Receptor Expressed on Myeloid Cells 2.   
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2.7 Discussion 
In this chapter I combined point-prevalence with an unrestricted age-range and the 2011/2013 
revised diagnostic criteria for major FTLD-associated clinical syndromes. By not restricting 
analysis to either young-onset cases or tertiary referral centres I show that the prevalence of all 
disorders taken together is 10.84/100,000 with similar prevalence of bvFTD, PSP and CBS and 
PPA (all subtypes). The estimated lifetime risk of one of these disorders is 1-in-742.  
 Many previous epidemiological studies restricted assessment of the under 65 population 
(76,79,80,88,89,91).  My data indicate that prevalence increases beyond 65, such that the 
prevalence amongst those 65 years and older is more than double that of the 40-64 year age 
group.  While FTLD is one of the commonest causes of young onset dementia(80,92) it is more 
common in absolute terms as age increases.  Previous studies emphasising the relative 
prevalence amongst all causes of dementia in younger cohorts may have the unintended effect 
giving the impression that FTLD is a disease of middle age, reducing the index of suspicion in 
older cohorts and hence reducing rates of diagnosis in the elderly.  This may in part explain the 
decease in incidence and prevalence rates I observed in the very elderly.  Rather than a true 
decline in the incidence of FTLD in old age it may be that as other forms of dementia, such as 
Alzheimer’s and vascular disease, become more common, FTLD becomes overshadowed.  As a 
consequence it is not considered and not diagnosed.   
 To illustrate this point, one of the more elderly cases of PSP I identified in this study had 
previously been referred to our clinical services by a clinician who suspected PSP.  The patient’s 
general practitioner had subsequently written to question whether a referral was necessary as 
the patient already had an established diagnosis of Alzheimer’s dementia and it was not clear 
what another neurodegenerative diagnosis (if present) would add to their care.  The patient was 
reviewed on a research basis and had clear features of PSP-RS.  In retrospect all of the cognitive 
and speech impairments that had been attributed to Alzheimer’s disease were more typical of 
FTLD (namely a non-fluent, dysexecutive syndrome, bradyphrenia and dysarthria).   While rising 
rates of non-FTLD neurodegeneration (e.g. Alzheimer’s disease) may overshadow less common 
conditions, such as FTLD, another potential explanation for the decrease in prevalence and 
incidence rates in the very elderly is that additional pathology alters the clinical phenotype such 
that FTLD is not simply under-recognised but also not recognisable.  As rates of vascular and 
Alzheimer’s pathology increase it is possible that these change the clinical phenotype of FTLD 
when it is present such that patients with FTLD do not resemble FTLD in younger cohorts and 
do not meet current criteria.  One study showed neuropathologically defined Alzheimer’s 
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disease in a third of people over 85 years(124) half of these had clinically diagnosed Alzheimer’s 
disease which would preclude a diagnosis of FTLD by current criteria and also very likely change 
the clinical presentation and severity of FTLD pathology when it does occur.  
 Previously, many studies have been restricted to individual syndromes.   For example 
some studies of the prevalence of FTD have included behavioural and language 
variants(76,89,91) while others are restricted to just bvFTD(79,80,88).  This limits 
comparability between studies.  Also the diagnostic criteria used in these studies may have 
included non progressive ‘phenocopies’(36).  During the PiPPIN studies I identified (and 
excluded) three such cases (all men, two within the catchment area, one outside).  The discovery 
of C9ORF72 has renewed interest in phenocopies.  Both cases within the catchment area that I 
excluded were negative for C9ORF72.  One slowly progressive cases case was identified (and 
included) who at initial presentation had normal neuroimaging and would not have met current 
criteria for probable bvFTD.  They subsequently developed generalised atrophy and were found 
to carry a pathological expansion in C9ORF72.  
Epidemiological studies of PSP have mainly used case-notification to specialist centres, 
or reviewed cases of Parkinsonism. For example, Golbe et al.(97) surveyed neurologists for cases 
of suspected PSP, re-examining suspected cases. They estimated a prevalence of 0.15/100,000 
and incidence of 0.3-0.4/100,000.  In contrast, Schrag et al.(86) used a computerised search of 
terms relating to Parkinsonism and clinical re-evaluation to estimate prevalence of 6.4/100,000 
(2.3-10.6).  Nath et al.(96) used both methods to estimate prevalence of 0.3 and 5.0/100,000.  
These studies focused on the motor aspects of PSP, whereas non-motor features are common in 
PSP, suggesting that previous studies may not have identified the significant proportion of cases 
(up to 30%) who present initially with cognitive or behavioural features of PSP(111). 
There are limited data on the epidemiology of CBS.  From 534 incident cases of 
Parkinsonism, Winter et al.(108) identified one case of CBS.  Schrag et al.(86) identified no cases 
amongst a population of 121,628.  A limiting factor for studies of CBS is diagnostic uncertainty. 
Fewer than 2/3 of cases with a diagnosis of CBS have pathological features of Corticobasal 
Degeneration and vice versa(7).  This is the first epidemiological study of CBS to use the revised 
diagnostic criteria(12) which aim to improve sensitivity. I also did not restrict the cohort to 
movement disorder clinics or incident cases of Parkinsonism.  By selecting cases based on both 
motor and non-motor aspects of their illness, we were able to identify substantially more cases 
than previous studies(86,108).   
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I have estimated the prevalence for FTLD associated syndromes for each of the local 
authority areas within the catchment area for the PiPPIN study (Figure 2.1 A).   The population 
size for these areas ranges from approximately 85,000 to 190,000 with small numbers of 
individual cases in each area.  It is therefore unsurprising to see large variation in the prevalence 
estimates for these small groups.  The area with the highest prevalence (Fenland) is relatively 
small in population terms but does have a high number of nursing homes that provide specialist 
dementia care for a wider area which may explain the high number of prevalent cases resident 
there. This demonstrates the importance of a large catchment area/population of study when 
estimating the epidemiology of rarer diseases. 
 Despite improved criteria, diagnostic difficulties remain that will impact on 
epidemiological research, especially for studies that focus on one syndrome rather than the 
broader spectrum of FTLD-associated syndromes. Categorical decisions are required for 
diagnosis; however, the boundaries between FTLD-associated syndromes are not always 
distinct.  95% of the cases of svPPA identified here developed behavioural changes within a 
mean of 4.35 years from onset.  Conversely, nearly three quarters of bvFTD subsequently 
developed language impairment.  Similarly language impairments were common in CBS 
(66.7%), behavioural changes in PSP (83.3%) and motor features commonly emerged in all FTD 
subtypes.  This inclusive approach does not undermine the importance of diagnostic 
classification but emphasises the heterogeneous and progressive nature of these disorders.  
Without an inclusive approach to the FTLD spectrum, borderline or intermediate phenotypes 
reduce the precision of prevalence estimates of individual disorders. Furthermore the nosology 
and nomenclature of FTLD syndromes have changed many times(85) and will no doubt continue 
to do so.  
 Within the spectrum of FTLD, the pathological subtypes of FTLD are each associated with 
more than one clinical syndrome and vice versa. I cannot speak to the pathology of these cases 
(except in the genetic cases), and instead reference published studies of clinicopathological 
correlation(7,25,125–128).  
 Whilst I sought to identify and examine all cases where FTLD was considered, those cases 
in which it was not will have been missed.  To overcome this fundamental limitation of an 
epidemiological study of diagnosed cases, systematic neuropathology in a population cohort 
would be required.  
 In a brain bank series from a community based study of the elderly(129),  three out of 456 
post-mortem cases had evidence of PSP. All had symptoms that could be retrospectively 
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attributed to PSP but none were diagnosed during life (Brayne C. et al, Unpublished data, 2014).  
Recruitment to brain banking in this study was disproportionately weighted to those with 
symptoms of dementia so while these data can not be used to draw firm conclusions regarding 
the actual prevalence of FTLD they do suggest that the prevalence of FTLD pathology may be 
higher than that of diagnosed cases that we report here.   
 It is also inevitable that pre- or oligosymptomatic subjects who nevertheless have FTLD 
pathology will not acquire a diagnosis of FTLD until sufficient neural disruption/degeneration 
has developed to produce symptoms sufficient to establish a diagnosis.  By examining 
presymptomatic carriers of pathogenic gene mutations causing FTLD Rohrer et al.(56) showed 
that imaging and cognitive changes can be demonstrated 5-10 years before the expected onset of 
symptoms (calculated using the average age of onset within families).   How these results relate 
to sporadic cases is unclear. I would argue that truly presymptomatic cases should be 
considered differently to symptomatic disease for the purposes of epidemiological research. The 
inclusion of presymptomatic disease in epidemiological studies would inflate epidemiological 
estimates and potentially overestimate the true burden of (symptomatic) disease.  It is less clear 
how one should consider oligosymptomatic cases i.e. people who have FTLD type pathology and 
exhibit symptoms that are related to it but who do not yet have sufficient symptoms to establish 
a diagnosis.  Such people have symptomatic FTLD and associated morbidity but with current 
criteria cannot be reliably diagnosed or differentiated from other conditions.  
 FTLD presents insidiously and as such time of onset can be difficult to establish.  Current 
criteria provide a threshold of disease burden that must be reached and a surrogate for 
incident/prevalent cases but when using several sets of criteria for different clinical syndromes 
it is not necessarily the case that all patients are at the same stage of disease (in terms of life 
expectancy, disability burden, amount of neurodegeneration, or any other measure) at the point 
at which they first meet criteria.  This is illustrated by the cases who have died (Figure 2.3).  
Although accepting that the numbers of patients are small, compared to other FTLD associated 
syndromes those patients with svPPA were diagnosed with a neurodegenerative illness 
relatively soon after symptoms first emerged and quickly with an FTLD associated diagnosis 
which they then lived with for a long time before death.  Subjects with other syndromes had 
symptoms for longer before reaching a diagnosis and died sooner.  Hence it may be that a 
patient who has accrued sufficient symptomatic disease to acquire a diagnosis by current 
criteria of svPPA may not be at the same stage of their illness as another who just meets criteria 
for PSP.   
 Since undertaking the PiPPIN study a new set of criteria have been published for 
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PSP(130).  These criteria expand the range of clinical syndromes associated with PSP pathology 
and suggest (for example) subjects with predominantly oculomotor dysfunction without other 
features of PSP-RS should be included in epidemiological studies of PSP.  PAGF (PSP-PGF) and 
PSP-P are also included within these new criteria as are overlap syndromes with CBS, PPA and 
bvFTD.  These criteria have been derived from pathologically confirmed cohorts but not yet 
subjected to prospective pathological validation.  I suggest that use of these new criteria at this 
point in time would be unlikely to substantially change the results and conclusions of this work.  
Firstly because the inclusive approach to syndromes associated with FTLD and inclusion of 
intermediate cases was a key feature of the PiPPIN study.  Most of the ‘overlap’ syndromes 
included in the new PSP criteria would have been captured by the PiPPIN criteria.  Second I 
suggest that the majority of cases that would fall outside of the PiPPIN criteria (e.g. PSP-PGF or 
PSP-P) would not have been recognised as related to PSP and referred into a study of this 
nature.  As these new criteria are subject to further validation and become more widely adopted 
it may be necessary to revisit their impact on the epidemiology of PSP but how this should be 
reconciled with the negative effects on other syndromes (such as CBS, almost all of whom could 
now meet PSP criteria) is yet to be established.  The data presented here demonstrate high 
frequency of shared clinical characteristics of both motor and non motor features across all 
syndromes associated with FTLD again emphasising the importance of a transdiagnostic 
approach to clinical syndromes within this spectrum of disorders. 
 Time from onset to diagnosis and subsequent survival varied widely between syndromes.  
The time from onset to neurodegenerative, and subsequent FTLD, diagnosis for those people 
presenting with language disorders was shorter than those with predominantly motor (PSP, 
CBS) or behavioural syndromes (bvFTD). This may reflect different indices of suspicion for an 
underlying neurological condition for different presentations, or common misdiagnosis as a 
primary psychiatric disorder.  
 I confirmed all identified cases were alive and resident within the catchment area during 
the study.  By liaising with national charities and clinical services beyond the PiPPIN catchment 
area we aimed to identify any cases not have been previously known to our services that 
migrated into the area.  I did not include cases of MND without FTD but only those that also met 
FTD criteria.  Whilst some MND cases will have mild cognitive impairments, MND is a commoner 
illness with a lifetime risk of approximately 1-in-400(119).  Including those cases with milder 
cognitive impairment or screening all regional MND would overestimate the prevalence of 
symptomatic FTD syndromes. Eight (19%) of the bvFTD cases identified in this study had 
clinical features of MND.  The case of CBS with MND features is notable, possibly reflecting the 
range of pathological correlates of CBS; but I could not exclude other causes of denervation. 
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 The frequency of genetic mutations identified is similar to previous studies since the 
discovery of C9ORF72(1); however most subjects screened had predominantly non-motor 
syndromes (PPA or bvFTD).  The finding of relevant mutations in two subjects with typically 
sporadic syndromes (svPPA and CBS) further illustrates the challenges to clinical segregation of 
FTLD.   
The incidence of 1.61/100,000 person-years is similar to the mortality (1.56/100,000 
person-years). Assuming constant prevalence, mortality serves as an additional surrogate 
estimate of incidence, suggesting that the study achieved ‘steady state’ of referrals of incident 
cases.  I report standardised prevalence and incidence estimates across all ages rather than 
report peak rates in the highest risk groups to allow comparison with other studies and other 
conditions.   
 
2.8 Conclusions 
In conclusion, I have shown that the revised diagnostic criteria for FTLD associated syndromes 
can be applied jointly in a multi-source epidemiological study without restriction to young onset 
cases or single syndromes. The resulting prevalence, incidence and survival data will allow 
better generalisation of results from clinical, genetic and pathological studies of FTLD and also 
enable unbiased interventional studies with reference to the whole population of affected 
patients including sporadic cases and those over 65 years.    
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Chapter 3 
Neuropsychiatric Symptoms in FTLD 
3.1 Summary 
In this chapter I discuss neuropsychological symptoms in FTLD with a particular emphasis on 
apathy and impulsivity.  I consider the methods by which these symptoms may be assessed and 
then outline the approach taken in the PiPPIN study.   I show that a wide range of cognitive 
assessments and questionnaire based assessments of mood and motivation can be applied to a 
group of subjects with syndromes associated with FTLD.  Compared with healthy older controls, 
such individuals have significant cognitive impairment across multiple cognitive domains and 
exhibit a range of behavioural and neuropsychiatric symptoms which are often severe and a 
source of distress to their carers. Using a number of assessments I show that subjects with FTLD 
associated syndromes have higher levels of apathetic and impulsive behaviours than healthy 
older controls and that in a number of subjects apathetic and impulsive behaviours coexist. 
 
3.2 Introduction 
Neuropsychiatric symptoms such as anxiety, depression, psychosis and aggression are common 
in dementia.  While considered ‘non cognitive’ symptoms they have associations with other 
measures of cognition(131) and may reflect more rapid decline(132,133), higher treatment 
costs and poorer outcome(134–136).    
Neuropsychiatric symptoms contribute to both patient and carer distress and are 
associated with lower quality of life measures amongst patients, have a negative impact on 
interpersonal relationships(137), and are associated with increased rates carer burden, distress 
and depression(134,138–141).   Neuropsychiatric and behavioural symptoms are described 
across the entire spectrum of FTLD.  They are a defining characteristic of bvFTD and while 
prominent initial behavioural disturbance is considered an exclusion criterion for PPA(11), 
neuropsychiatric symptoms are prevalent amongst those with PPA and may evolve over the 
course of their illness(142).  Most historical emphasis has been on the motor aspects of PSP and 
CBS, but neuropsychiatric symptoms are again common and may be the dominant clinical 
feature.  For example, amongst 62 subjects with PSP Kobylecki et al (111) found that cognitive 
and behavioural features were the predominant presenting feature in 58% of cases. Other 
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studies have also demonstrated that neuropsychiatric symptoms are commonly reported in PSP 
(143–145) and CBS(146).  
   As these symptoms are common in dementia and associated with significant morbidity 
they are attractive targets for the development of symptomatic therapies.  In order to facilitate 
effective trials of future therapies there is a clear need for a better understanding of the 
underlying neuropsychological mechanisms that lead to these symptoms and how they can be 
quantifiably measured in disease states.  Two such symptoms are apathy and impulsivity, which 
are both particularly prominent across the entire spectrum of FTLD associated syndromes 
making this a particularly well-suited group in which to study them.  A variety of other 
neuropsychiatric symptoms are observed in FTLD, for example obsessive, disinhibited and 
compulsive symptoms (especially in bvFTD) and social withdrawal, depression and feelings of 
isolation.   Many of these symptoms may result from disruption of goal directed behaviour, 
response selection, motivation and suppression which may also result in apathetic or impulsive 
symptomatology.  Hence it seems likely that the mechanisms underlying apathetic and impulsive 
symptoms may also contribute to the wider range of neuropsychiatric symptoms in FTLD.   
In the following sections I discuss the neuropsychiatric symptoms in the syndromes 
associated with FTLD with a particular emphasis on apathy and impulsivity and then outline the 
methods and results of a neuropsychological battery of assessments used to assess them 
amongst the PiPPIN cohort of subjects with FTLD associated syndromes.  
3.2.1 Apathy  
Apathy is a commonly reported neuropsychiatric symptom in neurodegenerative disease(147) 
particularly FTLD where it is highly disabling(141,148–151); a major cause of carer 
distress(152); and a diagnostic criterion(10,45,82,153,154).  Previous studies have linked 
higher rates of apathy with more severe disease, poorer prognosis and more rapid decline in 
Alzheimer’s disease(132,133) and negative implications for treatment and long term outcome in 
Parkinson’s disease(135,136) and the wider spectrum of dementia(147).  However, most studies 
linking apathy to disease outcomes or patient/carer morbidity (e.g. (133)) have relied on simple 
questionnaire based screening tests of apathetic symptoms often using a carer or spouse as an 
informant and have not considered the multidimensional aspects of apathy as both a clinical and 
a neurocognitive syndrome(155–157).  
Despite its importance, apathy is poorly understood.  Authors vary in whether they 
define apathy as a cognitive syndrome e.g. ‘a lack of motivation not attributable to diminished 
level of consciousness, cognitive impairment or emotional distress’ (158), or the resultant 
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behavioural syndrome e.g. ‘the reduction of self-generated voluntary and purposeful behaviours’ 
(17).  Whilst the latter is a useful observable and quantifiable definition it needs to be further 
qualified to take into account additional factors that may reduce goal directed behaviour.  If, for 
example, it is more difficult or painful to move a limb it requires greater motivation to move it.  
Simply measuring goal directed behaviour is therefore insufficient to measure apathy.  Observed 
reduction in goal directed behaviour is multifactorial, it relies upon how one acts, interacts, feels, 
appears or is motivated.  Similarly apathy as a cognitive syndrome must be a multifactorial 
construct relying upon motivation (which in turn relies on both perception of reward and 
responsiveness to it), decision making, ability to generate goal directed behaviour etc.  Also 
other physical, cognitive and emotional factors may result in decreased goal directed behaviour 
and an ‘apathetic’ syndrome.  For example, depression, characterised by persistent low mood, 
may coexist with apathetic symptoms and contribute to them.  However while persistent low 
mood may be sufficient to produce an apathetic syndrome is not necessary and the two 
cognitive constructs can be dissociated amongst groups of patients with neurodegenerative 
disease(159).  Levy et al(160) showed patients with FTD and PSP could be discriminated from 
patients with Alzheimer’s Dementia by their more severe apathy and relatively less depression.   
On the basis of previous behavioural and imaging studies in disease and animal lesional 
models, Levy et al(17) attempt to divide apathy into three subtypes of disrupted processing: 
disruption of emotional affective, cognitive and autoactivation processing.  They related these to 
distinct anatomical correlates in the prefrontal cortex-basal ganglia circuits.  Similarly, drawing 
from a range of studies in disease states Heron et al(161) relate deficits in self initiated goal 
directed behaviour to dysfunction of the anterior cingulate cortex and ventral striatum 
(including the nucleus accumbens) and connected structures (including the orbitofrontal cortex, 
ventral pallidum and ventral tegmental area).  Referencing studies of Parkinson’s, FTLD, AD, 
stroke, Huntington’s and traumatic brain injury they summarise that evidence that disruption of 
white matter tracts, cortical volume loss and metabolism in these areas has been consistently 
linked to apathetic symptoms.   They propose apathy should be considered a deficit in cost-
benefit evaluation when choosing whether to pursue a behaviour, persist with a behaviour and 
evaluating and learning the costs and benefits of acting.   
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Figure 3.1 A model of Goal Directed Behaviour. Adapted from Levy and Dubois (2006)(17). 
Figure 3.1 shows a model of organisation of goal directed behaviour.  Disruption at any 
stage of this may result in decreased goal directed behaviour and an apathetic syndrome.   While 
Figure 3.2 shows how dysfunction in a range of brain areas may result in reduced goal directed 
cognition and behaviour.  Both are adapted from Levy and Dubois’s paper(17) outlining a 
proposed model of apathy resulting from disruption of the functional anatomy of prefrontal-
basal ganglia circuits.  They propose three subtypes of apathetic syndrome resulting from 
disruption of emotional affective processing, cognitive processing and auto-activation 
processing.  From the results of lesional and functional imaging studies in humans and lesional 
and electrophysiological studies in animals, they relate each cognitive sub-syndrome to 
disruption of prefrontal cortex-basal ganglia circuits.  These are summarised in Figure 3.2 (in 
blue).  In red additional elements of neurodegenerative disease (disorders of language, 
emotional distress/depression, and disruption of motor circuits) are also shown as these may 
also produce an apathetic syndrome even in the absence of decreased goal directed cognition.  
Finally carer distress as a consequence of any of these aspects of neurodegeneration or 
misinterpretation of behaviour and disability may also lead to identification/reporting of an 
apathetic syndrome even when ‘true’ apathy is not present or prominent.  
Evaluation 
Comparitor: 
Match/Mismatch 
Detector 
Intention: Desired 
Outcome/Motivation 
Goal Selection 
Planning 
Intiation and Execution 
Action 
Outcome 
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Figure 3.2. Disruption of the Functional Anatomy of the Prefontal Cotex-Basal Ganglia 
Circuits leading to Apathetic Syndromes.   The top row of boxes show brain areas where 
dysfunction may lead to reduced goal directed cognition (in blue) and apathy (adapted from 
Levy and Dubois 2006(17)) while disruption of other brain areas (in red) may also lead to a 
similar ‘apathetic’ syndrome without reduced goal directed cognition.  In addition carer (as 
opposed to subject factors) may also influence reports of an apathetic syndrome.  
PFC=Prefrontal Cortex, CN=Caudate Nucleus, GPi=Globus Pallidus Internus, SNpr=Substantia 
Nigra pars reticulata, Pv=Parvocellular, MD=Medial Dosal, Ant.=Anterior, WM=White Matter. 
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3.2.2 Impulsivity 
Impulsivity, the tendency to act prematurely, at risk or without foresight(162), is a common 
behavioural feature of  many forms of dementia and is frequently present in frontotemporal 
lobar degeneration (10).   In contrast to apathy where goal directed behaviour is diminished, 
impulsivity may be associated with an increase in such activity.   
   In Parkinson’s Disease (PD) for example, impulse control disorders such as pathological 
gambling, hypersexuality or hoarding are frequently observed and often associated with 
dopaminergic therapy, particularly dopamine agonists(163).  Apathy is also commonly observed 
in PD but with the caveat that decreased motor function and disability (particularly at lower 
dopamine states where motor disturbance is worst) may lead to diminished goal directed 
behaviour regardless of states of goal directed cognition.  It has been proposed that apathy and 
impulsivity may exist as opposite extremes of a single dimensional spectrum where 
hyperdopaminergic states within cortico-striatal circuits result in impulsivity and 
hypodopaminergic states within the same circuit lead to apathy(164).   
There are several arguments against this unidimensional model.  Firstly both apathy and 
impulsivity are multidimensional constructs (17,162,165) including when observed in the 
context of PD(166,167).   There is strong evidence that there exist dissociable neural 
components of impulsivity(162,164).  For example, lesions of the subthalamic nucleus in rats 
impair cancellation of planned responses without affecting premature responding in the waiting 
task whereas lesions in the core of the nucleus accumbens cause the opposite pattern (168).  In 
humans, analysis of self-reported questionnaires (such as the Barrett Impulsiveness Scale) 
designed to assess long term personality traits relative to impulsivity reveals several potentially 
dissociable aspects of personality that may produce impulsiveness(169).   Second impulsive and 
compulsive behaviour can be observed in treatment naïve patients with PD (albeit at similar 
rates to those observed in healthy controls) (170).  Thirdly impulsive and apathetic syndromes 
have been observed to coexist within the same patients with PD(171).  Finally both apathetic 
and impulsive behaviour may be attributed to reduced goal directed cognition.  Impulsive 
behaviour may be defined by either by a reduction in foresight (planning) or by reduced ‘top-
down’ inhibitory control(162) hence impulsive behaviour in the context of neurodegeneration is 
attributable to a reduction in the cognitive processes related to goal directed behaviour.  Apathy 
may lead to diminished planning of behaviour or reduced responsiveness to negative outcomes 
and lead to impulsive behaviour.  Put simply, reckless or impulsive behaviour is more likely if a 
subject is not motivated to plan out their actions or does not care about the consequences. 
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3.2.3  Apathy and Impulsivity in FTLD 
Both apathy and impulsivity are common in FTLD.  They are defining characteristics of 
bvFTD(10),  supportive criteria for the diagnosis of PSP(128),  and included amongst the 
behavioural changes used to diagnose CBS-FBS(12).  Prominent behavioural features are 
considered exclusion criteria for the diagnosis of PPA however they can be seen as early features 
particularly in nfv-PPA and sv-PPA but should not be the dominant clinical features or main 
source of functional impairment(11).  Comparison between informant reported apathy on the 
Neuropsychiatric Inventory (NPI) between subjects diagnosed with FTD (PPA and bvFTD) and 
Alzheimer’s Disease (AD) showed more frequent apathetic and impulsive symptoms in 
FTD(172).  Interestingly while the same study found similar profiles of apathetic symptoms in 
FTD and AD, concurrent dysphoria and apathy was unique to the AD group and the two domains 
were negatively correlated in FTD(172).  This suggests either different mechanisms underlying 
apathetic syndromes in AD and FTD (where depression may have a contributory role in AD 
associated apathetic syndromes) or that perception and processing of negative emotional states 
are also impaired in FTD (so that a neurally mediated depressive state is exhibited as an 
apathetic syndrome without the associated dysphoria). 
 Zamboni et al (15) used Voxel Based Morphometry (VBM) to assess structural MRI 
changes in grey matter associated with informant reported apathy and disinhibition via 
subscales of the Frontal Systems Behaviour Scale amongst 62 patients with FTD.  Apathetic 
profiles were associated with reduced grey matter in the dorsolateral prefrontal cortex, lateral 
orbitofrontal cortex, medial prefrontal cortex, striatum and temporoparietal junction.  
Disinhibited profiles were associated with decreased grey matter in limbic and lateral temporal 
lobes and the nucleus accumbens.  In another study(173) disinhibition on the NPI was 
associated with atrophy in the left temporal pole and bilateral orbitofrontal cortex. 
 An association between the orbitofrontal cortex and disinhibition has also been proposed 
using FDG-PET imaging. Amongst 41 patients with bvFTD higher levels of disinhibition on the 
NPI subscale correlated with orbitofrontal hypometabolism.  While no significant correlates of 
the apathy subscale were demonstrated, a subgroup of bvFTD with higher scores on the 
Neuropsychiatric Inventory (NPI) apathy subscale also had specific hypometabolism in the 
orbitofrontal cortex compared with healthy controls (which was not seen in the bvFTD groups 
without high apathy subscores)(174). 
Fractional anisotropy has been used to demonstrate a relationship in FTD between 
disrupted white matter in the right superior longitudinal fasiculus and disinhibintion (measured 
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by the Frontal Behavioural Inventory)(175),  the temporal portion of the left uncinate fasiculus 
and apathy scores (on the NPI)(176),  the right corona radiata and disinhibition (on the 
NPI)(176).   
Taken together these studies suggest that both apathy and impulsivity are frequently 
observed in FTLD and can be related to anatomical changes within the brain.  However in the 
majority of cases a single measure of apathy has been relied upon, usually carer based 
information and views apathy and impulsivity as single unitary constructs which is in sharp 
contrast to neuropsychological models of apathy and impulsivity(17,165).   
3.2.4 Measuring Apathy and Impulsivity 
Measuring apathy and impulsivity has been attempted using a number of different 
methodologies. A range of structured questionnaires have been devised for the assessment of 
apathy(177).  Amongst the most commonly used and best validated is the Apathy Evaluation 
Scale (AES)(158).  Respondents are asked to rate the subject’s based on the patient’s thoughts 
feelings and activity in the past four weeks with respect to 18 items (e.g. item 4: He/She is 
interested in having new experiences) on a Likert type scale (Not at all, slightly, somewhat, a lot) 
each scoring 1 to 4 points such that the answers indicating greater levels of apathetic behaviour 
score more highly.  Three versions are available presenting the same 18 items to either the 
subject/patient (AES-S), an informant/carer (AES-I) or via a clinical evaluation (AES-C) which 
uses the items in the AES-S as a basis for a structured interview where the patient’s responses 
are combined with the level of detail and elaboration they are able to provide and clinical 
observation during the interview.  In a previous study of 99 patients with Parkinson’s disease 
the mean AES-C was 29.37 (SD 13.99) factor analysis suggested a 2 factor solution(171) termed “cognitive behavioural” and “social indifference”.  Another study of 45 patients with Parkinson’s 
disease found a mean AES-C of 34.9 (11.3) compared with a mean of 23.3 (3.8) in 17 older adults 
with osteoarthritis (136).  Marin’s original paper(158) reports mean AES scores of amongst 
healthy older controls and amongst subjects with probable Alzheimer’s disease. Using Principal 
Components Factor Analysis they propose a three-factor solution accounting for 50-65% of the 
variance supporting their view that apathy is a multidimensional construct. 
Similarly a range of questionnaires designed to assess impulsivity (such as a the Barratt 
Impulsiveness Scale(169), Behavioural Inhibition System/Behavioural Approach System 
(BIS/BAS) scale(178)), anhedonia (the Snaith Hamilton Anhedonia Pleasure Scale, SHAPS(179)), 
depression (the Beck Depression Inventory, BDI-II (180), and sleep/arousal (Parkinson’s 
Disease Sleep Scale, PDSS (181)). These rely on the perspective of the patient as opposed to 
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clinician or informant assessment per se.   The Barrett Impulsiveness Scale (BIS-11) is one of the 
most widely cited instruments for the assessment of impulsive behaviour(182).  It consists of 30 
items where subjects are asked to grade their thoughts and actions on a four point scale (from 
rarely/never to almost always/always) their answers are scored out 120 of so that higher scores 
reflect more impulsive thoughts/behaviour.  Previous Principal Component Analysis on a 
sample of 248 psychiatric inpatients and 412 university students revealed and 6 oblique first 
order factors and three second order factors (169).  The BIS/BAS scales are split into the BIS 
scale, which is designed to measure sensitivity to anxiety provoking stimuli, and the BAS scales, 
which are designed to measure responsiveness to cues of reward.  The concept of the two 
behavioural systems is based on the theory that two dimensions of personality contribute to 
impulsive behaviour.  The Behavioural Inhibition System (BIS) is proposed as the system that 
controls the experience of anxiety and, in response to anxiety related cues, inhibits behaviour 
that may lead to negative consequences.  In contrast the Behavioural Approach, or Activation, 
System (BAS) is sensitive to signals of reward or escape from punishment and is believed to 
control appetitive motivation (178).  As such it is suggested that under activation of the 
behavioural inhibition system or over activation of the behavioural inhibition system may lead 
to impulsive behaviour.  Some work has been done to relate both systems to distinct neural 
systems.  For example, monoaminergic afferents from the brainstem to the frontal lobe are 
thought to be related to the behavioural inhibition system while dopaminergic pathways have 
been related to the behavioural activation systems (178). 
In dementia, informant (rather than subject) based reports are often used to assess 
apathy and impulsivity, where by the informant (usually the patient’s spouse or main carer) is 
asked about the presence and severity of particular symptoms.  The Neuropsychiatric Inventory 
(NPI) is an example of this approach and features a range of neuropsychiatric symptoms 
(including apathy and impulsivity) and asks the informant to report whether they are present or 
not and to grade their severity.   The Cambridge Behavioural Inventory -Revised (CBI-R) is 
similar except that it enquires about particular behavioural changes (such as making tactless or 
suggestive remarks) and asks the informant to grade the frequency (rather than a severity).   
Hence the CBI-R enquires about the results of neuropsychological and cognitive changes 
(including apathy and impulsivity) rather than explicitly about each individual symptom as in 
the NPI.  While the NPI asks informants to make a judgement regarding severity, the CBI-R uses 
frequency, which while more clearly operationalised, may not always be an appropriate 
surrogate.  Both the NPI and the CBI-R enquire about a wide range of symptoms in contrast the 
AES-I is an informant version of the Apathy Evaluation Scale and is designed to enquire with 
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specific regard to symptoms of apathy.   The AES, NPI and CBI have all been extensively used in 
the evaluation of neuropsychiatric features of dementia including FTLD (183–185). 
Questionnaire based assessments have many advantages - they are simple to administer 
and can relate to real world experience. However, they rely on the subject (or informant) to 
understand the questions posed and then be able to reflect on their experience and report 
accurately.  Even despite clear and specific instructions a respondent may well take other 
aspects of their situation into account.  For example when answering questions relating to the 
social interactivity of a subject with dysphasia a respondent is likely to take language 
impairments into account when responding, even if such a questionnaire is designed to assess 
social interest. In addition a patient’s insight into their condition, or a carer’s own conceptions or 
psychological state are likely to influence the accuracy of responses.  Even if accurate reporting 
is assumed questionnaires are limited in their ability to dissociate individual neuropsychological 
constructs.  For example, disruption to several neural systems may lead to reduced spontaneity 
in day to day behaviour (a feature of apathy) but a purely questionnaire based assessment may 
not be able to dissociate such underlying neural mechanisms. Finally, questionnaires often use a 
Likert scale and provide a quantifiable score this does not necessarily imply that all items within 
a questionnaire are truly of equal importance or that the final total score accurately reflects the 
severity of the underlying disease process either in terms of degree of neural damage or in 
relation to patient and carer morbidity.   
To overcome some of these issues one could consider objective performance on 
behavioural or cognitive tasks.  These may be administered via a range of methods including 
paper and pencil tasks (such as the Kirby delayed discounting task where subjects select options 
from a range of choices) or more automated computerised tasks.  Computerised tests of reaction 
time and decision making have been used to investigate neuropsychological processes in healthy 
individuals(186) and those with brain disease such as FTD(187).  The Cambridge 
Neuropsychological Test Automated Battery (CANTAB, © Cambridge Cognition Ltd) is an 
example of a battery of computerised tests where subjects interact with a computer via touch 
screen, button boxes or joysticks to interact with a customised battery of cognitive tests.  The 
computer software allows the examiner to vary test parameters and can vary a range of test 
parameters (for example the time and manner of cue presentation, presentation of feedback or 
amount of reward) and in doing so calculate a range of outcome variables.   
This approach has been used successfully to investigate goal directed behaviour 
including impulsivity using the stop-signal and Go/NoGo tests.  The Go/NoGo paradigm consists 
of a series of ‘Go’ or ‘NoGo’ cues presented at the same time as arrow pointing left or right.  
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Subjects are instructed to make speeded motor responses depending on the direction of the 
arrow on ‘Go’ trials but withhold responses on ‘NoGo’ trials.  Responses are rendered prepotent 
by including more ‘Go’ than ‘NoGo’ trials.  By recording the number of inappropriate responses 
on ‘NoGo’ trials a measure of motor impulsivity can be obtained(165).  By replacing the initial 
Go/NoGo cue with a ‘stop signal’, such as a beep, shortly after the directional stimulus the task 
become one of cancelling an already selected response rather than selecting or withholding a 
response at the outset.  By varying the time between the initial cue and the stop signal it is 
possible to obtain a measure of the ‘Stop Signal Reaction Time (SSRT)’ i.e. the time taken by the 
brain to suppress prepotent motor signals (165).  There appear to be overlapping but different 
neural correlates of the No/NoGo task and the SSRT task.  Functional imaging studies have 
defined a ‘stop circuit’ including the right inferior frontal gyrus, anterior cingulate cortex 
presupplementary and motor cortex and basal ganglia (188).  The Go/NoGo task activates the 
left frontal cortex more consistently than the SSRT (189).  Pharmacological manipulation of 
serotonergic neurotransmission affects performance on the No/NoGo task but not the 
SSRT(168). 
Performance on the Go/NoGo and SSRT tasks is impaired amongst patients with impulse 
control disorders including ADHD.  Subjects with ADHD also tend to choose immediate smaller 
rewards over larger delayed reward (intolerance to delay of gratification as measured by 
delayed discounting paradigms).  Despite impulsive behaviour on the SSRT tasks and delayed 
discounting tasks being highly sensitive to ADHD (identifying 90% of patients) performance on 
the two paradigms do not correlate with each other (190,191). 
This behavioural testing approach has significant advantages over questionnaire or 
interview based methods as it is not asking the subject or informant to explicitly report their 
own perceptions of symptoms or behaviour.  As such behavioural testing is not limited by the 
accuracy of reporting but is limited by its applicability to clinical practice.  For example, apathy 
is known to be a frequent symptom in dementia because it is frequently reported.  When 
reported it is associated with significant morbidity (192).  Whether diminished goal directed 
behaviour measured on a computerised test of reaction times and the influence of various 
rewards relates directly to the apathetic symptoms being reported by patients and their carers 
is less clear.  Accepting that apathy is a multidimensional construct (and reports of apathetic 
syndromes even more complex) it seems unlikely that a single behavioural test used in isolation 
would be sufficient to explore a particular neuropsychiatric symptom or syndrome.  In addition 
particular groups of individuals may have difficulties with some methodologies that are 
independent of their neurodegenerative disease or cognitive impairments.  For example more 
elderly cohorts may be less used to computers affecting performance on computerised testing 
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paradigms, non native English speaking subjects or subjects with dyslexia may have more 
difficulty with questionnaire/language based assessments.  
3.2.5 Measuring Apathy and Impulsivity in FTLD: The PiPPIN Study  
The syndromes associated with FTLD are well suited to studying apathetic and impulsive 
syndromes because they are particularly prominent (although not completely universal) 
features amongst patients with FTLD.   
I hypothesised that apathetic and impulsive states within the syndromes associated with 
FTLD are due to dissociable neural and psychological mechanisms and that different apathetic 
and impulsive states may in some instances coexist and correlate with each other.  Rather than 
choose one particular syndrome (e.g. PSP) within the spectrum of FTLD-associated disorders, I 
have taken a more inclusive, transdiagnostic approach.   
This has several advantages:  Firstly, apathy and impulsivity are common to all of the 
syndromes offering the possibility of identifying common underlying constructs of 
apathy/impulsivity.   Secondly, using an alternative approach to these conditions focusing on 
particular behavioural syndromes may offer a novel method for patient stratification and 
classification, which is particularly needed in this patient group where clinico-pathologicial 
correlation is challenging.  Thirdly, using a syndromically heterogeneous patient group allows 
testing procedures to be incorporated that would otherwise be impossible in certain groups 
because of their physical or cognitive disabilities. 
Testing this hypothesis requires a method of identifying and measuring dissociable 
apathetic and impulsive behaviours.  Previous studies have used questionnaires e.g. 
(133,135,136,144,158,193,194) whilst others have relied on carer observation/reports.   
Questionnaire based assessments have several advantages.  Firstly they allow a structured and 
reproducible interview and assessment.  They can be used to produce a quantitative score (such 
as the AES) based on the subject’s qualitative reports of their symptoms.  Perhaps most 
importantly they aim to address how the patient actually feels as opposed to measuring a 
behavioural surrogate which may, or may not, relate to goal directed behaviour or cognition.  
There are also clear disadvantages to a questionnaire based approach.  They rely on language 
and accurate understanding of the items presented.   This may be particularly problematic in 
FTLD where language disorders are common.  Second they rely upon accurate reporting and 
insight on the part of the reporter.  This may be an issue not only for the subject with FTLD 
(where loss of insight may be present(195)) but also when using informant/carer reports where 
responses will be subject to the informants interpretations of patient behaviour and also their 
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own psychological stress.  For example lack of facial expression (hypomimia) in PSP may be 
mistakenly interpreted as lack of interest.  
An alternative approach to assessing apathy and impulsivity is to measure a behavioural 
surrogate either by passive observation or by testing performance on tasks designed to address 
specific aspects of behaviour. Behavioural testing has been extensively used in patient groups to 
investigate impulsivity e.g.(190,196,197) but is less well established in apathy.  One example of 
passive observation is actimetry.  One study(198) used a wrist mounted device to record 
periods of activity (motion) and showed a positive correlation between carer reported apathy 
and periods of inactivity amongst patients with bvFTD but not semantic dementia.   Behavioural 
tasks such the Go/NoGo task have also been used in FTLD.  Hughes et al.(187) used a Go/NoGo 
paradigm to investigate disinhibition amongst a group of patients with bvFTD. Using 
magnetoencephalography and electroencephalography they showed evoked responses in the 
right inferior frontal gyrus and anterior temporal lobe were associated with successful response 
inhibition in age matched controls and that these were reduced amongst subjects bvFTD.  These 
responses were enhanced by citalopram suggesting a serotinergic aspect to response inhibition. 
Whilst this more behavioural approach to assessing apathy and impulsivity has the 
advantage of being a more ‘objective’ method of assessment, behavioural testing also has 
limitations, particularly in this patient group.  For non-passive measures, language impairment, 
communication and understanding can be difficult and limit assessment.  With a questionnaire 
based approach it may be easier to assess understanding and clarify responses.  More 
problematic is that most non-passive assessments rely on the subject’s ability to perform a task.  
Apraxia, which is a hallmark of CBS, limits the ability to manipulate a joystick, press buttons or 
write.  Eye movements are severely impaired in PSP (and together with apraxia of eyelid 
opening this can produce a functional blindness).  A more fundamental issue is whether the task 
actually relates to apathy or impulsivity.  For example amongst bvFTD Go/NoGo performance 
correlates with performance on the Hayling and reports of stereotypic and motor behaviours 
and general disinhibition (as reported on the Cambridge Behavioural Inventory) (187).  While 
these results support an association between a behavioural task (Go/NoGo) and reports of 
impulsivity in bvFTD, these data in isolation do not demonstrate a direct association between 
performance on the task and the reported symptoms. Performance on the task and symptom 
reports may both be indicative of more general cognitive or behavioural impairment or 
alternatively there may be another confounding element influencing both symptom reports and 
task performance.  Furthermore, accepting the proposal that apathy and impulsivity are 
multidimensional, it is not clear to what extent performance on one task or questionnaire may 
relate to performance on another.  While one study may demonstrate that (for example) a set of 
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apathetic symptoms relates to increased carer distress, it is not necessarily the case that the 
reported symptoms would also relate to impairment on behavioural testing in another study or 
functional imaging changes in another. 
In the remainder of this chapter I outline the methods used to assess neuropsychiatric 
symptoms (particularly apathy and impulsivity) in the PiPPIN cohort of subjects with FTLD 
associated syndromes and a group of healthy older volunteers and the results obtained.  
Additional ‘objective’ behavioural testing was also performed and is discussed in more detail in 
Chapter Four and an integrative multimodal approach to the assessment of apathy and 
impulsivity in Chapter Five. 
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3.3 Methods 
Patients and their carers identified with FTLD associated syndromes from the epidemiology 
aspect of the PiPPIN study were invited to participate in a battery of cognitive, behavioural and 
neuropsychological tests with particular emphasis on aspects of apathy and impulsivity (Table 
3.1).   Fifty healthy older people without dementia were asked to complete the same battery of 
tests to act as a control group. As an assessment of cognitive ability across a range of domains 
subjects completed the Addenbrooke’s Cognitive Examination –Revised (ACE-R) and Frontal 
Assessment Battery (FAB) which were administered in person by either myself, a clinical 
research assistant or a research assistant that I had trained to administer these tasks.   
Subjects completed a number of questionnaire-based assessments chosen to assess a 
range of symptoms and clinical features relevant to apathy and impulsivity.  These included 
assessments of: mood and mental state (Snaith Hamilton Anhedonia Pleasure Scale, 
SHAPS(179), Beck Depressive Inventory II, BDI-II(180), Visual Analogue Scales, VAS, Motivation 
and Energy Inventory, MEI(199) , Parkinson’s Disease Sleep Scale, PDSS(181); behavioural and 
neuropsychiatric symptoms (Neuropsychiatric Inventory –Questionnaire, NPI-Q(200), 
Cambridge Behavioural Inventory –Revised, CBI-R(184)); disease severity (Progressive 
Supranuclear Palsy Rating Scale, PSP-RS(201), Frontotemporal Dementia Rating Scale, 
FRS(202)); apathy (The Apathy Evaluation Scale, Informant, Clinician and Subject versions, AES-
I, AES-C, AES-S(158)), compulsiveness and impulsivity (Barratt Impulsiveness Scale, BIS(169), 
Behavioural Inhibition System/Behavioural Activation System, BIS/BAS(178), Obsessive 
Compulsive Inventory-Revised, OCI-R (203)).  
The assessments were administered in person in the form of a structured interview 
using paper and pen.  For patient assessments the subjects were presented with each 
assessment on paper and each item of the assessment read out loud to them.  With the exception 
of those items that are dependent on the subject physically marking the page themselves (such 
as drawing tasks in the ACE-R) the examiner would assist the subject with physical response 
entry as necessary.  An informant who knew the patient well (usually a carer or the patient’s 
partner/spouse) was asked to complete the NPI-Q, CBI-R, AES-I, FRS usually whilst the subject 
completed other aspects of the assessment battery so the examiner was available to clarify any 
particular issues.  As some of these assessments are used in routine clinical practice occasionally 
when the patient had recently undergone an assessment and results were available (and the 
patient consented) these were used to avoid repetition of assessments and learning effects. 
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Multiple questionnaires were used.  While there is some overlap between items on each 
instrument, the focus (target symptoms), language and scoring of each is different and each has 
been validated in different cohorts and disease states.  Accepting that this approach does lead to 
some repetition it also allows clarification and corroboration of subject reports, which is of 
particular importance when assessing symptoms in dementia, and also explores a wider 
spectrum of goal directed cognition. 
These questionnaire based assessments explicitly ask about relevant symptoms or 
behaviour in addition subjects were asked to attempt a number of behavioural tasks using a 
range of methodologies including the Cambridge Gambling Task (CGT), Information Sampling 
Task (IST), Go/NoGo task, saccadometry and actimetry monitoring, Stop Signal Reaction Time 
task (SSRT), Kirby delayed discounting task, the Cued Reinforcement Reaction Time task 
(CRRT).  These behavioural tasks are discussed in Chapter Four. 
 
Informant Assessments (Questionnaires) AES-I, NPI-Q, CBI-R, FRS 
Patient Assessments (Questionnaires) SHAPS, AES-S, BDI-II, BIS, BIS/BAS, OCIR, PDSS, 
MEI, Kirby2, CBI-R1, VAS  
Clinician Assessments AES-C, PSP-RS, clinical history and physical 
examination 
Cognitive Assessments ACE-R, FAB 
Computerised Assessments2 CGT, IST, SSRT, CRRT, Go/NoGo, Saccadometry, 
Actimetry 
 
Table 3.1 Assessments in the PiPPIN Battery. 
1Patients were not asked to complete all 45 items on the CBI-R but was asked to self-rate 
behaviours on a subset of 10 items consisting of the first item from each of the ten domains. 
2The Kirby and Computerised assessments are discussed in Chapter Four 
I expected that not all patients would be able to complete all aspects of the battery and 
took a pragmatic approach to the protocol limiting aspects of the protocol to those that the 
patient was willing and able to complete.  Similarly the order in which aspects of the battery 
were applied was varied in order to maintain patient engagement with the tasks and maximise 
testing opportunities. 
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3.3.1 The Addenbrooke’s Cognitive Examination Revised 
The Addenbrooke’s Cognitive Examination Revised (ACE-R) (204) is a 100 point bedside 
cognitive examination developed from the older Addenbrooke’s Cognitive Examination as a 
screening test for dementia.  Incorporating the Mini Mental State Examination (MMSE)(205) 
itself a bedside tool for grading the cognitive ability of patients.  Widely used in clinical and 
research settings the ACE-R can be administered with a pen and paper and assesses several 
cognitive domains including attention and orientation, memory, fluency, language, visuospatial 
function. 
3.3.2 The Frontal Assessment Battery 
The Frontal Assessment Battery (FAB)(206) is a bedside tool designed to assess frontal 
executive function via six tasks including similarities (conceptualisation), lexical fluency (mental 
flexibility), motor series (the Luria test of programming), conflicting instructions (sensitivity to 
interference), go-no-go (inhibitory control) and prehension behaviour (environmental 
autonomy).  I used letter fluency from the ACE-R to score lexical fluency (both ask subjects to as 
many words as they can generate words beginning with a given letter in one minute, the ACE-R 
version used here uses the letter P, the FAB normally uses S).  Each task is scored from 0 (worst 
performance) to 3 (best) giving a maximum possible score of 18.  A cut off of 12 differentiated 
between bvFTD and Alzheimer’s disease with sensitivity 81% of and specificity 71% of in one 
study of 90 patients (64 AD and 26 FTD) with lower sensitivity (77%) but higher specificity 
(87%) amongst subjects with mild dementia (defined as MMSE≥24)(207). 
3.3.3 The Apathy Evaluation Scale 
The Apathy Evaluation Scale(158) consists of 18 items (e.g. item 4: He/She is interested in 
having new experiences) respondents are asked to grade each item based on the patient’s 
thoughts feelings and activity in the past four weeks.  Four options are given (Not at all, slightly, 
somewhat, a lot) and the answers scored so from 1 to 4 so that the answers indicating greater 
levels of apathetic behaviour score more highly. 
Three versions of the scale were administered when possible.  The informant/carer 
version (AES-I) -where a relative or carer is asked to rate the subject, a self-administered 
version (AES-S)–where subjects are asked to rate themselves, and a clinician version (AES-C) –
where a clinician administers the scale and grades the subject based on their responses.  The 
clinician version includes some self-evaluated questions as well as others where the clinician is 
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asked to grade the response based on the subjects affect whilst responding and detail of answer 
during a semi structured interview. 
3.3.4 The Cambridge Behavioural Inventory –Revised 
The Cambridge Behavioural Inventory –Revised (CBI-R, (184)) consists of 45 behavioural 
symptoms which are arranged into 10 groups (e.g. eating habits, sleep).  Carers are asked to rate 
the frequency of each behavioural change from 0 (never) to 4 (constantly).  As a surrogate 
marker of patient insight I asked the patients to self-evaluate their own behaviour for 10 
behaviours (the first presented in each of the ten groups). 
3.3.5 The Neuropsychiatric Inventory –Questionnaire 
The Neuropsychiatric Inventory –Questionnaire (NPI-Q, (200)) is a brief questionnaire form of 
the Neuropsychiatric Inventory(185), designed for use in clinical practice to evaluate 
neuropsychiatric symptoms in dementia.   An informant (usually the subject’s spouse or other 
main carer) is asked whether specific symptoms/behaviours (such as apathy, hallucinations, 
night time behaviours) have been present over the last month and if so how severe they are (on 
a scale of 1-3, 1 being mild, 3 severe) and how much distress they cause the informant from 0 
(not distressing at all) to 5 (extremely distressing). 
3.3.6 The Frontotemporal Rating Scale 
The Frontotemporal Rating Scale(202) consists of 30 behavioural changes seen in 
frontotemporal dementia.  Carers are asked whether they are never present, sometimes present, 
or present all the time.  A score of 1 awarded for each behavioural change that is never present 
(i.e. no change from premorbid function) and 0 for any other response.  Hence a score of 30 
would be no symptomatic change and lower scores indicative of more marked behavioural 
changes.  The authors of the scale also suggest a percentage conversion and Logit score 
conversion to separate scores into very mild, mild, moderate, severe, very severe and profound 
categories(202). 
3.3.7 Visual Analogue Scales 
At the start of the testing protocol subjects were shown a set of 14 visual analogue scales (VAS).  
Each scale consists of a line 20 cm long with ‘Not at all’ and ‘Extremely’ printed above opposite 
ends of the scale (left and right respectively).  Above this is a stimulus word printed in bold 
below the instruction ‘Point to the appropriate point on the line to rate how closely the word 
below matches how you are feeling right now?’. 
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The 14 stimulus words are presented to each subject in the same randomised order. The 
subjects were also instructed to indicate a point on each line that was then marked with a pen by 
the subject (if able) or the examiner.  The intersection of this mark and the line was measured 
from left to right and recorded (in cm). 
The stimulus words used were: Stimulated, Interested, Clear Headed, Tired, Apathetic, 
Depressed, Happy, Calm, Alert, Motivated, Sad, Excited, Impulsive, Bored. 
3.3.8 The BIS/BAS Scales 
The Behavioural Inhibition System and Behavioural Approach System (BIS/BAS) Scales (178) 
are presented as a single questionnaire consisting of 30 items.  Subjects state how much they 
agree or disagree with 24 statements (e.g. ‘I go out of my way to get the things I want’).  These 
are then scored and grouped into four scales to assess the Behavioural Inhibition System (one 
scale, 7 items), and Behavioural Activation System (3 scales; Reward Responsiveness -5 items, 
Drive -4 items, Fun Seeking -4 items).  Two items are reverse scored and four items are fillers 
that do not contribute to any scales.  The structure of the BIS and BAS subscales was derived 
from factor analysis of 732 college students(178).   
3.3.9 The Barrett Impulsiveness Scale 
The Barrett Impulsiveness Scale (BIS-11,(169)) is one of the most widely cited instruments for 
the assessment of impulsive behaviour(182).  It consists of 30 items where subjects are asked to 
grade their thoughts and actions on a four point scale (from rarely/never to almost 
always/always) their answers are scored out 120 of so that higher scores reflect more impulsive 
thoughts/behaviour.  Previous Principal Component Analysis on a sample of 248 psychiatric 
inpatients and 412 university students(169) revealed and 6 oblique first order factors and three 
second order factors.  Higher scores on the BIS scale suggest more behavioural inhibition and 
hence a lower tendency towards impulsive actions while higher scores on BAS subscales 
suggests greater behavioural activation and more impulsive tendencies. 
3.3.10 The Obsessive-Compulsive Inventory –Revised 
The Obsessive-Compulsive Inventory -Revised(203) is an 18 item questionnaire where subjects 
are asked how much particular behaviour, thoughts or experiences related to 
obsessive/compulsive behaviour have distressed or bothered them during the past month on a 
scale of 0 (not at all) to 4 (extremely).  The range of possible scores is 0-72 with a suggested cut-
off of 21 where scores above this are indicative of an obsessive compulsive disorder(203). 
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3.3.11 The Snaith-Hamilton Anhedonia Pleasure Scale 
The Snaith-Hamilton Anhedonia Pleasure Scale (SHAPS) is a 14 item self rated questionnaire 
designed to evaluate hedonic tone(179).  Subjects are presented with a short statement such as ‘’I would enjoy my favourite television or radio programme” and asked how much they agree or 
disagree (strongly agree, agree, disagree, strongly disagree).  The order and exact wording of 
responses varies between items (e.g. the word ‘strongly’ is sometimes replaced by ‘definitely’).  
The scale is presented so that it may used either in a Likert-style scoring (each item being scored 
from one to four, with 4 being the most anhedonic) giving a range of 14-56 or alternatively 
simplified approach whereby either agree response scores no points and either disagree one 
point making the maximum (most anhedonic) score 14(179).  In order to allow the greatest 
flexibility I chose the former method. 
3.3.12 The Beck Depressive Inventory II 
The Beck Depressive Inventory II (BDI-II)(180) is the second revision of the Beck Depressive 
Inventory and consists of 21 groups of statements under subheadings such as ‘Pessimism’ and ‘Past Failure’.  Subjects are asked to choose the statement that best describes how they have 
been feeling over the past two weeks.  Responses for each statement are scored from 0 (least 
depressed) to 3 (most depressed) giving a range of 0-63 possible total scores.  The BDI-II is 
amongst the most widely used tools to screen and assess depression amongst healthy 
populations and in disease states (including dementia)(208–210). 
3.3.13 The Motivation and Energy Inventory 
The Motivation and Energy Inventory (MEI) is a 27 item self rated questionnaire originally 
designed to evaluate motivation and energy in depression and hence facilitate the evaluation of 
treatments intended to alleviate fatigue and lassitude(199).  Items are scored from 0-6 with the 
maximum score for each individual item varying between four, five and six.  The range of 
possible scores is 0-144.  Based on two studies of around 800 subjects diagnosed with a 
recurrent major depressive episode exploratory factor analysis demonstrated three factor 
solution (termed physical energy, mental energy and social motivation)(199). 
3.3.14 The Parkinson’s Disease Sleep Scale 
The Parkinson’s Disease Sleep Scale (PDSS) consists of 15 self-rated visual analogue scales 
assessing 15 commonly reported symptoms associated with sleep disturbance in Parkinson’s 
disease(181).  Each scale is presented as a graduated line from zero to ten with zero indicating 
the symptom occurs frequently/always and ten equating to never.  While the scales relate to 
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symptoms reported in Parkinson’s disease many also occur in other disease states or in the 
absence of disease (for example getting up to pass urine at night, unexpectedly falling asleep 
during the day or fidgeting in bed). 
3.3.15 The Progressive Supranuclear Palsy Rating Scale 
The Progressive Supranuclear Palsy Rating Scale(201) is a 100 point scale consisting of 28 items 
in six categories (daily activity, behaviour, bulbar, ocular motor, limb motor and gait/midline).  
It combines clinical history and examination in a well operationalized set of criteria by which the 
severity of PSP-RS may be assessed.  In one study of 162 patients mean rate of progression was 
11.3 points per year and the total score was a good independent predictor of subsequent 
survival(201). 
3.3.16 Statistical Analysis 
Statistical analysis was carried out using SPSS v22 (IBM 2013).  Differences between groups 
were calculated using two tailed T-tests between groups.  Where a subject was unable to 
complete a particular aspect of the protocol it was removed from the testing battery and 
analysis but the subject was still asked to attempt other tests.  For carer/informant assessments 
most carers were able to complete the full battery of assessments.  Occasional omission errors 
were dealt with by replacement with mean within group.  For example a single omission on the 
CBI-R would be replaced with the mean score of the carer’s responses for that particular 
category of behaviours.   
Principal Component Analysis (PCA) was performed using orthogonal varimax rotation 
with Kaiser normalisation.   Adequacy of sample size was assessed using Kaiser-Meyer-Olkin 
(KMO) test and Bartlett’s test of sphericity.  The standardised correlation matrix was used for 
extraction of components (as opposed to the unstandardized covariance matrix) and extraction 
of significant components was based on Kaiser’s criteria (i.e. those with Eigenvalues greater 
than 1). 
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3.4 Results 
As expected, not all patients were able to complete the full battery of questionnaires or 
behavioural tests.  In this, and following chapters, for each measure and exploration the number 
of individuals included is stated but note that different patients completed different tests and 
hence each correlation and analysis is performed on a different patient subgroup.  The exact 
data pertaining to FTLD subtype and clinical characteristics for each subgroup is no longer 
available. 
Table 3.2 summarises the results of questionnaire based testing of patients and controls 
with subscale scores and mean standard deviation (within subject) on VAS scales shown in 
Table 3.3.  As expected, average patient scores across a range of cognitive tasks (FAB, ACE-R, 
MMSE) were lower than amongst control groups.  The carers of patients with FTLD reported 
more symptoms associated with dementia and behavioural changes (CBI-R, NPI-Q) than 
partners of healthy controls and patients and their carers reported more severe symptoms of 
apathy, impulsivity, obsessive compulsive behaviour, depression and anhedonia (AES-S, AES-I, 
BIS, BIS/BAS, OCI-R, BDI-II, SHAPS) and lower levels of motivation and energy (MEI).   
T-test comparisons of all differences were statistically significant with the exception of 
age and mean scores on VAS, BIS, Funseeking and Reward Responsiveness subscales of the 
BIS/BAS, average severity and distress associated with symptoms on the NPI-Q and Attention, 
Self control, Cognitive complexity and Cognitive instability subscales of the BIS-11.  
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Variable Controls (N, 
SD) 
Patients (N,SD) P value 
(T-test) 
Age 70.6 (50, 6.5) 69.8 (113, 8.3) 0.543 
MMSE Total score (max. 30) 29.3 (50, 1.2) 22.1 (85, 7.0) 0.000 
ACE-R Total score (max. 100) 95.6 (50, 4.4) 64.3 (84, 23.2) 0.000 
FAB Total score (max. 18) 16.8 (50,1.2) 10.0 (86, 4.5) 0.000 
FRS Total score (max.  30) 26.7 (49, 3.8) 10.16 (106, 7.5) 0.000 
FRS Per cent score (max. 100) 92.1 (49, 
10.8) 
38.1 (106, 26.8) 0.000 
AES-I Total score (max. 72) 24.2 (49, 5.7) 48.2 (104, 12.7) 0.000 
AES-S Total score (max. 72) 25.9 (50, 7.3) 35.7 (70, 9.5) 0.000 
AES-C Total score (max. 72) 25.9 (50, 7.3) 43.1 (76, 10.3) 0.000 
NPI-Q Total number 
symptoms (max. 12) 
0.3 (50, 0.7) 4.4 (106, 2.6) 0.000 
NPI-Q Mean severity1 (max. 3) 1.4 (5, 0.5) 1.7 (100, 0.5) 0.184 
NPI-Q Mean distress1 (max. 5) 0.8 (4, 1.0) 1.9 (98, 1.2) 0.051 
CBI-R Total score (max. 180) 5.2 (49, 5.6) 66.9 (107, 35.5) 0.000 
CBI-R Self score (max. 40) NA2 17.4 (32, 9.2) NA2 
BIS-11 Total Score  (max. 120) 57.0 (50, 7.4) 63.5 (67, 8.0) 0.000 
BIS/BAS BAS Drive 10.0 (50, 2.1) 11.2 (66, 3.2) 0.030 
BIS/BAS BAS Funseeking  10.7 (50, 2.2) 11.4 (66. 3.1) 0.181 
BIS/BAS BAS Reward 
responsiveness  
15.8 (50, 2.4) 16.7 (66, 2.7) 0.085 
BIS/BAS BIS  19.9 (50, 
14.4) 
20.6 (66, 4.6) 0.353 
PDSS Total score (max. 150) 121.5 (50, 
14.4) 
112.9 (64, 23.7) 0.026 
MEI Total score (max. 144) 108.9 (50, 
17.2) 
81.8 (64, 25.6) 0.000 
SHAPS (max. 56) 18.7 (50, 4.4) 22.8 (66, 4.8) 0.000 
BDI-II (max. 63) 4.4 (50, 4.0) 12.8 (70, 9.9) 0.000 
OCI-R  (max. 72) 8.5 (50, 6.4) 14.8 (64, 11.4) 0.001 
VAS mean score (max. 20) 10.1 (50,1.3) 9.9 (71, 2.1) 0.615 
PSP-RS Total score (max. 100) NA2 31.5 (70, 20.5) NA2 
 
Table 3.2 Mean scores for interview/questionnaire based assessments for healthy older 
controls and subjects with syndromes associated with FTLD recruited in the PiPPIN study. 
1When completing the NPI-Q respondents are asked only to grade distress and severity only 
when a symptom is reported as present.  Hence the average scores for severity and distress are 
calculated from only those subjects where symptoms have been reported and only from those 
where a rating for severity or distress has been recorded. 
2Control subjects were not asked to self-rate on the CBI-R or assessed on the PSP-RS 
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Variable Controls  
(N, SD) 
Patients  
(N,SD) 
P-value  
(T-test) 
ACE-R Attention & Orientation (max. 
18) 
17.7 (50, 0.9) 13.8 (85, 4.5) 0.000 
ACE-R Memory (max. 26) 24.2 (50, 2.2) 15.4 (84, 7.9) 0.000 
ACE-R Fluency (max. 14) 12.6 (50, 2.1) 4.5 (84, 3.7) 0.000 
ACE-R Language (max. 26) 25.4 (50, 1.0) 19.3 (84, 6.8) 0.000 
ACE-R Visuospatial (max. 16) 15.6 (50, 0.72) 11.2 (84,4.1) 0.000 
CBI-R Memory/Orientation 2.2 (49, 2.3) 14.8 (107, 9.6) 0.000 
CBI-R Everyday skills 0.2 (49, 0.5) 11.4 (107, 7.3) 0.000 
CBI-R Abnormal behaviour 0.4 (49, 1.1) 5.7 (107, 5.4) 0.000 
CBI-R Mood 0.4 (49, 0.8) 4.3 (107, 3.3) 0.000 
CBI-R Beliefs 0.0 (49, 0.0) 0.6 (107, 1.3) 0.000 
CBI-R Eating Habits 0.1 (49, 0.3) 4.6 (107, 4.2) 0.000 
CBI-R Sleep 0.9 (48, 1.0) 3.5 (107, 2.3) 0.000 
CBI-R Stereotypic behaviour 0.3 (49, 1.0) 5.0 (107, 5.0) 0.000 
CBI-R Motivation 0.5 (49, 1.5) 9.8 (107, 6.9) 0.000 
BIS Attention 8.86 (50, 2.1) 10.5 (67, 2.3) 0.579 
BIS Motor 14.0 (50, 2.7) 14.7 (67 (4.0) 0.003 
BIS Self control 10.5 (50, 2.8) 12.9 (67, 3.5) 0.129 
BIS Cognitive complexity 10.6 (50, 2.3) 12.1 (67, 2.5) 0.649 
BIS Perseverance 7.4 (50, 1.4) 8.1 (67, 2.1) 0.007 
BIS Cognitive instability 5.6 (50, 1.6) 5.2 (67, 2.0) 0.165 
VAS Mean standard deviation 
(within subject)  
5.5 (50, 1.2) 4.7 (71, 1.9) 0.007 
 
Table 3.3 Mean subscale scores for ACE-R, CBI-R, BIS assessments and mean standard 
deviation (within subject) on the VAS for healthy older controls and subjects with 
syndromes associated with FTLD recruited in the PiPPIN study. 
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Figure 3.3 shows standardised subscores for the individual domains for the ACE-R and FAB.   
Patients performed more poorly than controls (T-tests p<0.001 for all) across all tested 
domains, the largest discrepancy is seen in fluency.   Note that Fluency and Lexical Fluency are 
derived from the same data but scored slightly differently when included in the ACE-R or FAB. 
 
Figure 3.3 Standardised scores for Subscales of the ACE-R and FAB for subjects with FTLD 
associated syndromes (red columns) and healthy older volunteers (blue).  Error bars show 
95% confidence intervals. 
  One hundred and six carers of patients completed the NPI-Q.  The commonest reported 
symptoms were night time behaviours (in 58.8% of cases) followed closely by 
apathy/indifference (57.9%), and changes in appetite/eating (56.1%).  Figure 3.4 shows the 
frequency of symptoms reported amongst respondents, the average severity of each symptom 
rated by the carer and the average rating of distress it caused them (as opposed to the patient). 
Twenty six (24%) of informants reported both apathetic and impulsive behaviour occurring in 
the same subject on the NPI-Q. 
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Figure 3.4. Neuropsychiatric symptoms amongst 106 subjects with syndromes associated 
with FTLD as reported by informants using the Neuropsychiatric Inventory. A shows the 
percentage frequency of informants who considered each symptom present.  B shows the mean 
severity rating (from 1=mild to 3=severe) the informants gave each symptom (when present) 
and C the mean distress the informant experienced (from 0=not distressing at all to 5=extreme 
or very severe) from each symptom (when present). 
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One hundred and seven carers completed the CBI-R endorsing symptomatic behavioural 
changes across a range of activities.  Standardised scores (for the total number of points 
available for each category) showed the highest endorsement for impairments in everyday 
skills, followed secondly for motivational changes (Figure 3.5).  Similarly to the low frequency of 
reported delusions or hallucinations on the NPI-Q abnormal beliefs were the least frequently 
reported set of behavioural changes on the CBI-R. 
   
Figure 3.5.  Symptom frequency reporting by informants amongst 107 subjects with 
syndromes associated with FTLD using the Cambridge Behavioural Inventory-Revised 
(CBI-R).  Each column shows standardised frequency for each of the ten groups of symptoms in 
the CBI-R as reported by informants on a scale of 0=never occurs to 5=constantly occurring. 
Seventy-one patients completed the visual analogue scales.  Patients reported 
significantly higher levels of emotional and behavioural states with negative valence (e.g. sad, 
depressed, bored) than healthy controls and lower levels of states with positive valence (e.g. 
happy, stimulated, excited).  On an individual level some patients appeared to have substantial 
difficulty on the VAS task despite their apparent simplicity. This seemed disproportionate to 
their functioning day-to-day or performance on some other cognitive tasks (see Figure 3.6).  
Mean scores for patients and controls self ratings on the scales are shown in Figure 3.7.  
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Interested Happy 
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A B  
Figure 3.6. A. Visual analogue scale responses from a single case.  The subject was a woman in 
her early 60s with a recent diagnosis of bvFTD.  At the time of testing she was living semi-
independently in her own home and continued to manage her own financial affairs.  She scored 
76/100 on the ACE-R, 28/30 on the MMSE, 17/18 on the FAB and had a FRS score of 44% 
(classified as moderate disease).   When instructed to put a mark on the line to indicate how ‘interested’ she felt right now she drew a box around the word extremely.  She was corrected 
and told to draw a line on the scale to indicate how she felt.  On the next scale ‘bored’ she drew a 
line through the word ‘extremely’ to indicate ‘not at all’ (the remaining response).  She was 
corrected and asked to put the line where she felt and so put a line through ‘not at all’.  A final 
attempt was made asking her to put a mark on the scale at which point she ticked ‘not at all’.  She 
answered several other scales in the same manner despite repeated attempts to correct her and 
being shown numerous examples. B. To test her understanding of the cue words used in the 
visual analogue scales the same patient was asked to draw faces for each of the cue words.  Note 
that while she correctly identifies the positive and negative qualities of each word, each face 
looks otherwise extremely similar.    
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Figure 3.7.  Standardised mean scores for the visual analogue scales.  Patients with 
FTLD associated syndromes (red columns) and healthy control subjects (blue columns) self 
rated for each of the emotional states from 0 (not at all) to 1 (very).  Error bars show 95% 
confidence intervals.  
Principal Component Analysis for VAS responses for both patients and controls 
combined revealed a four-factor solution explaining 64% of the variance.  The rotated 
component matrix (Table 3.4) shows the factor loading for each component.   
Item 
Component 
1 2 3 4 
Excited 0.788 0.161 0.042 -0.03 
Stimulated 0.746 -0.092 -0.184 -0.124 
Motivated 0.671 0.404 -0.258 -0.05 
Interested 0.592 0.295 -0.365 -0.048 
Clear 
headed 0.584 0.462 -0.003 -0.135 
Impulsive 0.55 0.171 0.536 0.164 
Alert 0.478 0.526 -0.023 -0.335 
Happy 0.288 0.704 -0.168 -0.041 
Calm 0.022 0.899 -0.026 -0.036 
Bored -0.068 -0.141 0.798 0.059 
Sad -0.274 -0.082 0.678 0.23 
Tired 0.036 -0.014 -0.075 0.856 
Depressed -0.165 -0.15 0.248 0.705 
Apathetic -0.091 -0.044 0.429 0.657 
 
Table 3.4 Rotated component matrix for responses of seventy one patients with 
syndromes associated with FTLD and fifty healthy older control subjects on fourteen 
visual analogue scales of mood and motivational state. Weightings >0.5 or <-0.5 highlighted 
and in bold.  
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Component One in Table 3.4 comprised of stimulus words attributable to high levels of 
energy and motivation (e.g. stimulated, excited, motivated). Component Two comprised of 
stimulus words with positive valence attributable to calm, focus and happy feelings (e.g. calm, 
alert, happy). Component Three comprised of stimulus words with more negative valence and 
low mood (e.g. sad, apathetic, bored). Component Four also comprised negative valence with 
possibly more emphasis on low energy, fatigue and depression (e.g. tired, apathetic, depressed).  
To explore the proposed factor structure further post hoc correlation analysis was performed.  
The rotated component matrix was used to transform the raw VAS scores to extract four new 
variables.   Amongst patients (not controls) these extracted variables were then subjected to 
bivariate correlation analysis against the AES-S, MEI, SHAPS, BDI-II and PDSS. Statistically 
significant correlations were seen between the MEI (positive correlation), SHAPS (negative 
correlation) and Components One and Two (which also correlated positively with the PDSS), the 
BDI-II and AES-S and Component Three (which also had negative correlation with the MEI) and 
a negative correlation between the PDSS and Component Four (see Table 3.5).  Despite strong 
factor loadings for the stimulus words ‘apathetic’ and ‘depressed’ onto Component Four the 
extracted variable did not significantly correlate with either the AES-S or BDI-II but instead 
correlated significantly with the PDSS which focuses more on fatigue and tiredness (note the 
stimulus word ‘tired’ also loads strongly onto Component Four).  In contrast the stimulus words ‘sad’ and ‘bored’ both loaded onto Component Three with significant correlations for the 
extracted variable and both AES-S and BDI-II.  
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Component 
 
MEI SHAPS BDI-II AES-S PDSS 
1 
 
 
Pearson 
Correlation 
.426** -.374** -0.226 -0.23 0.164 
Sig. (2-tailed) 0.001 0.002 0.063 0.062 0.199 
N 63 65 68 67 63 
2 
 
 
Pearson 
Correlation 
.371** -.367** -0.09 -0.217 .255* 
Sig. (2-tailed) 0.003 0.003 0.464 0.077 0.043 
N 63 65 68 67 63 
3 
 
 
Pearson 
Correlation 
-.309* 0.211 .330** .459** -0.125 
Sig. (2-tailed) 0.014 0.092 0.006 0 0.331 
N 63 65 68 67 63 
4 
 
 
Pearson 
Correlation 
-0.045 0.057 0.118 0 -.266* 
Sig. (2-tailed) 0.728 0.654 0.338 0.999 0.035 
N 63 65 68 67 63 
 
Table 3.5 Correlation of the four components extracted from Principal Component 
Analysis of responses on visual analogue scales with the Motivation and Energy Inventory 
(MEI), Beck Depressive Inventory II, self rated version of the Apathy Evaluation Scale 
(AES-S) and Parkinson’s Disease Sleep Scale (PDSS). ** Correlation is significant at the 0.01 
level (2-tailed). * Correlation is significant at the 0.05 level (2-tailed). 
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3.5 Discussion 
In this chapter I have shown that a wide range of cognitive assessments and questionnaire based 
assessments of mood and motivation can be applied to a group of subjects with syndromes 
associated with FTLD.  Compared with healthy older controls, such individuals have significant 
cognitive impairment as measured by a range of assessments (MMSE, ACE-R, FAB) across a 
range of cognitive domains.   
I have not presented results separated by individual clinical syndromes (such as bvFTD 
or PSP-RS).  This is for several reasons:  Clinical features overlap between individual syndromes 
(as I demonstrated in Chapter Two), while particular syndromes may be recognisable at a 
particular stage of symptomatic disease patients may transition between syndromes over the 
course of their illness or present with an intermediate clinical syndrome with features of 
multiple diagnostic criteria. I have taken an inclusive approach and recruited subjects at every 
stage of symptomatic disease (some at the point of clinical diagnosis, others shortly before their 
death).  While subjects will have fulfilled criteria for a diagnosis of FTLD they may subsequently 
have acquired additional features beyond the limited criteria by which they were diagnosed (e.g. 
a subject with a diagnosis of bvFTD who later acquires additional features of CBS).  How such 
subjects should be divided is not clear (on the basis of presenting features or on features at the 
time of testing).  The emphasis of most of the diagnostic criteria for FTLD is placed on either the 
cognitive syndrome or movement disorder, not the neuropsychiatric profile.  For all these 
reasons it seems counterintuitive to divide this cross sectional cohort on the basis of a diagnosis 
either at first presentation or at the time of assessment.  In addition to these reasons, as I have 
argued previously, taking a transdiagnostic and inclusive approach to clinical syndromes 
associated with FTLD exploits syndromic heterogeneity providing insights into clinical features 
that would not otherwise be possible.  This approach is central to the Research Domain Criteria 
(RDoC) approach to neuropsychiatry advocated by the National Institute for Mental 
Health(211).  While individual subjects had difficulty with particular aspects of the assessments 
(e.g. the patient described earlier in Figure 3.6) as a group they are able to reflect on and report 
symptoms in a consistent manner across a range of assessment tools.  
When an informant who knows the patient well was asked, they reported a range of 
behavioural and neuropsychiatric symptoms which, when present, are often severe and a source 
of distress to the informant.  Apathy, night-time behaviours and changes in appetite/eating were 
the most commonly reported symptoms on the NPI.  The least commonly reported symptoms 
were delusions, hallucinations and elation/euphoria.  Similarly psychotic symptoms of 
hallucinations or delusions were also the least commonly reported symptoms on the CBI-R.  The 
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most commonly reported behavioural symptoms on the CBI included the subject’s ability to 
perform day-to-day tasks such as using a telephone or handling money/paying for items.  
Behaviours related to motivation and apathy (e.g. ‘Shows less enthusiasm for his or her usual 
interests’, ‘Shows little interest in doing new things’) were also amongst the most frequently 
reported symptoms.  Changes in memory were commonly reported on the NPI and CBI-R and 
also seen on cognitive testing (e.g. ACE-R).   
The (rare) reports of psychotic symptoms in the PiPPIN cohort and more frequent 
reports of memory impairments could reflect the presence of patients with non-FTLD pathology 
within this cohort. Psychotic symptoms are uncommonly reported in FTLD but commonly seen 
in Dementia with Lewy Bodies(212).   Primarily psychiatric diseases may also mimic 
bvFTD(213).  Episodic memory and visuospatial impairments are more commonly associated 
with Alzheimer’s disease than FTLD(214,215).  However I suggest the presence of these features 
in this cohort does not undermine the diagnosis of an FTLD related syndrome.  Memory 
symptoms are found in FTLD(216) and were prominent in Pick’s original cases.  Early episodic 
memory impairment may indicate underlying Alzheimer’s type pathology and hence is often 
used as an exclusion criteria for FTLD associated syndromes(35) but these criteria do not 
preclude memory symptoms at any stage of disease (including at onset provided they are not a 
prominent feature).   
Similarly psychotic features were an exclusion criteria for the diagnosis of CBD (e.g. 
(12)) and psychiatric disease that may better account for symptoms is an exclusion criteria for 
bvFTD(35) but psychotic symptoms may still be seen in FTLD.  In this cross sectional cohort 
study the presence of some psychotic features does not undermine the validity of diagnoses.  It 
may even be that because of current diagnostic criteria, psychotic features are 
underrepresented in this cohort.  Psychosis is a common and prominent feature amongst 
patients with C9ORF72(217).  Prior to this discovery psychosis was considered unusual in FTLD 
and rarely reported.  It is possible that patients with FTLD and prominent early psychosis may 
not have had the diagnosis considered and hence would not have been included in this study. 
It is striking that across a range of different assessment tools patients consistently report 
higher levels of symptoms with negative valence (e.g. depression as measured by the BDI-II, 
Apathy as measured by the AES-S, sadness as measured by the VAS) and lower levels of 
symptoms with positive valence (e.g. happiness, interest on the VAS) than controls.  Regardless 
of the version used (AES-S, AES-I or AES-C) subjects with syndromes associated with FTLD 
scored significantly higher on the AES than healthy older subjects, consistent with previously 
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reports of increased apathy in dementia(147) and specifically FTLD(183) and informant reports 
of apathy via the NPI and CBI-R. 
Reports of both apathetic and impulsive symptoms occurring in the same subject were 
common on the NPI-Q, consistent with high self-rated apathetic and impulsive symptomatology 
on (for example) the AES and BIS.  This is consistent with previous reports of co-occurrence of 
apathy and impulsivity in other disease states such as Parkinson’s(171).  
Subjects with FTLD may have diminished insight into their own disabilities, emotional or 
cognitive state(195), subjects with language disorders may not understand the testing material 
when using self reported questionnaires.  I have presented the responses from one illustrative 
subject who despite remaining independent and living alone with reasonably well preserved 
cognition in most modalities had great difficulty completing visual analogue scales.  While some 
of this difficulty appears to be her ability to comprehend the task itself her ability to dissociate 
distinct emotional states beyond a unipolar positive/negative valence appeared to be impaired.  
However, at a group level, when completing the visual analogue scales, most subjects did not use 
a unipolar happy/sad or positive/negative scale but instead Principal Component Analysis 
revealed four factors correlating with other measures of motivation, positive and negative 
emotional states and fatigue separately. Hence while some subjects with syndromes associated 
with FTLD may have diminished insight, or a simplified comprehension of emotional states, 
when considered at a group level they are still able to respond to questionnaire and structured 
interview to provide meaningful insights into how they are feeling.  Consistent with the reports 
of their carers they report increased negative emotional feelings, symptoms of apathy and 
depression, decreased motivation and hedonic tone.  These reports cannot be simplified into a 
single negative state but reflect complex and multifaceted symptomatology. 
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3.6 Conclusions 
I have shown that a range of questionnaire and paper and pencil tests of cognition, emotion and 
motivation can be applied to a cohort of subjects with syndromes associated with FTLD.  
Regardless of whether the subject is asked, or an informant who knows them well, subjects with 
FTLD associated syndromes have higher levels of cognitive impairment and neuropsychiatric 
symptomatology across a range of cognitive and behavioural domains and these are a frequent 
source of distress for those around the subject.  Apathy and impulsivity are frequently reported 
in FTLD and frequently coexist within a single subject.  While some subjects with FTLD do have 
impaired ability to self report psychological symptoms and understand some aspects of this 
form of testing, considered together they are able to provide meaningful insights into their own 
emotional and motivational states.  Consistent with the reports of their carers, subjects with 
FTLD associated syndromes report increased negative emotional feelings, symptoms of apathy 
and depression. They also report decreased motivation and hedonic tone.  Finally I have shown 
that these reports cannot be simplified into a single uni-dimensional positive/negative valence 
state but instead reflects complex and multifaceted symptomatology.  
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Chapter Four 
Behavioural Assessment of Apathy and Impulsivity in FTLD  
4.1 Summary 
In this chapter I discuss the limitations of questionnaire-based assessments of apathy and 
impulsivity and how an alternative approach, assessing behavioural surrogates of goal directed 
cognition may overcome some of these.  I then present the methods by which I have done this 
amongst the PiPPIN cohort of patients with syndromes associated with FTLD and a group of 
healthy older controls.  I show that the patient group perform differently to controls across the 
entire range of tasks and respond more slowly and less accurately. I also show that the patient 
group are still sensitive to changes in potential reward and adapt their responses accordingly 
but do so differently to healthy older controls.  Compared with controls, patients demonstrated 
deficits in action restraint, action cancellation and higher temporal discounting rates.  I suggest 
that these data cannot be explained by disruption of a single cognitive process and may all 
contribute to apathetic and impulsive behaviour in FTLD. 
 
4.2 Introduction 
In Chapter Three I discussed apathy and impulsivity in FTLD.  As seen in other studies 
(e.g.(147)), within the PiPPIN cohort of subjects with FTLD associated syndromes apathetic and 
impulsive symptoms are common and a source of patient and carer morbidity.  I have shown it is 
possible to quickly and simply identify problematic symptomatology by using informant 
questionnaires. Despite their cognitive impairments, subjects with FTLD associated syndromes 
are mostly able to provide insights into some aspects of their motor, functional, cognitive, 
emotional and motivational states using structured interviews and questionnaires (except see 
Figure 3.6 for some of the problems that may be encountered).   
This approach is relatively straightforward and inexpensive but has limitations.  
Responses to informant-based assessments are influenced not only by the subject’s symptoms 
but also by the informant’s interpretation of them and the questions asked.  The informant’s 
own mental state and levels of distress may also influence their responses.  Similarly subject 
interviews and questionnaires are limited by the subject’s understanding and interpretation of 
the questions asked and their ability (and desire) to perform the introspective self-analysis 
necessary for accurate responding.  While I have shown that subjects with FTLD associated 
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syndromes are able to provide meaningful responses, this approach when used in isolation, 
cannot demonstrate that their responses are entirely accurate and representative of their 
underlying neuropsychiatric state.  I have also shown that this approach cannot be applied 
equally for all subjects.  Language and other cognitive impairments limited some subjects’ ability 
to accurately respond to questionnaire-based assessments.  While I have argued that my results 
demonstrate some ability for meaningful introspection, it was clear during testing that some 
subjects insight into their own behaviour was limited, others found particular aspects of the 
testing difficult.  For example some subjects with svPPA did not understand particular words or 
the underlying concepts in some aspects of the questionnaires. Responses to questionnaires are 
also dependant on the specific questions asked and how they relate to the subject’s individual 
circumstances.  Some questionnaires (such as the CBI-R) use behaviour as a surrogate for 
cognitive and psychological state.  Asking (for example) whether the subject shows less 
enthusiasm for his or her usual activities may identify changes in motivation or apathy but this 
is a presumption, the subject may lose interest for other reasons such as physical disability or 
decline in visuospatial function.  
Questionnaire based approaches may offer a ‘score’ or scale by which symptomatology 
may be graded but whether such as scale is an appropriate way in which to quantify 
symptomatology is questionable.  Whether a particular score on the AES (for example) can be 
equated to a particular stage of disease, amount of neurodegeneration, or change in behaviour is 
not clear.  Similarly it cannot be assumed that all items within a scale should be considered of 
equal value (for example suicidal feelings compared with feelings of guilt on the BDI-II). 
Questionnaires may have been validated by replication and psychometric properties 
assessment, but often only in a very different clinical context e.g. young adult depression, rather 
than late life dementia.  As a result questionnaire based assessments may provide useful insights 
and effective screening tests for neuropsychiatric disease but there is also a need for more 
objective and quantifiable measures, particularly with a view to understanding the biology of 
neuropsychiatric symptoms and evaluating response to symptomatic therapies.  
One approach to overcome the limitations of questionnaire/interview evaluations is to 
use behavioural testing.  Rather than directly enquire about a particular symptom or its 
consequences, by instead asking the subject to perform a relevant task designed to correspond 
to a particular symptom it is possible to measure their performance in a more objective and 
quantifiable fashion.  For example subject speed and accuracy on a theoretical task that requires 
them to make quick decisions in response to a stimulus cue may be used as a surrogate marker 
for aspects of attentiveness or impulsivity.  A simple task may be designed to measure particular 
aspects of behaviour and decision-making and hence delineate aspects of behaviour that may be 
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preferentially impaired in disease states.  This method potentially may allow the examiner to 
examine the underlying cognitive processes responsible for symptomatology in disease and 
hence the underlying neural mechanisms, offering insights which may pave the way to better 
symptomatic therapies and methods by which their effects can be quantified and tested. 
The Go/NoGo task and Stop Signal Reaction Time (SSRT) task are two examples of 
behavioural testing which have been used to assess impulsivity.  For the Go/NoGo task the 
subject is shown a randomised series of directional cues with either a ‘Go’ or ‘NoGo’ cue (e.g. a 
green or red light) they are instructed to make speeded responses in the direction indicated 
when presented with a ‘Go’ but not to respond when ‘NoGo’ is presented.  The SSRT is similar in 
that the subject is asked to make speeded directional responses except that instead of a ‘NoGo’ 
cue on a minority of trials a beep is heard shortly after the initial cue.  When this occurs the 
subject is instructed to inhibit their response.  Hence in the Go/NoGo task the subject is asked to 
refrain from making a response whereas the SSRT task tests their ability to cancel their 
response.  This subtle different in response inhibition has been shown to have dissociable 
neuroanatomical and neurotransmitter systems across a range of species, including 
humans(168).  A similar approach has been used in disease states such as Parkinson’s(218) to 
demonstrate impulsivity is not a unitary construct but has a range of underlying neural 
mechanisms. 
Based on the hypothesis that apathy and impulsivity are multidimensional constructs 
related to disruption of goal directed cognition, reward responsiveness, action initiation and 
inhibition, I aimed to use behavioural tasks that have been designed assess these aspects of 
behaviour to measure selective but objective impairments in the PiPPIN cohort.   
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4.3 Methods 
Patients with syndromes associated with FTLD identified in the PiPPIN study, and fifty healthy 
older controls, and were invited to complete a range of behavioural tasks.  The tasks selected 
were chosen to assess particular behavioural and cognitive processes considered relevant to 
apathy and impulsivity after discussion with Professors James Rowe (my supervisor), Barbarah 
Sahakian and Trevor Robbins.  The tasks were presented along with the questionnaires 
discussed in Chapter Three.   
A pragmatic approach was taken to maximise participant inclusivity and enable subjects 
with significant disabilities to contribute to the study.  Therefore, the order of 
tasks/questionnaires was not fixed and not every subject was expected to be able to complete 
every aspect of the testing battery.  Instead where a subject had marked difficulty understanding 
or completing one aspect of the protocol the particular test would be terminated and they would 
be asked to move on to another.  The assessments were varied to maintain subject interest and 
attentiveness.  Frequent breaks were offered and on some occasions the testing would be split 
over a number of sessions on different days.   
4.3.1 The Go/NoGo Task.  
Two versions of the Go/NoGo task were administered.  Firstly with the patient sitting in front of 
a Panasonic Toughbook laptop.  An initial cue of a red and a green circle is presented on the 
centre of the computer screen.  One circle then disappears and an arrow pointing left or right 
appears.  Subjects are asked to move a joystick in the direction of the arrow when the green 
circle remains but not when the red circle remains.  150 trials were administered to each 
subject. 
The second version of the Go/NoGo task was administered using a head mounted 
saccadometer (Ober Consulting) a similar Go/NoGo task also administered.  Instead of a 
computer screen lasers are projected onto a wall approximately 1.5m from the subject.  A green 
and a red laser dot form the initial cue and then one is removed and a directional cue (another 
red laser) appears ten degrees to the left or right of the initial cue (replacing the arrow on the 
computer version).  Instead of a joystick subjects simply make a saccadic eye movement to the 
left or right which is tracked using the reflection of an infrared bean projected onto their 
corneas.  300 trials are administered per subject.  As the projection and recording equipment is 
head mounted and moves as the subject does head fixation is not required.  Data was 
downloaded and analysed using the LatencyMeter software package (Ober Consulting Version 
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6.5) and automatic trials validation used to exclude non saccadic responses based on position 
and velocity profiles of each individual trace. 
There are six possible responses for each trial; Go Correct Right Direction (GCRD), Go 
Correct Wrong Direction (GCWD), Go Incorrect Right Direction (GIRD), Go Incorrect Wrong 
Direction (GIWD), Nogo Correct (NC), Nogo Incorrect (NI).  Mean reaction times (in 
milliseconds) were calculated for each of the Go responses and the mean number of each 
response type were calculated.  Outliers greater than three standard deviations from the mean 
(within patient or control group) were excluded from each outcome variable.  The sensitivity 
index (d’), calculated to give a measure of subject’s ability to discriminate between Go and Nogo 
trials through their responses.  First the proportion of Go trials to which the subject responded 
Go (in either direction) was calculated (hit rate) and the portion of incorrect Go responses for all 
NoGo trials (false alarm rate) were calculated.  The difference between Z-transformations of hit 
rate and false alarm rate were calculated to give d’ as follows:  
 
𝑑′ = 𝑍 ( 𝐺𝐶𝑅𝐷 + 𝐺𝐶𝑊𝐷𝐺𝐶𝑅𝐷 + 𝐺𝐶𝑊𝐷 +𝑁𝐼) − 𝑍 ( 𝐺𝐼𝑅𝐷 + 𝐺𝐼𝑊𝐷𝐺𝐼𝑅𝐷 + 𝐺𝐼𝑊𝐷 + 𝑁𝐶) 
 
Where GCRD, GCWD, GIRD, GIWD, NI and NC represent the total number of Go Correct Right 
Direction, Go Correct Wrong Direction, Go Incorrect Right Direction, Go Incorrect Wrong 
Direction, Nogo Incorrect and Nogo Correct responses for each subject.  Where either hit rate or 
false alarm rate were 0 or 1 values were adjusted up or down to 0.99 or 0.01 to allow Z 
transformation. 
4.3.2 The Stop Signal Task  
The Stop Signal Task (SST) was administered using the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) (Cambridge Cognition).  Stimuli were present on a computer 
screen and responses made by pressing one of two buttons (left and right) on a two buttoned 
press pad.  The test is administered in two parts, the first is a practice session where subjects are 
shown an arrow pointing either left or right and asked to press the corresponding left or right 
button as quickly as possible.  In the second part the subject is told to continue pressing buttons 
in response to the arrows but if they hear an auditory beep (stop signal) they should not press 
the button.  The second part of the task was administered in five blocks of 64 trials.  Stop signals 
were present in 25% of trials (randomly dispersed) and the delay between the arrow cue and 
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stop signal varied (Stop Signal Delay, SSD) to give an estimate of the stop signal reaction time 
(SSRT) i.e. the time it takes to internally suppress a response.  Between trials the SSD varies 
according to previous responses.  After successfully inhibited responses the SSD is increased 
making it more difficult, when the subject fails to inhibit a response the SSD is decreased.  An 
estimate of SSRT is calculated by subtracting the mean SSD at which the subject is able to stop 
on 50% of trials (SSD (50%)) from the mean reaction time on go trials (where no stop signal is 
present).  Total correct responses on stop and go trials, direction errors on stop and go trials, 
median reaction times for correct and incorrect direction responses on go trials were also 
recorded. 
4.3.3 The Information Sampling Task 
The Information Sampling Task (IST) was administered using the CANTAB touch screen 
computer.  The subject is presented with a 5x5 array of grey boxes and two larger coloured 
panels below the boxes.  They are instructed that they are playing a game for points that they 
can win by making a correct decision about which colour is under the majority of grey boxes.  By 
touching the boxes one at a time they open (and remain so) to reveal one of the two colours 
shown at the bottom of the screen.  When the subject is ready to make a decision about which 
colour is the majority they touch the panel of that colour.  All the remaining boxes then open and 
a message informs the subject whether they were correct.   
The colours change for each trial.  After a single practice trial subjects complete 10 trials 
where they are awarded 100 points for a correct decision regardless of how many boxes are 
opened and then 10 trials where the number of points for a correct decision starts with 250 
points and decreases by 10 points with each box opened.  For all trials an incorrect decision 
costs 100 points.  Errors, total correct trials, mean number of boxes opened per trial and 
probability of a correct decision based on the available evidence at the time of decision are 
automatically calculated by the Cambridge Cognition software and downloaded. 
4.3.4 The Kirby Temporal Discounting Task 
The Kirby Temporal Discounting Task is a 27-item questionnaire.  For each item subjects are 
asked to choose between an immediate smaller monetary reward today or a larger reward in a 
specified number of days.  Delay discounting refers to the perceptual decrease in value of an 
item (in this case money) as the delay to reward increases.  Subjects vary in their rates of delay 
discounting, with more impulsive individuals less prepared to wait for larger deferred rewards 
and the rate of delayed discounting also varies within subject based on the size of the rewards.  
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The rate of delay discounting are modelled by discount curves which fit well to the hyperbolic 
function: 
 
V = A1 + kD 
 
Where V is the present value of reward A available at delay D and k is the discount rate 
parameter.  Their responses are grouped into those for small, medium and large rewards and an 
estimate of indifference factor k determined for each.  By determining the value of k for each of 
the 27 choices it is possible to estimate the value of k for which an individual switches 
preference for immediate smaller rewards from the larger delayed reward.  The Kirby is 
designed so that the items presented can be grouped into small, medium and high delayed 
rewards where the reward increases between items and the length of delay decreases.  
Calculating the geometric mean between the values of k for the two items where the subject 
switches from immediate to delayed reward gives an estimation of k at which the subject is 
indifferent for each of the three delayed reward sizes, as not every response will necessarily be 
entirely consistent with a single value of k and in such circumstances the value which is 
consistent with the most responses is used.  The proportion of responses consistent with the 
calculated k was also calculated (from a value of zero to one, with one denoting all responses 
consistent with the calculated value of k) (219). 
4.3.5 The Cambridge Gambling Task  
The Cambridge Gambling Task (CGT) was administered using the CANTAB touchscreen 
computer (Cambridge Cognition).  Subjects are shown a row of red and blue ‘boxes’ (presented 
as coloured squares on the screen) and asked to bet on whether a reward is hidden in a blue box 
or a red box.  The ration of blue to red boxes varies between trials.  The stake value (in points) 
varies over time allowing the subject to bet more or less points depending on when they place 
their bet.  Increasing and decreasing stake over time conditions can be set.  
    105 
4.3.6 The Cued Reinforcement Reaction Time Task 
The Cued Reinforcement Reaction Time Task (CRRT) was based on the description from Cools et 
al (220).  It is designed to assess the influence of cues that signal reward on motivation when 
completing an odd one out reaction time task.   Figure 4.1 explains the paradigm which was 
simplified from Cools et al’s original task (two colour/probability arrangements used instead of 
3 and 50 trials as opposed to 100).  
Figure 4.1 The Modified Cued Reaction Reinforcement Time Task.  Subjects are presented 
50 trials each starting with a fixation cue (first box) followed by the three circular arrangements 
(second row).  They are instructed to select the odd one out (in this case the right circular 
arrangement) by pressing one of three buttons on a press pad.  On half of the trials the 
probability of receiving feedback is 80%, on the other half the probability is 20%.  The 
probability of receiving feedback is indicated by one of two colour boxes surrounding the circles 
(red or blue).  The pairing colour to probabilities is varied between subjects.  When feedback is 
given, rapid correct responses score 100 points and are shown a green smiley face together with 
a fanfare sound.  Slow correct responses score 1 point and are accompanied by a high frequency 
ping sound and green smiley face.  Incorrect responses score 0 points and are accompanied by a 
red unhappy face and a low frequency sound.  The cut off for fast/slow responses is calculated 
from the subtracting the standard deviation from the mean response time for 20 practice trials 
where no feedback is given and the fixation cue is shown.  Before this subjects are familiarised 
with the protocol with a block of 20 practice trials without feedback or recording response time. 
100 100 
80% 20% 20% 80% 
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4.3.7 Statistical Analysis 
Statistical analysis was carried out using SPSS v22.  Differences between groups were calculated 
using two tailed T-tests between groups unless otherwise stated. 
 
4.4 Results 
4.4.1 The Go/NoGo Task 
Results from 64 patients and 50 controls were included for the joystick version and 34 patients 
and 43 controls for the oculomotor versions of the task (Tables 4.1 and 4.2).  For all trials where 
subjects went (Go) regardless of trial type (Go/NoGo) or direction, patients were significantly 
slower than controls on the joystick version of the task (p<0.001 for all).  The only significant 
difference between reaction times on the oculomotor task was amongst mean GIRD response 
times (p=0.03).  Omission error (NoGo response to a Go cue) rates in the Go condition were 
higher in patients than controls in both joystick and oculomotor versions of the task (p<0.001 
and p=0.002 respectively). Commission (Go response to NoGo cue) rates in the NoGo condition 
were higher in controls than patients in the joystick version (p=0.002) and the oculomotor task 
(p<0.001).  In the Go condition higher rates of direction error were seen amongst patients 
compared with controls for both versions of the task (joystick: p<0.001, oculomotor: p=0.003). 
Compared with the oculomotor version, on the joystick version of the task both patients and 
controls had a higher d’ (p<0.001) and lower commission errors rate in NoGo trials (p<0.001).  
Direction error rates were lower for the joystick task amongst controls (p=0.004) but not 
significant for patients (p=0.385).  Differences for omission error rates between tasks were not 
significant for patients or controls. 
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 Joystick Task Oculomotor Task 
 Patients  
(N=64) 
Controls 
(N=50) 
Patients 
(N=34) 
Controls 
(N=43) 
Type RT  
(SD) 
No  
(SD) 
RT  
(SD) 
No (SD) RT  
(SD) 
No  
(SD) 
RT  
(SD) 
No  
(SD) 
GCRD  1126.91***
(274.95) 
52.87*** 
(20.75) 
757.99*** 
(108.54) 
68.52*** 
(2.61) 
459.38 
(168.99) 
100.82*** 
(29.89) 
486.95 
(66.64) 
127.49*** 
(12.32) 
GCWD 695.71*** 
(590.46) 
4.19*** 
(9.94) 
156.41*** 
(323.22) 
0.24*** 
(0.52) 
689.00 
(475.16) 
6.21** 
(8.01) 
648.60 
(418.9) 
1.81** 
(3.15) 
GIRD 699.91*** 
(475.69) 
3.56* 
(9.85) 
234.76*** 
(344.65) 
0.56* 
(0.88) 
408.82* 
(132.20) 
74.88*** 
(35.92) 
490.86* 
(174.30) 
40.63*** 
(23.67) 
GIWD 297.29*** 
(463.41) 
0.91** 
(1.97) 
0.00*** 
(0.00) 
0.00** 
(0.00) 
749.07 
(364.22) 
9.06 
(11.26) 
867.59 
(240.16) 
11.70 
(240.16) 
NC NA 71.83** 
(16.74) 
NA 79.42** 
(0.88) 
NA 42.85*** 
(42.50) 
NA 83.05*** 
(37.49) 
NI NA 10.09*** 
(13.62) 
NA 0.96*** 
(2.36) 
NA 17.79*** 
(24.49) 
NA 4.40*** 
(7.82) 
 
Table 4.1 Mean Response Times (milliseconds) by response type for patients with FTLD 
associated syndromes and healthy older controls on the joystick and oculomotor versions 
of the Go/NoGo task.  GCRD=Go Correct Right Direction, GCWD=Go Correct Wrong Direction, 
GIRD=Go Incorrect Right Direction, GIWD=Go Incorrect Wrong Direction, Nogo Correct (NC), 
Nogo Incorrect (NI).  No=Mean Number of Response Type, RT=Response Time, SD=Standard 
Deviation, NA=Not Applicable ***P≤0.001 **P≤0.01 *P≤0.05 Two tailed T-tests comparing 
patients and controls. 
 
 
 Joystick Task Oculomotor Task 
 Patients  
(SD) 
N=64 
Controls 
(SD) 
N=50 
Patients 
(SD) 
N=34 
Controls 
(SD) 
N=43 
Omission error rate 
in Go trials 
0.18 (0.25)*** 0.01 (0.03)*** 0.14 (0.17)** 0.03 (0.06)** 
Commission Error 
rate in NoGo Trials 
0.07 (0.14)** 0.01 (0.01)** 0.68 (0.29)*** 0.39 (0.26)*** 
Directional Error rate 
in Correct Go Trials 
0.10 (0.20)** 0.00 (0.01)** 0.06 (0.08)** 0.01 (0.03)** 
d’ 3.12 (1.31)*** 4.42 (0.32)*** 0.75 (1.10)*** 2.40 (0.94)*** 
 
Table 4.2 Error rates (standard deviation) by error type and sensitivity index, d’, amongst 
patients with FTLD Associated Syndromes and healthy older controls during joystick and 
oculomotor versions of the Go/NoGo task ***P≤0.001 **P≤0.01 *P≤0.05 Two tailed T-
tests comparing patients and controls. 
 
  
    108
4.4.2 The Stop Signal Task 
Sixty-three patients and all controls completed the task (Table 4.3).  Controls responded more 
accurately than patients and made no direction errors.  Median reaction times on correct Go 
trials were significantly faster for controls than patients, SSD(50%) and SSRT significantly were 
significantly shorter for controls compared with patients.  
 Patients  (SD)  
N=63 
Controls (SD)  
N=50 
SSRT 574.67 (1094.51)* 181.08 (41.78)* 
SSD (50%) 570.10 (231.74)*** 362.19 (125.57)*** 
Direction errors on Go trials 7.43 (15.77) 0 
Direction errors on Stop trials 52.00 (17.22) 0 
Median Reaction Time on Go 
trials (correct direction) 
1144.77 (1137.86)*** 535.88 (113.23)*** 
Median Reaction Time on Go 
trials (incorrect direction) 
808.25 (1231.50) NA 
 
Table 4.3 Calculated stop signal reaction times (milliseconds), stop signal delay 
(milliseconds) and error rates amongst patients with FTLD associated syndromes and 
healthy older controls on the Stop Signal Reaction Time Task.  SSRT=Stop Signal Reaction 
Time, SSD=Stop Signal Delay, SD=Standard Deviation.  ***P≤0.001 **P≤0.01 *P≤0.05 Two 
tailed T-tests comparing patients and controls. 
4.4.3 The Information Sampling Task 
Fifty controls and 61 patients completed the IST.  Table 4.4 shows outcome measures for 
patients and controls for both fixed and decreasing reward trial types.  All differences between 
patient and control groups were statistically significant (two tailed T-tests). Patients made 
decisions at lower probability thresholds (probability of being correct) for both decreasing and 
fixed conditions compared to controls. Both groups opened less boxes in the decreasing 
condition compared with fixed (repeated measure ANOVAs: Controls F=40.39, df=1, p<0.001; 
Patients F=35.43, df=1, p<0.001) and made decisions at a lower probability of being correct 
(repeated measure ANOVAs: Controls F=14.80, df=1, P<0.001; Patients F=19.31, df=1 p<0.001).  
Repeated measure ANOVAs for probability of being correct at the time of decision or mean 
number of boxes opened between condition and control vs. patient did not show a significant 
difference between groups (F=1.03, df=1, p=0.313 and F=0.00, df=1, p=0.997 respectively). 
Amongst controls box opening latency was significantly slower for decreased condition 
compared with fixed (repeated measure ANOVA, F=15.61, df=1, p<0.001) but this was not the 
case for patients (repeated measure ANOVA, F=0.02 df=1, p=0.894). 
 
    109 
 Patients (SD) N=61 Controls (SD) N=50 
Condition Type Fixed Decreasing Fixed Decreasing 
Probability of 
being Correct 
0.75 (0.14)*** 0.66 (0.16)*** 0.87 (0.11)*** 0.81 (0.10)*** 
Mean box opening 
latency 
2.11 (2.67)** 2.07 (1.47)*** 0.96 (0.52)** 1.12 (0.44)*** 
Mean colour 
decision latency 
29.33 
(25.78)*** 
26.09 (28.57)*** 18.74 
(8.17)*** 
18.30 (9.54)*** 
Mean boxes 
opened per trial 
14.39 (7.30)** 10.36 (6.01)** 17.84 (5.37)** 13.80 (5.01)** 
Sampling error 1.25 (1.42)*** 1.69 (1.48)** 0.42 (0.73)*** 0.94 (1.00)** 
Discrimination 
errors 
1.50 (1.78)** 1.92 (2.04)*** 0.72 (0.94)** 0.54 (0.76)*** 
Total correct 7.70 (1.76)*** 6.64 (2.28)*** 9.04 (1.12)*** 8.68 (1.15)*** 
Table 4.4 Performance on the Information Sampling Task of Patients with FTLD 
Associated Syndromes and Healthy Older controls.  Latency is in seconds. SD=Standard 
Deviation. ***P≤0.001 **P≤0.01 *P≤0.05 Two tailed T-tests comparing patients and 
controls. 
4.4.4 The Kirby Delayed Discounting Task 
Forty-nine controls and 67 patients completed the Kirby Delayed Discounting task.  Values for k 
for small, medium and large monetary amounts were calculated and shown in Table 4.5.  Mean 
discounting rates (k) were significantly higher in patients than controls with the highest rates 
observed in patients considering the smallest monetary amounts.  Repeated measures ANOVA 
comparing values of k for high and low monetary amounts across patients and controls did not 
show a significant interaction (F=1.72, df=1, p=0.19). Between subjects (patients vs controls) 
ANOVA for k was significant (F=5.03, df=1, p=0.027).  
 Patients (SD) N=67 Controls (SD) N=49 
K Mean 0.037 (0.052)* 0.018 (0.030)* 
K Large 0.031 (0.060) 0.016 (0.050) 
K Medium 0.029 (0.046) 0.016 (0.025) 
K Small 0.049 (0.074)* 0.021 (0.029)* 
Difference (K small-K large) 0.018 (0.057) 0.005 (0.044) 
Consistency Large 0.937 (0.085) 0.984 (0.068) 
Consistency Medium 0.937 (0.085)*** 0.986 (0.025)*** 
Consistency Small 0.932 (0.093)** 0.982 (0.069)** 
 
Table 4.5 Discounting rates, K, for patients with FTLD Associated Syndromes and Healthy 
older controls on the Kirby Delayed Discounting Task.  Large/Medium/Small refers to 
monetary value. SD=Standard Deviation. ***P≤0.001 **P≤0.01 *P≤0.05 Two tailed T-tests 
comparing patients and controls. 
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4.4.5 The Cambridge Gambling Task 
Despite using a modified and reduced version of the CGT patients found the task overly fatiguing 
and difficult.  So few subjects were able to complete the task that it was removed after 
attempting amongst 28 participants and not included in further analysis. 
4.4.6 The Cued Reinforcement Reaction Time Task 
Forty-nine controls and 51 patients completed the CRRTT (Table 4.6).  Controls responded more 
quickly than patients throughout the task.  
Repeated measures ANOVA of difference in response time by condition (0.8 probability 
of reward-0.2 probability of reward) between the first and second half of the trial by patient vs. 
control revealed a significant interaction (F=4.86, df=1, p=0.03).  Reaction times were 
significantly faster in the second half of trials amongst controls for both conditions (T-test, 20% 
condition t=3.14, df 48 p=0.003, 80% condition t=6.83, df=48 p<0.001) but not patients (T-test, 
20% t=1.53, df=50, p=0.134, 80% t=-1.23, df=50, p=0.23). 
  Patients (SD) N=51 Controls (SD) N=49 
Mean Reaction 
Times: First half of 
Trials 
 
20% Chance of 
Reward 
2359.53 (707.90)*** 1013.12 (252.65)*** 
80% Chance of 
Reward 
2200.47 (645.87)*** 1029.48 (253.56)*** 
Mean Reaction 
Times: Second 
Half of Trials 
20% Chance of 
Reward 
2221.58 (646.21)*** 976.04 (242.71)*** 
80% Chance of 
Reward 
2262.08 (627.29)*** 948.09 (225.15)*** 
Table 4.6 Mean Reaction Time (milliseconds) for patients with FTLD associated 
syndromes and healthy older controls on the Cued Reinforcement Reaction Time task. 
***P≤0.001 Two tailed T-tests comparing patients and controls. 
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4.5 Discussion 
Across a range of behavioural tasks aimed at decision-making and reflection impulsivity (IST), 
perception and responsiveness to reward (Kirby, CRRTT, IST), and response inhibition 
(Go/NoGo, SSRTT), patients with FTLD associated syndromes performed differently to healthy 
older controls.  Response times across a range of tasks were consistently slower amongst the 
FTLD group compared with controls with the only exception being the oculomotor task, where 
mean responses were marginally faster for subjects with FTLD associated syndromes compared 
with controls (although most not statistically significant).  As the majority of patients with FTLD 
have some form of movement disorder it is unsurprising that limb reaction times are impaired.  
The relative lack of difference between patients with FTLD associated syndromes and controls 
when considering crude reaction times on the oculomotor task is more notable particularly 
when considering a significant number of subjects with FTLD have impaired saccadic eye 
movements.  This cannot be fully explained by the automated validation process used to filter 
saccadic responses as the mean number of rejected responses was similar for both patients with 
FTLD associated syndromes 30.46 (SD, 17.57) and controls 29.77 (SD, 9.29).  However, the 
calculated d’ for subjects with FTLD associated syndromes was significantly lower on the 
oculomotor task compared with the joystick task demonstrating that while the subjects with 
FTLD associated syndromes were responding quickly, accuracy was substantially diminished. 
Despite responding more slowly on most tasks the patients with FTLD associated 
syndromes were less accurate than controls reflected by higher omission, commission and 
directional errors on both forms of the Go/NoGo task, higher rates of sampling and 
discrimination errors on the IST and more direction errors on the SSRTT. 
While reaction times per se may not be the most useful surrogate of goal directed 
cognition in this FTLD group (because of additional impairments of motor control) changes in 
response to anticipated reward can be interpreted in terms of motivation and goal-directness.  
When responding to the CRRTT, I anticipated healthy controls would respond more quickly in 
the second half of the test for the higher probability of reward condition (i.e. when they 
anticipate a greater chance of reward they respond more quickly).  This is the case in the healthy 
older cohort but the effect is not seen amongst patients, in fact they were marginally slower in 
the higher probability condition in the second half of the task (although the difference was not 
statistically significant).  In absolute terms the patient group were marginally quicker 
responding in the second half of the task for the lower probability condition suggesting that 
different susceptibility to fatigue is not sufficient to explain the lack of a significant response in 
terms of reaction times for the higher probability condition amongst patients in the second half 
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of the trial.  Two alternative explanations may account for the difference between patients and 
controls.  Firstly that controls are able to detect and respond to the difference between 
conditions after the first half of trials while the patients are not, or alternatively, both groups are 
able to detect the difference between conditions after the first half of trials but respond in a 
different way:  Healthy controls, detecting that one condition leads to a higher probability of 
reward, respond more quickly when a greater probability of reward is present.  Patients also 
detect the different probability of reward but respond more slowly either to attempt to increase 
accuracy or to avoid negative feedback (such risk-aversion is only relevant on those trials where 
feedback is given).  Hence the difference between groups may be explained by; (i) decreased 
ability to detect the difference between conditions amongst the patients; (ii)by reduced reward 
responsiveness; (iii) preserved reward responsiveness but inability to increase response speed 
(and hence increased response time to attempt to improve accuracy); or finally (iv) increased 
aversion to negative feedback amongst patients with FTLD associated syndromes. 
While reaction times are measured during the IST (as mean box opening latency and 
colour decision latency) they are not an explicit part of the task and subjects were permitted to 
take as long as they needed to make decisions during the task.  The difference between the two 
conditions (where points available for a correct decision diminishes with each box opened in the 
diminishing condition) may serve as an alternative surrogate of responsiveness to both positive 
and negative feedback.  Negative feedback, when the subject makes an incorrect decision and 
loses 100 points, remains constant between the two conditions and regardless of the number of 
boxes opened.  Hence a subject who is more averse to negative feedback may choose to open 
more boxes and increase their chance of success even when this reduces the potential number of 
points available for a correct decision.  However this was not the case.  Both patients and 
controls opened less boxes and made decisions at a lower probability of being correct in the 
decreasing condition compared to the fixed condition, suggesting at least for the IST, the patient 
group were able to recognise the difference between the two conditions and adapt their 
technique in response to diminishing rewards in a similar fashion to controls. 
Taken together these results suggest that compared to controls, patients with FTLD 
associated syndromes respond more slowly and less accurately.  When potential reward or 
negative feedback is presented, both patients and healthy controls are responsive to feedback 
and adapt their response strategies.  Unlike controls, patients are unable to improve response 
time but they still sacrifice accuracy when response time is explicitly connected to reward. 
Controls, but not patients, spent significantly longer deciding whether to continue 
sampling or make a final decision on the IST (mean box opening latency) during the decreasing 
    113 
condition compared with the fixed.  While patients adapted their strategy to the change in 
condition (fixed vs. decreasing) deliberation time during sampling did not change significantly 
(in fact it was marginally shorter during the decreasing condition).  Box opening latency was 
however substantially longer across all conditions for the patient group compared with controls.  
It may be that the lack of change in deliberation time between conditions amongst patients is 
explained by the time it takes for any response being sufficiently long to allow sufficient 
deliberation regardless of condition (because motor disability delays the time to make a 
response and hence already allows more than sufficient deliberation time) or alternatively that 
the patient group are unable to adapt deliberation time in response to change in condition.  On 
average patients made a decision after opening less boxes than controls across both conditions.  
Hence the patient group make decisions based on less information, they are sensitive to changes 
in condition and reward and adapt their response strategy accordingly but do not adapt 
response time. 
Performance on both the SSRT and Go/NoGo tasks relies on action inhibition i.e. the 
inhibition of a pre-planned response(168).  These tasks have been used to investigate 
impulsivity in a range of disorders such as Attention Deficit Hyperactivity Disorder(221), 
Parkinson’s Disease(222),  PSP(223) and FTD(187).  Despite their similarities there is evidence 
from a range of animal and human studies that performance on the two tasks depends on 
different neuroanatomical networks and may be modulated by different neuropharmacological 
interventions (with 5-HT implicated in the inhibitory control on the Go/NoGo task but not the 
SSRT task which is more sensitive to noradrenaline)(168).  While the Go/NoGo task tests action 
restraint (inhibiting a response before the response is started) the additional element of the stop 
signal after the initial stimulus during the SSRT task tests action cancellation (the ability to 
inhibit a response after it has started).  The highest error rate on the oculomotor task was seen 
amongst the patient groups’ rates of commission errors.  During the oculomotor task both 
patients and healthy controls had higher rates of commission (as opposed to omission) errors 
but the reverse was seen amongst patients during the joystick task and the same low rate seen 
for both error types amongst controls.   The oculomotor version of the Go/NoGo task has the 
advantage of measuring the time to initiate movement as opposed to execution time and relies 
on the patient initiating a smaller action (initiation of a saccade) to register a response.  In 
contrast the joystick version requires a greater movement and it is conceivable that subjects are 
able to inhibit a smaller response after it has been initiated (action cancellation) and not register 
a response by full movement of the joystick.  However, compared with controls, patients also 
had longer SSD and SSRT on the SSRT task suggesting both action restraint and action inhibition 
are impaired in FTLD.  
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Delayed discounting refers to the tendency for more remote outcomes to have less 
perceived value(224).  Individuals would prefer greater and more immediate rewards but when 
a temporal delay is introduced the perceived value diminishes such that (for example) an 
individual may prefer to receive £100 today rather than wait a year and receive £150.  The 
discounting rate, k, reflects the rate at which the perceived reward diminishes with delay (such 
that a higher value of k reflects a more steep discounting of future rewards and a greater 
tendency to choose an immediate reward).  Healthy controls tend to have higher discounting 
rates when considering smaller monetary amounts(224) and discounting rates are higher 
amongst groups with impulsive behaviour such as compulsive gamblers(225), heroin addicts, 
and patients with orbitofrontal damage(226) and schizophrenia(227).    
Amongst this cohort the patient group had higher rates of temporal discounting than 
controls. The highest rates of temporal discounting were seen for smaller monetary amounts for 
both the patient group and healthy controls which was similar to previous studies (e.g. (219)).  
While patients had overall higher rates of temporal discounting their consistency rates were 
lower such that the point at which they chose to switch from higher delayed reward to smaller 
immediate reward was not consistent across all their responses.  A similar effect has been 
reported in other disease groups (e.g. schizophrenia (227)) and inconsistency in response may 
also be a contributory factor in reported impulsivity in this disease group. 
The effect of FTLD on discounting rates has been reported previously but is not clear.  
One study found increased discounting rates in patients with bvFTD(228) however in a another 
discounting rates were not significantly different compared with healthy older controls or 
patients with Alzheimer’s Disease.  This was in contrast to a group of patients with svPPA who 
demonstrated higher discounting rates(229).  One explanation for the discrepancy is by 
specifically screening and excluding patients with semantic deficits from the bvFTD the second 
study selected less severely affected patients with bvFTD and damage to anterior temporal lobe 
structures related to the more pronounced semantic symptoms in svPPA may contribute to 
more rapid delay discounting.  The authors suggest that delay discounting may be unaffected 
early in bvFTD but is affected as the disease progresses and spreads to involve more brain 
regions overlapping with svPPA(229).  This serves to emphasise that using the existing 
diagnostic criteria used to define the syndromes associated with FTLD may inadvertently lead to 
misrepresentative cohorts when researching particular neurocognitive aspects of the disease as 
a whole. 
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4.6 Limitations 
In this chapter, and also in Chapter Three, I investigated a range of neuropsychiatric features of 
FTLD, focussing in particular on the symptoms of apathy and impulsivity.  I have recruited 
subjects with FTLD associated syndromes from a population based epidemiological study and 
using a range of techniques (including clinical assessment, carer reports, patient questionnaires 
and behavioural testing) demonstrated increased rates of apathetic and impulsive 
symptomatology.  I have suggested that these data show that these are prevalent symptoms in a 
representative cohort of subjects.   
However there are several limitations.  Firstly this sub-group may not be representative 
of FTLD associated syndromes as a whole.  I was not able to assess every subject identified in the 
epidemiological study in person.  In Chapter Two I presented the frequency of particular 
symptoms across the entire cohort but in some cases I relied on specialist assessments and 
subsequent clinical records.  It may well be in such cases the focus of the clinical encounter was 
directed at particular symptoms such that other features (which may have been present) were 
not specifically enquired about or recorded.  In this chapter, and Chapter Three, I have focussed 
on only those subjects I was able to meet in person who were able to engage in some form of 
testing (even if this was limited to clinical assessment and carer interview).  Whilst I travelled 
out to meet subjects in their own home and met subjects at every stage of disease, it is possible 
that those patients and carers who were willing to participate were less severely affected than 
those who refused any participation beyond case notification and clinical records review.  In 
addition to this, the nature and amount of testing possible amongst those subjects I met was 
dependant on their physical and cognitive abilities.  Some tests (such as the Cambridge 
Gambling Task) had to be abandoned completely as subjects with FTLD associated syndromes 
were so often simply not able to fully understand and complete the task.  Other tests such as the 
Go/NoGo were only completed by a large subset of subjects who were physically able to move a 
joystick and had sufficient cognitive ability to understand the task.  Additional elements of their 
clinical syndromes such as limb dystonia, myoclonus or apraxia prevented some subjects from 
completing the task and may have contributed to the responses recorded of others who were 
less severely affected and hence able to participate in the task.  The oculomotor version of the 
Go/NoGo task overcomes any difficulties presented by limb movement disorders but other 
subjects had difficulty completing the task because of impairments of voluntary eye movements, 
blepharospasm or severe apraxia of eyelid opening.  Similarly language disorders may have 
impaired responses to some questionnaires, visuospatial problems may affect responses on the 
IST and so on. As a result while I have demonstrated high levels of apathetic and impulsive 
symptomatology amongst patients with FTLD regardless of the testing modality used or subset 
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of subjects assessed I have not been able to demonstrate changes in every subject for every 
testing modality.   Only a minority of patients with FTLD associated syndromes were able to 
complete every aspect of the testing protocol.  Restricting analysis to only this subset of subjects 
would firstly have led to substantially reduced sample size but also more importantly lead to a 
cohort that is less representative of the syndromes associated with FTLD as a whole. 
In this chapter I have demonstrated that this patient group show respond differently to 
healthy controls across a range of tasks that have been used to test a range of neuropsychiatric 
symptoms and components of decision making which have previously been used to test 
components of apathy and impulsivity in a range of clinical conditions (e.g. (17,165)).  While 
patients with FTLD associated syndromes and their carers reported higher levels of apathy and 
impulsivity compared with controls and performed differently on these tasks, I have not 
attempted to demonstrate that performance on these more “objective” tests directly relates to 
levels of reported apathy/impulsivity per se. 
Most of the justification for studying apathy and impulsivity is derived from patient and 
carer based reports and the correlation between these and disease morbidity 
(132,133,147,164).   It is not certain that the specific neurocognitive processes that these 
behavioural tasks seek to test are directly responsible for the patient and carer based reports of 
apathy or impulsivity.  Other factors such as patient insight, mood, fatigue or depression may 
relate to their own reports of symptoms.  Similarly carer based interviews are limited by their 
own perspectives where symptoms may be misinterpreted or influenced by other factors (such 
as the carer’s own psychological state).  For example, one study comparing fitness to drive 
(assessed by naturalistic driving assessment and instructor based standardised road test) with 
carer and clinician rating of driving safety amongst patients with Alzheimer’s disease found only 
weak associations between clinician assessment and driving performance and an inverse 
association between spousal ratings and naturalistic driving scores.  In another study of 156 
patients with Alzheimer’s disease significant disagreement was found between carer and 
clinician assessment of neuropsychiatric symptoms, particularly those that may be related to 
apathy and impulsivity(230).   
A questionnaire-based assessment is limited by the nature of the question asked.  Simply 
asking whether the subject is apathetic relies on their own understanding of the concept of 
apathy and even a more detailed assessment based on symptoms in a range of situations may 
not fully apply to the respondent’s particular circumstances (for example asking about social 
interactions or day to day conversation may not be appropriate when the respondent has 
expressive language difficulties). It is not clear that the symptoms that are reported by patients 
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or their carers are an accurate assessment of apathy or impulsivity as specific 
neuropsychological constructs, or that objective behavioural testing directly relates to clinically 
important outcome measures (something I address in more detail in subsequent chapters).  By 
not relying on a single testing modality, using a range of testing techniques and multiple sources 
of information I have demonstrated that while each individual test may have limitations this 
patient group consistently performs differently in these tasks and have higher reported rates of 
apathy and impulsivity compared to a similarly aged group of healthy older people.   
 
4.7 Conclusions 
Using a range of behavioural tasks directed at decision-making, reward responsiveness and 
action inhibition I have shown that patients with FTLD associated syndromes respond 
differently to healthy older controls.  Patients respond more slowly and are less accurate across 
a range of tasks.  The data I have presented here suggest that subjects with FTLD associated 
syndromes are able to detect and adapt their responses to changes in perceived reward but do 
so differently than healthy older controls.  Furthermore I argue that these differences cannot be 
explained by disruption of a single cognitive process.  I suggest these data demonstrate that 
subjects with FTLD associated syndromes have deficits in both action restraint and action 
cancellation.  They have higher rates of temporal discounting and different responses to the 
healthy group when presented with positive and negative feedback.  All of these processes may 
be contributory to the observed increase in both apathetic and impulsive behaviour observed in 
this patient group.  
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Chapter 5 
A Multidimensional Approach to Apathy and Impulsivity in 
FTLD 
5.1 Summary 
In this chapter I discuss the multidimensional nature of apathy and impulsivity and the 
relationship between questionnaire based and behavioural forms of assessments in the PiPPIN 
study of subjects with syndromes associated with FTLD.  Through Principal Component 
Analyses I show that variation in responses on the Apathy Evaluation Scale appears to be 
multifactorial and while some aspects may be related to the original component structure others 
appear more related to the manner in which the items on the scale are presented.  I also show 
that while multiple respondents (patient, carer, clinician) report high levels of apathetic 
symptomatology, patient and carer reports do not correlate well with each other and that these 
discrepancies may be quantified and may reflect a useful form of assessment.  Next I separate 
patients into those rated as apathetic, impulsive or not by their carers and show that 
comparisons of behavioural surrogate measures of these symptoms do not show significant 
differences between groups.  Finally I perform a further Principal Component Analysis 
combining assessment of apathy and impulsivity by multiple methodologies and show that these 
measures dissociate into a number of components.  Behavioural and questionnaire based 
assessments largely do not overlap and appear to be measuring different things.  I conclude that 
apathy and impulsivity are multidimensional and that while different testing modalities each 
have their own advantages and limitations no single method in isolation is sufficient for the 
assessment of apathy and impulsivity and that a multidimensional approach is necessary. 
 
5.2 Introduction 
In Chapter Three I demonstrated that both apathetic and impulsive behaviour are commonly 
reported by patients with syndromes associated with FTLD in the PiPPIN cohort and also by 
informants close to them.  I also showed that a range of questionnaire based assessments can be 
used to record and quantify some of these symptoms.  For example, using Apathy Evaluation 
Scale I demonstrated that regardless of whether the scale is completed by the patients, an 
informant who knows them well or by a trained assessor using a structured interview, higher 
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frequency of apathetic symptoms are reported amongst patients than amongst healthy subjects 
of a similar age. 
 The Apathy Evaluation Scale was derived from several hundred items designed to address 
apathetic symptoms based on the authors’ observations and conceptualisation of apathetic 
subjects(158).  After further consultation this was reduced to a preliminary scale of 70 items 
that were considered unambiguous, easily understood and representative of the domains of 
interest.  This 70-item scale was administered to 40 subjects with a diagnosis of major 
depression or dementia, a further 14 items removed again on the basis of simplicity and clarity 
and a revised 56 item scale administered to a group of 122 subjects aged 55-85 years old and 
comprising of well elderly, patients with left or right hemisphere strokes, probable Alzheimer’s 
disease or major depression.  Subjects with other neurological or psychiatric diagnoses were 
excluded.  Informant, clinician and patient versions of the scale were administered and the total 
number of items reduced to include only those than had item total correlations between at least 
three of the four versions of the scale of 0.4.  The resultant 27 items were reduced to 18 on the 
basis of non significant correlations with the Hamilton Rating Scale for Depression (seven items, 
in order to differentiate apathy from depression) and using the Principal Component Analysis 
method(158).  The resultant 18 items are classified into four types (Cognitive, Emotional, 
Behavioural and Other), three items are presented with negative syntax and for the Clinician 
version, four are self evaluated directly by the subject (as opposed to relating to the clinical 
impression) and four are quantifiable (based on the number of examples of a particular 
behaviour the subject can present). Principal Component Analysis (PCA) of the 18 item scale 
identified three similar factors for each version of the scale accounting for 50-65% of the 
variance with a single factor accounting for 32-53% of the variance(158).  
 This partially data driven approach has been used to design numerous scales for the 
assessment of psychological symptoms.  These scales have many advantages; they are quick and 
relatively simple to administer and score and offer a degree of uniformity and inter-rater 
reliability that is difficult to achieve using less structured subject interviews and assessment. 
Using a simple points allocation for each item within a scale allows quantitative scoring of 
individual subjects and groups.  However there are limitations to this approach.  Firstly any 
questionnaire is limited by the subject’s capacity to understand each item and apply it to their 
own circumstances in the manner in which the questionnaire’s designer intended.  Many 
questionnaires (for example the BIS/BAS scales) were designed and validated in healthy 
younger subjects (178) while others (e.g. BIS-11 and AES) used a combination of healthy 
subjects, psychiatric patients and patients with non-FTLD neurological disorders(158,169). 
Using a semi data driven approach such as PCA to gain insights into common components of 
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heterogeneity amongst subjects’ responses potentially leads to several issues, particularly when 
these scales are applied to different patient groups.   
 Amongst a cohort consisting of patients and healthy volunteers one of the greatest 
differences between subjects’ responses is likely to be disease state.  A single factor explaining a 
large amount of heterogeneity between subjects may account for the majority of variance 
between subjects’ responses and obscure subtler variance using the PCA method.  Hence the 
concept of apathy as measured in the AES may appear more uniform than it is in reality.  In 
Marin’s original paper we see more than half the variance accounted for by PCA attributed to a 
single factor(158).  This may be the case, but an alternative explanation is that the inclusion of 
healthy older volunteers introduces a single large difference between subjects that obscures 
more subtle factors responsible for apathetic symptoms when present in disease states. 
Furthermore while the component structure maybe uniform across different diseases but this is 
not necessarily the case.  The causes and symptoms related to apathy in depressed individuals 
maybe very different to those seen in FTLD and hence a purely data driven set of subscales 
derived from one subject group with a particular set of disorders may not be directly applicable 
to another. 
 Questionnaire-based assessments rely on the respondent’s understanding and 
interpretation of the questions set and their own insight in their condition.  Some subjects 
(especially those with FLTD) may lack insight into their condition(195) but informant responses 
may also be limited by their own interpretations of the patient’s cognitive state or their own 
psychological state and distress(231).  While in other disease states Marin demonstrated good 
internal consistency, test-retest and interrater reliability(158) behavioural changes and 
anosognosia seen amongst subjects with FTLD are particularly severe compared to other 
diseases and distressing for carers.  Hence while good interrater reliability for the AES has been 
demonstrated in other disease states there are good reasons that it should not be assumed that 
this is also the case for FTLD. 
In Chapter Four I discussed some of these limitations of a questionnaire based approach 
and demonstrated that using a range of behavioural tasks designed to assess goal directed 
behaviour, patients with FTLD associated syndromes perform differently to healthy older 
controls.  I suggested that using such a behavioural approach may overcome some of the 
limitations of questionnaires and provide a more objective and quantifiable method of assessing 
changes in cognition that could lead to apathetic or impulsive behaviour.  This approach has 
previously been successful in demonstrating that different behavioural tasks have different 
neuroanatomical and neurotransmitter correlates, even when the differences between tasks 
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seem relatively subtle(162).  Experimental modulation of these neural systems may offer further 
insights not only into the underlying mechanisms responsible for apathy and impulsivity but 
also ways into methods by which they may be treated.  For example, one study used 
magnetoencephalopthy recording of subjects with bvFTD and healthy controls during a 
Go/NoGo task to show that successful response inhibition related to cortical sources in the right 
inferior frontal gyrus and anterior temporal lobe.  These sources were significantly attenuated in 
bvFTD but could be partially restored using the Selective Serotonin Reuptake Inhibitor (SSRI) 
citalopram(187).  SSRIs have been used in the treatment of behavioural symptoms amongst 
patients with bvFTD but despite promising reports of improvements in small open label case 
series, these have not been replicated in larger randomised, placebo-controlled trials(232).  
Similarly there is evidence that noradrenergic and dopaminergic systems have a role in goal 
directed behaviour.  Blockade of alpha-2 adrenoreceptors in rats during the stop signal task 
improved attention and response inhibition while modulation of dopamine D3 receptors 
appears to modulate error monitoring and perseverative behaviours(233).  In a human study 
some, but not all, subjects with Parkinson’s disease showed enhanced response inhibition on the 
SSRT and GoNo tasks with the noradrenaline reuptake inhibitor atomoxetine and when present 
this was associated with increased right inferior frontal gyrus activation and frontostriatal 
connectivity on functional MRI(222).  Another study demonstrated improvement across a range 
of tasks of decision making, response inhibition and goal directed behaviour(234) but there is 
only very limited open label data suggesting any clinically meaningful effects in Parkinson’s (e.g. 
(235)).  
Accepting that goal directed behaviour is a complex and multifaceted construct and that 
disruption in any stage may result in the syndromes of apathy and impulsivity, it is unsurprising 
that attempts to assess specific cognitive aspects using focussed behavioural tasks have not 
yielded immediate dramatic clinical results.  Despite a predilection for specific areas of the brain, 
neurodegenerative diseases such as Parkinson’s and FTLD have, at least by the time of diagnosis, 
widespread effects on multiple areas of the brain. For the same reasons it is unsurprising that 
subjects in the PiPPIN cohort performed differently across the whole range of behavioural tasks 
in a manner that cannot be easily attributed to disruption of a single simple cognitive process.  
In Chapter Three I demonstrated that these subjects show impairments across a range of 
cognitive domains and in Chapter Two that they have a range of overlapping physical and 
cognitive impairments, all of which may have an effect on their ability to perform behavioural 
tasks.  It is comparatively easy to show that subjects with FTLD and their carers report apathetic 
and impulsive behaviour, symptoms of apathy and impulsivity and that they are impaired on 
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tasks of action selection, response inhibition and reward responsiveness but it is much more 
difficult to establish which of these are clinically relevant. 
While questionnaire-based assessments are subject the limitations of the questions set 
and the respondent’s interpretation of them, they do enquire about symptoms in ‘real world’ 
scenarios.   However the validity applying of a set of questionnaires derived from one of set of 
clinical disorders to another (such as FTLD) can be challenged. Behavioural tasks are still limited 
by the subjects’ understanding of the task and their other physical and cognitive abilities, but 
may be more objective and offer the opportunity to examine more specific, focussed areas of 
cognition/behaviour than is possible when using a questionnaire.   However performance on 
behavioural tasks is less explicitly related to symptoms in everyday life.  When moving beyond 
purely academic observation of cognitive processes and towards symptomatic therapy, clinically 
meaningful outcomes measures are needed and hence more than one methodology is required. 
In this chapter I explore the multifaceted nature of apathy and impulsivity and the 
intercorrelation of different methods used in their assessment.  Firstly I explore factor structure 
of the AES-I in relation to Marin’s original three factor solution(158) and test whether PCA 
performed across groups and on patient’s alone produce similar results.  Secondly I examine the 
relationship between subject (AES-S), informant (AES-I) and clinician (AES-C) versions of the 
scale.  I also examine where discrepancies exist between subject and informant reports on the 
AES and CBI-R and the relationship between these and other measures of mood (BDI-II) and 
behaviour (CBI-R) and overall cognition (FAB and ACE-R). Next using the NPI-Q I examine 
whether any of the behavioural measures a significantly different amongst those subjects rated 
by their informant as apathetic or impulsive are statistically different.  Finally I demonstrate 
how a more integrative, mixed methodology approach may be useful to overcome some of the 
limitations of any single approach. 
 
5.3 Methods 
Subjects with syndromes associated with FTLD identified in the PiPPIN study and 50 healthy 
similarly aged volunteers were invited to complete a battery of questionnaires and behavioural 
tasks (described in Chapters Three and Four).  Note that while the healthy volunteers completed 
all assessments not all patients completed all assessments.  As a result each Principal 
Component Analysis was performed on a different subset of patients. 
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5.3.1 Statistical Analysis 
Statistical analysis was performed in SPSS (IBM v22).  Principal Component Analysis (PCA) was 
using orthogonal varimax rotation with Kaiser normalisation.   Adequacy of sample size was 
assessed using Kaiser-Meyer-Olkin (KMO) test and Bartlett’s test of sphericity.  The standardised 
correlation matrix was used for extraction of components (as opposed to the unstandardized 
covariance matrix) and extraction of significant components was based on Kaiser’s criteria (i.e. 
those with Eigenvalues greater than 1).  
5.3.2 Discrepancy Scores 
In order to further explore variation between subject and information versions of the AES two 
additional discrepancy measures were calculated from the differences between each item within 
the AES-S and AES-I.  Described in relation to the AES-I; AESOverscore describes the sum of 
differences between each item of the AES where the subject scored themselves higher on the 
AES-S than the informant on the equivalent item on the AES-I and AESUnderscore describes the 
sum of differences between each item where the patient scores themselves lower on the AES-S 
compared with the equivalent item on the AES-I (and both AESOverscore and AESUnderscore 
described as positive integers).  Using exactly the same method two additional measures were 
derived from the CBI-R using the first item from each of the ten groups of behavioural symptoms 
where both subject (with FTLD associated syndrome) and informant (their carer) rated the 
frequency of the subject’s behavioural symptoms.  From the differences between subject and 
informant CBIUnderscore and CBIOverscore were calculated as a measure of how much the 
subject underestimated and over estimated symptoms in comparison with the informant’s 
estimation. 
5.3.3 Comparison of Behavioural Testing Performance Based on Informant Ratings of 
Apathy and Impulsiveness  
To examine whether subjects rated by informants as apathetic or impulsive performed 
differently on behavioural testing subjects with syndromes associated with FTLD were divided 
based on informant rating of Apathy (‘Does the patient seem less interesting in his/her usual 
activities or in the activities and plans of others?’) and Disinhibition ‘Does the patient seem to 
act impulsively, for example, talking to strangers as if he/she knows them, or saying things that 
may hurt people’s feelings?’) on the NPI-Q.  Results on behavioural testing were between the 
resulting groups using independent samples T-tests.  The following measures were compared: 
From the Kirby Mean K, mean consistency and difference between K for small and large 
monetary amounts; From Joystick and Saccadometer Go/NoGo trials mean D’, and omission and 
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commission error rates; From the Stop Signal Reaction Time Task the Stop Signal Reaction Time 
calculated from the last half of trials; From the Information Sampling Task mean probability of 
being correct for Fixed and Decreasing conditions and difference between conditions; From the 
Cued Reinforcement Reaction Time Task the difference between change in response time for 
higher probability of feedback in the second half of trials compared with the first. 
5.3.4 Principal Component Analysis Across Multiple Testing Modalities 
Principal Component Analysis (PCA) was performed using orthogonal varimax rotation with 
Kaiser normalisation.  PCA was performed twice, firstly using both patient and healthy 
volunteers and secondly with the patient group alone.  As multiple testing modalities and 
scoring scales were included in each PCA Z scores were calculated from each variable prior to 
each PCA.  Missing values were replaced with the mean.  While this approach has the 
disadvantage of reducing variance of variables and correlations between them it has the 
advantage of simplicity and speed.  Furthermore the effects of replacing with the mean are to 
some extent predictable.  Alternative approaches include replace missing data by imputation 
and statistical modelling, skipping or considering explicitly missing values.  While each approach 
has particular advantages and limitations I chose the simplest approach to produce a set of 
components and extracted variables that could then be evaluated and correlated against other 
assessments.  In doing so I sought to maximise the amount of data included in the analyses but 
not add a further layer of complexity and potential distortion of the results.  Adequacy of sample 
size was assessed using Kaiser-Meyer-Olkin (KMO) test and Bartlett’s test of sphericity. The 
standardised correlation matrix was used for extraction of components (as opposed to the 
unstandardized covariance matrix) and extraction of significant components was based on 
Kaiser’s criteria (i.e. those with Eigenvalues greater than 1). Table 5.1 shows the variables were 
included in the PCA:  
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Task/Questionnaire Variables used in Component Analysis 
Kirby Mean K, Mean Consistency, Difference in K 
between small and large values 
Go/NoGo tasks (saccadometer and joystick 
versions) 
D’, Omission error rate, Commission error 
rate 
Stop Signal Reaction Time Task SSRT from last half of trials 
Information Sampling Task Prob. Being correct for fixed and 
decreasing conditions 
Cued Reaction Reinforcement Time Task Difference in speeding between first and 
second half of trials 
Apathy Evaluation Scale Total score for subject, clinician and 
informant versions 
Behavioural Inhibition 
System/Behavioural Activation System 
Scales 
Drive, Funseeking, Reward 
Responsiveness, BIS scale 
Motivation and Energy Index Total score 
Snaith Hamilton Anhedonia Pleasure Scale Total score 
Barrett Impulsiveness Scale II Total score 
Obsessive Compulsive Inventory (Revised) Total score 
Table 5.1 Variables included in Principal Component Analysis 
To further characterise the extracted components these were expressed as variables and for the 
patient group Pearson’s bivariate correlations were performed between these and the total 
scores for ACE-R (as a surrogate of global cognitive ability), the BDI-II (as a surrogate of 
mood/depression) and discrepancy scores for the CBI-R.  Note none of these tests (ACE-R, CBI-R 
or BDI-II) were used in the PCA.     
 
5.4 Results 
5.4.1 Principal Component Analysis of the Apathy Evaluation Scale 
The results of the PCA for each version of the AES are shown in Table 5.2.  Separate analyses 
were performed for Controls (C), Patients (P) and both groups together (C+P).  The total number 
of components extracted varied between 3 (AES-I (C+P)) and 6 (AES-I (C)) explaining 60.4% 
(AES-S (P)) and 78.6% (AES-I (C)) of the variance.   
The rotated component structures are shown in graph form in Figure 5.1.  On initial 
visual inspection of the extracted components from the PCAs, some components appeared 
similar in structure to others from different analyses.  For example factors three from AES-
S(C+P), three from AES-S (C) and two from AES-I (P) all have strong positive weightings from 
items 12, 13 and 14 with comparatively little contribution from other items.  Rather than rely on 
visual inspection for the forty extracted components I took a systematic approach and attempt 
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to classify the extracted components in relation to the item structure proposed by Marin(158), 
as follows.   
First I standardised component loadings by removing directionality from in each 
component matrix (so that negative and positive loadings were considered equally).  Next I 
calculated mean loadings for each item type (Cognitive, Behaviour, Emotional, Other) and 
question type (Self Evaluated, Quantifiable and Negative syntax).  I then set an arbitrary 
threshold of 0.499 so that if the mean standardised factor loading was above this threshold I 
considered the item/question type contributory to the extracted component and disregarded 
those that did not.  As only the Clinician version of the AES includes separately self-evaluated or 
quantifiable items (all items are self evaluated for the other versions of the AES) I only 
considered these items contributory for components extracted from the AES-C.  Of the 40 
extracted components thirteen (33%) had at least one of Marin’s item types meeting the 
threshold (Table 5.3).  Item type did not meet the threshold for any of the fourteen components 
extracted from the three PCA analyses of the AES-C.  Negative scoring met the threshold for six 
(15%) of extracted components and was the sole item/question type meeting the threshold in 
every case. Self evaluated or quantifiable question type met the threshold for three (21%) of the 
fourteen components extracted from the AES-C.  For nineteen (48%) of the extracted 
components, no item or question type met the threshold.  
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Questionnaire 
Assessed 
(Respondents) 
Number of 
respondents 
KMO Bartlett’s 
test of 
Sphericity 
Components 
Extracted 
(Eigenvalues) 
Variance 
Explained 
%(range) 
AES-I (C+P) 153 0.945 2289.11, 
p<0.001 
3 (1.14-10.57) 72.00 
(6.36-
58.71) 
AES-I (C) 49 0.650 454.21, 
p<0.001 
6 (1.01-5.84) 78.59 
(10.65-
21.32) 
AES-I (P) 104 0.913 1210.45, 
p<0.001 
4 (1.02-8.66) 70.17 
(7.01-
36.02) 
AES-S (C+P) 120 0.887 940.034, 
p<0.001 
4 (1.10-7.09) 61.79 
(6.13-
39.37) 
AES-S (C) 50 0.707 406.90, 
p<0.001 
5 (1.29-5.57) 68.20 
(7.16-
30.97) 
AES-S (P) 70 0.808 513.44, 
p<0.001 
4 (1.20-6.61) 60.35 
(6.67-
36.72) 
AES-C (C+P) 126 0.907 1306.17, 
p<0.001 
4 (1.04-8.39) 67.02 
(5.78-
46.60) 
AES-C (C) 50 0.716 488.27, 
p<0.001 
5 (1.12-6.15) 70.09 
(6.20-
34.15) 
AES-C (P) 76 0.820 572.96, 
p<0.001 
5 (1.06-6.36) 66.82 
(5.88-
35.33) 
 
Table 5.2 Results of separate Principal Component Analyses for the three versions of the Apathy 
Evaluation Scale performed for the Informant (AES-I), Subject (AES-S) and Clinician (AES-C) 
versions using results from Healthy older Controls (C), Subjects with FTLD Associated 
Syndromes (P) and both groups combined (C+P). 
 
    
Component AES-I AES-S AES-C 
All Subjects (CP) Controls (C) Patients (P) All Subjects (CP) Controls (C) Patients (P) All Subjects (CP) Controls (C) Patients (P) 
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Figure 5.1 Component structure extracted from nine Principal  Component Analyses of three versions of the Apathy Evaluation Scale (AES) 
using all subjects (CP), controls only (C) and patients only (P).  Each extracted component is shown in graph form with each column 
representing a single item from the 18 in the AES and the height of each column representing its contribution (positive or negative) to the 
component. 
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Extracted 
Component* 
Item Type Question Type 
Cognitive Behaviour Emotion Other 
Self 
Evaluated 
Quantitativ
e 
Negative 
Syntax 
ICP1 1  1 1 NA NA  
ICP2     NA NA  
ICP3     NA NA 1 
IC1    1 NA NA  
IC2     NA NA  
IC3     NA NA  
IC4   1  NA NA  
IC5     NA NA  
IC6     NA NA  
IP1 1  1 1 NA NA  
IP2     NA NA  
IP3     NA NA  
IP4     NA NA 1 
SCP1   1 1 NA NA  
SCP2     NA NA  
SCP3     NA NA  
SCP4     NA NA 1 
SC1    1 NA NA  
SC2     NA NA  
SC3   1  NA NA  
SC4     NA NA  
SC5     NA NA 1 
SP1   1  NA NA  
SP2     NA NA  
SP3    1 NA NA  
SP4     NA NA 1 
CCP1   1   1  
CCP2     1   
CCP3        
CCP4        
CC1    1    
CC2        
CC3        
CC4        
CC5        
CP1     1   
CP2  1      
CP3   1     
CP4        
CP5       1 
Table 5.3.  Components meeting ‘contribution threshold’ for each of the forty extracted 
components resulting from nine PCA analysis of AES-S, AES-I, AES-C responses using subjects 
with FTLD, healthy other controls and subjects and controls combined.  1=Threshold met (i.e. 
item/question type considered contributory) blank=Threshold not met.  NA=Not Applicable.  
*Key: First letter =AES Version (I=Informant, S=Subject, C=Clinician Version), Second (and third) 
letter =Subjects included in analysis (C=healthy older controls, P=subjects with FTLD associated 
syndromes), Number=component extracted from highest to lowest variance explained 
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5.4.2 Intercorrelation Between Versions of the Apathy Evaluation Scale 
 Amongst the patient group significant correlations were seen between subject and clinician, and 
clinician and informant versions of the AES.  No significant correlation was observed between 
subject and informant versions of the AES (Table 5.4).  Amongst the control group significant 
correlations were seen between subject and informant versions of the AES (Pearson 0.503, 
p<0.001) but not clinician and informant versions (0.261, p=0.07).   Post hoc partial correlation 
controlling for total score on the ACE-R and BDI-II showed significant correlations between all 
three versions of the AES amongst controls and amongst patients between subject and clinician 
(Pearson 0.605, p<0.001), clinician and informant (0.425, p=0.001) but the correlation between 
subject and informant scores remained non significant (0.012, p=0.926). 
 
 AES-I AES-S AES-C 
AES-I  Pearson Correlation 1 .238 0.589** 
Sig. (2-tailed)  0.051 0.000 
N 104 68 74 
AES-S  Pearson Correlation 0.238 1 0.718** 
Sig. (2-tailed) 0.051  0.000 
N 68 70 70 
AES-C Pearson Correlation 0.589** 0.718** 1 
Sig. (2-tailed) 0.000 0.000  
N 74 70 76 
Table 5.4.  Intercorrelation between three versions of the Apathy Evaluation Scale 
amongst patients with syndromes associated with FTLD. 
**Correlation is significant at the 0.01 level (2-tailed)(uncorrected for multiple comparisons). 
5.4.3 Discrepancies Between Subject and Informant Ratings on the AES and CBI-R 
Mean AESOverscore, AESUnderscore, CBIOverscore and CBIUnderscore are shown in Table 5.5.  
AESUnderscore was significantly lower amongst controls than patients (T-test, p<0.001) but 
AESOverscore was not significantly different between the two groups (T-test, p=0.417).  Table 
5.6 shows the results of correlations between Overscore and Underscore values on the AES and 
CBI-R.   Note that only the patient group completed the CBI-R for themselves hence no CBI-R 
discrepancy scores were calculated for the control group.  Significant negative correlations were 
seen between Underscore and Overscore values within and between questionnaires (AES and 
CBI-R) with the exception of the negative correlation between Underscore on the AES and 
Overscore on the CBI-R which did not reach significance.  Significant positive correlations were 
seen between Underscore values on both questionnaires and between Overscore values.  
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Score Group N Mean Std. 
Deviation 
Std. Error 
Mean 
 CBIOverscore  Patient 70 4.3286 5.06114 .60492 
 CBIUnderscore  Patient 70 6.21429 5.050162 .603610 
AESUnderscore Control 49 1.3673 3.90349 .55764 
 Patient 68 10.2500 11.31948 1.37269 
AESOverscore Control 49 6.7347 5.19525 .74218 
Patient 68 7.7794 8.62285 1.04567 
 
Table 5.5 Discrepancy scores between subject and informant rating of symptoms on the 
Apathy Evaluation Scale and Cambridge Behavioural Inventory for patients with FTLD 
associated syndromes and healthy older controls. 
 
  AESUnderscore AESOverscore CBIOverscore 
AESUnderscore Pearson 
Correlation 
1 -0.492** -0.139 
Sig. (2-tailed)  0.000 0.259 
N 117 117 68 
AESOverscore Pearson 
Correlation 
-0.492** 1 0.256* 
Sig. (2-tailed) 0.000  0.035 
N 117 117 68 
CBIOverscore Pearson 
Correlation 
-0.139 0.256* 1 
Sig. (2-tailed) 0.259 0.035  
N 68 68 70 
CBIUnderscore Pearson 
Correlation 
0.598** -0.422** -0.420** 
Sig. (2-tailed) 0.000 0.000 0.000 
N 68 68 70 
 
Table 5.6 Intercorrelation of discrepancy scores between subject and informant rating of 
symptoms on the Apathy Evaluation Scale and Cambridge Behavioural Inventory 
(Revised). *Correlation is significant at the 0.05 level (2-tailed). **Correlation is significant at 
the 0.01 level (2-tailed). 
 
Amongst patients significant correlation was observed between the total score on the BDI-II and 
CBIOverscore (Pearson correlation 0.419, p<0.001) but not AESOverscore (-0.057, p=0.647), 
Underscore on CBI (-0.035, p=0.778) or AES (0.079, p=0.526).  No significant correlations were 
seen between any of the Underscore or Overscore values and overall performance on the ACE-R 
or FAB. 
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5.4.4 Comparison of Behavioural Testing Performance Based on Informant Ratings of 
Apathy and Impulsiveness  
Of fourteen comparisons of behavioural task performance between those rated as apathetic or 
not and a further fourteen comparisons of those rated as impulsive or not, only one reached 
statistical significance without correction for multiple comparisons (Probability of being correct 
on the IST, decreasing condition, disinhibited vs. not groups, p=0.03), and this does not survive 
correction  (Table 5.7). 
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Test 
Apathy Disinhibition 
Yes No 
P 
Value 
Yes No 
P 
Value. 
N 
Mean 
(SD) 
N 
Mean 
(SD) 
 N 
Mean 
(SD) 
N 
Mean 
(SD) 
 
Kirby Mean K  33 0.04 
(0.05) 
31 0.03 
(0.04) 
0.666 19 0.04 
(0.06) 
45  0.03 
(0.04) 
0.453 
Kirby Mean 
Consistency 
33 0.94 
(0.05) 
31 0.93 
(0.11) 
0.693 19 0.96 
(0.12) 
45 0.02 
(0.04) 
0.303 
Kirby 
Difference K 
33 0.02 
(0.06) 
31 0.00 
(0.04) 
0.104 19 0.00 
(0.07) 
45 0.04 
(0.01) 
0.298 
Joystick 
Go/NoGo D’ 32 3.12 (1.33) 29  3.18 (1.31) 0.829 20 3.26 (1.43) 41 3.09 (1.26) 0.644 
Saccade 
Go/NoGo D’ 14 0.70 (1.00) 17 0.90 (1.24) 0.622 8  1.26 (1.46) 23  0.65 (0.98) 0.195 
Joystick 
Go/NoGo  
Ommission 
Error Rate 
32 0.19 
(0.24) 
29  0.17 
(0.25) 
0.863 20 0.15 
(0.19) 
41  0.19 
(0.25) 
0.555 
Joystick 
Go/NoGo  
Commision 
Error Rate 
32 0.06 
(0.17) 
29 0.07 
(0.11) 
0.879 20 0.07 
(0.21) 
41 0.19 
(0.25) 
0.876 
Saccade 
Go/NoGo  
Ommission 
Error Rate 
14 0.09 
(0.10) 
17 0.17 
(0.21) 
0.222 8 0.08 
(0.21) 
23  0.15 
(0.19) 
0.331 
Saccade 
Go/NoGo  
Comission 
Error Rate 
14 0.74 
(0.24) 
17 0.60 
(0.33) 
0.206 8 0.60 
(0.41) 
23  0.69 
(0.25) 
0.505 
SSRT 31 470.22 
(276.6
3) 
28 714.46 
(1616.
61) 
0.411 20 449.04 
(209.6
7) 
39  659.34 
(1379.
19) 
0.502 
IST P being 
Correct 
(fixed 
condition) 
30 0.77 
(0.15) 
27 0.72 
(0.14) 
0.184 17 0.80 
(0.10) 
40 0.72 
(0.15) 
0.072 
IST P being 
correct 
(decreasing 
condition) 
30 0.68 
(0.14) 
27 0.63 
(0.19) 
0.207 17 0.73 
(0.15) 
40 0.63 
(0.17) 
0.030 
IST 
Difference in 
P being 
correct 
between 
conditions 
30 0.09 
(0.16) 
27 0.09 
(0.16) 
0.937 17 0.07 
(0.12) 
40  0.10 
(0.17) 
0.571 
CRRT 
Difference in 
Speeding 
27 57.13 
(506.8
7) 
20 157.97 
(378.7
6) 
0.459 15 70.88 
(384.0
8) 
32 115.61 
(489.3
7) 
0.757 
 
Table 5.7 Comparisons of Behavioural Testing Performance of Subjects with Syndromes 
Associated with FTLD Based on Informant Ratings of Apathy and Impulsiveness.  P values 
are results of individual T-tests 
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5.4.5 Principal Component Analysis of Patients and Controls Across Testing Modalities 
For the PCA of patients with FLTD associated syndromes and healthy older subjects the 
combined KMO measure of sampling adequacy was 0.615 and Bartlett’s Test of sphericity 
significant (p<0.001). Repeating the analysis for subjects with FTLD associated syndromes alone 
KMO was 0.470 and Bartlett’s test not significant (p=0.999). Note these KMO values indicate 
weak to poor sampling adequacy and hence the results should be interpreted with caution.  
Eight factors were extracted from PCA of both subject groups (Tables 5.8 and 5.9) accounting for 
70% of the observed variance.  For subjects with FTLD associated syndromes alone nine factors 
were extracted accounting for 74% of the observed variance (Tables 5.10 and 5.11).  
Component Eigenvalue Total % of Variance Cumulative % 
1 3.956 16.485 16.485 
2 2.496 10.402 26.886 
3 2.446 10.19 37.076 
4 2.003 8.346 45.422 
5 1.895 7.895 53.317 
6 1.433 5.969 59.286 
7 1.395 5.814 65.1 
8 1.223 5.094 70.195 
 
Table 5.8. Total Variance Explained: Rotation sums of Square loadings for Principal 
Component Analysis of subjects with FTLD associated syndromes and healthy controls. 
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 1 2 3 4 5 6 7 8 
AES S 0.834 -0.096 -0.189 0.032 -0.045 -0.024 -0.055 -0.048 
MEI -0.824 0.071 0.162 -0.027 0.159 -0.015 -0.081 -0.031 
AES C 0.791 0.026 -0.097 0.107 -0.161 0.124 -0.171 -0.015 
SHAPS 0.756 -0.238 -0.097 -0.135 -0.036 0.048 0.122 -0.001 
AES I 0.62 0.124 0.02 0.202 -0.133 0.115 -0.249 -0.029 
BIS-II 0.613 0.31 -0.14 0.187 -0.084 -0.196 0.054 -0.109 
OCI-R 0.504 0.333 0.084 -0.001 -0.099 0.133 0.395 0.298 
BAS Funseeking 0.009 0.858 0.076 0.054 -0.029 -0.083 -0.015 -0.054 
BAS Drive 0.058 0.852 -0.044 -0.005 0.018 0.065 -0.1 -0.033 
BAS Reward 
Responsiveness -0.155 0.718 0.015 0.113 -0.176 0.009 0.214 -0.005 
Joystick Go/NoGo 
Omission Error Rate 0.088 -0.083 -0.783 0.157 -0.215 0.271 -0.11 -0.077 
Joystick Go/NoGO D' -0.213 -0.021 0.717 -0.182 0.127 -0.545 0.029 0.12 
Kirby Mean 
Consistency -0.136 -0.119 0.711 -0.024 0.082 0.092 -0.183 -0.196 
Saccadometer 
Go/NoGo Omission 
Error Rate 0.266 -0.172 -0.604 0.053 0.004 -0.124 -0.138 -0.249 
Saccadometer 
Go/NoGo 
Commission Error 
Rate 0.025 0.118 0.01 0.953 -0.08 0.003 0.025 0.076 
Go/NoGO 
Saccadometer D' -0.187 -0.016 0.284 -0.882 0.069 0.05 0.046 0.07 
IST Probability of 
being correct 
(decreasing 
condition) -0.199 -0.167 0.129 -0.093 0.849 0.166 0.065 0.115 
IST Probability of 
being correct (fixed 
condition) -0.21 0.195 0.086 -0.144 0.685 -0.114 -0.089 0.3 
SSRT (Last half of 
trials) 0.136 0.202 -0.105 -0.043 -0.67 0.082 0.06 0.275 
Joystick Go/NoGo 
Commission Error 
Rate 0.119 0.106 -0.278 0.059 0.099 0.781 0.077 -0.154 
Kirby Difference K 0.209 -0.048 0.243 0.134 -0.121 0.125 -0.592 -0.217 
BIS 0.044 -0.007 0.171 0.086 -0.13 0.125 0.79 -0.173 
CRRT difference in 
speedings -0.018 -0.112 0.055 0.024 0.063 -0.043 -0.011 0.817 
Kirby K mean 0.059 0.164 -0.22 0.267 0.1 -0.495 0.018 -0.191 
 
Table 5.9 Rotated component matrix for PCA of subjects with FTLD associated syndromes 
and healthy controls.  Weightings >0.5 or <-0.5 highlighted and in bold. 
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Component Eigenvalue Total % of Variance Cumulative % 
1 3.14 13.083 13.083 
2 2.743 11.43 24.513 
3 2.209 9.206 33.719 
4 1.948 8.118 41.837 
5 1.885 7.855 49.692 
6 1.762 7.34 57.032 
7 1.543 6.429 63.461 
8 1.271 5.297 68.758 
9 1.218 5.076 73.834 
 
Table 5.10 Total Variance Explained: Rotation sums of Square loadings for Principal 
Component Analysis of patients with FTLD associated syndromes only. 
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 1 2 3 4 5 6 7 8 9 
AES S 0.823 -0.083 -0.184 -0.058 0.086 -0.129 0.071 -0.109 -0.229 
MEI -0.82 0.136 0.064 0.024 0.111 -0.08 0.053 -0.092 -0.058 
AES C 0.726 0.016 -0.003 -0.1 -0.049 0.013 0.385 -0.022 -0.218 
SHAPS 0.675 -0.336 0.041 -0.145 -0.019 0.143 -0.067 0.237 0.27 
AES I 0.412 0.058 0.284 0.07 -0.059 0.085 0.521 0.066 0.017 
BIS-II 0.601 0.428 -0.18 0.282 -0.096 -0.188 0.071 -0.15 0.089 
OCI-R 0.309 0.337 0.215 -0.189 -0.139 0.15 -0.304 0.485 0.034 
BAS Funseeking 0.003 0.872 0.128 0.1 -0.036 -0.073 -0.005 -0.056 0.086 
BAS Drive -0.035 0.86 -0.009 -0.045 0.025 0.075 0.139 0.01 -0.012 
BAS Reward 
Responsiveness -0.279 0.747 0.098 -0.049 -0.12 0.006 -0.204 0.084 0.031 
Joystick Go/NoGo 
Omission Error Rate -0.039 -0.129 -0.723 0.191 -0.163 0.387 0.082 -0.048 -0.16 
Joystick Go/NoGO D' 0.004 0.065 0.566 -0.115 0.067 -0.764 -0.049 0.036 0.069 
Kirby Mean 
Consistency -0.071 -0.105 0.576 0.103 0.227 -0.167 0.054 -0.169 -0.129 
Saccadometer 
Go/NoGo Omission 
Error Rate 0.205 -0.201 -0.743 -0.084 0.056 -0.089 0.047 -0.164 0.065 
Saccadometer 
Go/NoGo 
Commission Error 
Rate -0.136 0.1 0.309 0.903 -0.036 0.027 0.023 0.072 0.006 
Go/NoGO 
Saccadometer D' -0.01 0.059 0.214 -0.918 -0.002 0.028 -0.048 0.027 -0.09 
IST Probability of 
being correct 
(decreasing 
condition) 0.002 -0.105 0.177 0.023 0.874 0.244 -0.054 0.074 -0.02 
IST Probability of 
being correct (fixed 
condition) -0.024 0.309 0.045 -0.102 0.624 0.018 0.047 0.31 0.302 
SSRT (Last half of 
trials) 0.105 0.161 -0.024 0.006 -0.712 0.137 -0.067 0.221 0.03 
Joystick Go/NoGo 
Commission Error 
Rate 0.011 0.041 -0.045 -0.076 0.12 0.849 -0.038 -0.102 -0.078 
Kirby Difference K 0.108 -0.097 0.106 0.145 -0.132 0.098 0.586 -0.187 0.339 
BIS 0.004 -0.038 0.254 0.047 -0.167 0.12 -0.754 -0.102 0.045 
CRRT difference in 
speedings -0.014 -0.075 -0.008 0.078 0.024 -0.162 0.067 0.804 -0.08 
Kirby K mean -0.101 0.098 -0.07 0.084 0.081 -0.15 0.085 -0.066 0.862 
 
Table 5.11 Rotated component matrix for Principal Component Analysis of patients with 
FTLD associated syndromes only.  Weightings >0.5 or <-0.5 highlighted and in bold. 
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5.4.6 Correlation Between Extracted Components and Measures of Cognition, Carer 
Distress, Subject Mood and Discrepancy Scores 
Tables 5.12 and 5.13 show the results of Pearson correlations between the extracted 
components of the two multimodal PCAs.  Significant correlations were seen for components 
one, three, five and six extracted from the PCA of patients with FTLD associated syndromes and 
healthy controls combined and components one, five, six and seven extracted from the PCA of 
patients with FTLD alone.  The ACE-R significantly correlated with three of eight components 
when healthy controls were included in the analysis.  When only subjects with FTLD associated 
syndromes were included correlation with the ACE-R and Component Three approaches 
significance (p=0.06), none of the other components correlations were significant. 
 
Component 1 2 3 4 5 6 7 8 
ACE-R Pearson 
Correlation -0.322** -0.055 0.270** -0.118 0.177* -0.099 0.041 0.049 
Sig. (2-
tailed) 0 0.524 0.002 0.176 0.041 0.255 0.64 0.574 
N 134 134 134 134 134 134 134 134 
Total Carer 
Distress (NPI-Q) 
Pearson 
Correlation 0.165 0.06 -0.003 0.084 0.301** 0.458** -0.084 -0.015 
Sig. (2-
tailed) 0.097 0.549 0.976 0.4 0.002 0 0.4 0.883 
N 102 102 102 102 102 102 102 102 
CBIOverscore Pearson 
Correlation 0.319** -0.002 -0.04 -0.232 0.08 -0.076 -0.017 0.052 
Sig. (2-
tailed) 0.007 0.984 0.74 0.053 0.509 0.529 0.886 0.669 
N 70 70 70 70 70 70 70 70 
CBIUnderscore Pearson 
Correlation 0.002 0.078 0.071 0.032 0.094 0.243* -0.186 -0.019 
Sig. (2-
tailed) 0.985 0.523 0.559 0.794 0.438 0.042 0.123 0.878 
N 70 70 70 70 70 70 70 70 
BDI-II Pearson 
Correlation 0.709** -0.004 -0.137 0.104 -0.117 0.099 0.036 -0.073 
Sig. (2-
tailed) 0 0.969 0.137 0.26 0.205 0.283 0.694 0.431 
N 120 120 120 120 120 120 120 120 
 
Table 5.12.  Two tailed Pearson correlations between extracted components from PCA of 
Patients with FTLD associated syndromes and healthy control subjects and scores on the 
Addenbrooke’s Cognitive Examination –Revised (ACE-R), Total Carer Distress reported on 
Neuropsychiatric Inventory (NPI-Q), Cambridge Behavioural Inventory Discrepancy 
Scores (CBIOverscore and CBIUnderscore) and Beck Depressive Inventory II (BDI-II). 
*Correlation is significant at the 0.05 level.  
**Correlation is significant at the p<0.01 level. 
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Component 1 2 3 4 5 6 7 8 
ACE-R Pearson 
Correlation -0.054 0.045 0.206 0.031 0.119 -0.072 -0.056 -0.005 
Sig. (2-
tailed) 0.628 0.683 0.06 0.777 0.282 0.517 0.614 0.962 
N 84 84 84 84 84 84 84 84 
Total Carer 
Distress (NPI-Q) 
Pearson 
Correlation 0.13 0.01 0.167 0.078 0.202* 0.484** 0.193 0.047 
Sig. (2-
tailed) 0.201 0.922 0.101 0.446 0.046 0 0.057 0.644 
N 98 98 98 98 98 98 98 98 
CBIOverscore Pearson 
Correlation 0.333** 0.035 -0.099 -0.188 0.031 -0.046 0.003 -0.001 
Sig. (2-
tailed) 0.005 0.774 0.417 0.12 0.8 0.704 0.978 0.996 
N 70 70 70 70 70 70 70 70 
CBIUnderscore Pearson 
Correlation -0.042 0.021 0.206 -0.008 0.058 .272* 0.310** 0.021 
Sig. (2-
tailed) 0.732 0.864 0.087 0.946 0.633 0.023 0.009 0.861 
N 70 70 70 70 70 70 70 70 
BDI-II Pearson 
Correlation 0.676** -0.031 -0.031 0.002 -0.082 0.151 0.039 -0.015 
Sig. (2-
tailed) 0 0.797 0.801 0.984 0.499 0.211 0.746 0.902 
N 70 70 70 70 70 70 70 70 
 
Table 5.13.  Two tailed Pearson correlations between extracted components from PCA of 
patients with FTLD associated syndromes only and scores on the Addenbrooke’s 
Cognitive Examination –Revised (ACE-R), Total Carer Distress reported on 
Neuropyschiatric Inventory (NPI-Q), Cambridge Behavioural Inventory Discrepancy 
Scores (CBIOverscore and CBIUnderscore) and Beck Depresssive Inventory II (BDI-II).  
*Correlation is significant at the 0.05 level.  
**Correlation is significant at the p<0.01 level. 
For both combined (patient and controls) and patient only PCA the first component 
comprises mainly of questionnaire-based assessments with positive weighting associated with 
higher scores towards states with a negative valence (e.g. the higher rates of apathetic 
symptoms on the AES, lower hedonic tone as measured by the SHAPS).  This component 
correlated positively with patient Overscore on the CBI-R and higher depressive symptoms on 
the BDI-II suggesting negative emotional states may by a substantial aspect of this component.   
Component Two comprises mainly of positive weighting from the BAS subscales.  These 
comprise of questions aimed at assessing behavioural activation and positive motivational states 
(reward responsiveness, drive and fun seeking).  The lack of substantial contribution from other 
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aspects of the testing battery or correlation with BDI-II, ACE-R or CBI-R discrepancy scores 
suggests that there may be particular aspects of subject response to the BAS sections of the 
BIS/BAS questionnaire which are not captured by the other tasks/questionnaires.   
Component Three comprises of substantial weighing from the consistency scores on the 
Kirby, D’ from the Joystick version of the Go/NoGo rates and low omission rates on both 
versions of the Go/NoGo rate.  Cognition as measured with the ACE-R significantly correlated 
with this component in combined (patient and control) analysis and neared significance on the 
patient only analysis. Performance on the ACE-R is substantially affected by attention and 
diminished attention will substantially impair performance on tests of episodic memory and 
orientation (which feature heavily in the ACE-R and would normally be relatively preserved in 
FTLD associated syndromes).  The Go/NoGo protocol is relatively lengthy and requires 
sustained concentration and attention, as does consistent performance on the Kirby.  Hence this 
component may reflect the subjects’ ability to attend to the tasks presented and maintain 
consistent performance and engagement.   
Component Four is heavily weighted by performance on the saccadometer task 
particularly D’ and commission error rates with very little contribution from other tasks and no 
significant correlations between component and ACE-R, BDI-II or CBI-R discrepancy scores.  It 
may be such a strong weighting towards saccadometry suggests that this component is strongly 
influenced by the subjects ability to engage with the saccadometer task, either for technical 
reasons or because of impairment in ability to direct saccades which appears somewhat distinct 
to other testing modalities.   
Component Five consists of substantial weighting from the IST and SSRT.  The 
association between higher sampling rates on the IST (hence a higher probability of being 
correct) and shorter SSRT suggests that greater action cancellation may be associated with 
increased IST sampling.   
Component Six comprises of strong positive weighting of commission error rate and 
negative weighting from D’ for the joystick task.  Again, as with Component Four (where 
saccadometry measures were the only major contributing factor), this may reflect a unique 
aspect of the manner in which the joystick task was administered such as the patient’s ability to 
use the joystick.  This component showed significant positive correlations with carer distress 
and patient underscore.   
Component Seven showed positive weighting from the difference between values of K 
for different monetary amounts on the Kirby and negative weighting from BIS score.  Making 
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this the only component with substantial weighting from behavioural and questionnaire based 
assessments.  The BIS subscale comprises of items related to perceived anxiety, worries and 
sensitivity to negative feedback/criticism from others.  Similarly the difference in values of K 
between monetary values may also reflect some aspect of reward responsiveness.  It is notable 
that the reward responsiveness subscale of the BAS makes very little contribution to this 
component. 
The major contribution to Component Eight was difference in speeding on the CRRTT 
again suggesting this measure may be relatively distinct to other measures in the analysis. 
PCA for subjects with FTLD associated syndromes alone resulted in an additional 
component.  This ninth component only met the threshold for inclusion for the PCA of the 
subjects with FTLD associated diagnoses.  The largest contribution was mean K on the Kirby.  
Whether this is of any true significance is unclear given the small sampling size and low KMO.   
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5.5 Discussion 
Principal Component Analysis of the three separate versions of the AES yielded different results 
depending on the version of the AES used and whether the analysis was restricted to patients, 
controls or both.  The resultant component structures vary in terms of number and variance 
explained but without more detailed inspection it is not clear how significant these differences 
between analyses are.   On first inspection some components do appear similar with strong 
loadings for the same items, but simple comparisons of forty components from nine separate 
analyses would be unreliable.  Instead I chose to use a standardised approach to attempt to 
classify each component based on the item and question type as set out in the original 
description of the AES(158).   
Using this method only a third of components, and none of the components extracted 
from the AES-C, could be classified by item type.  Including question type allowed for a further 
19% of components to be classified including 15% of all components that could only be 
classified by negative scoring.  By this method the components extracted from PCA of different 
versions of the AES and different cohorts are classified differently.  Some components may be 
classified in relation to Marin’s item type but others cannot.  Of the remaining components some 
may be classified by question type (for example negative syntax) but nearly half of the extracted 
components cannot be classified by this method.   These results demonstrate that despite 
sampling adequacy for each PCA, the results of the analysis vary and are dependent upon the 
groups from which the data are drawn.  Variation in patterns of response to the questions in the 
AES depend upon who is being asked (i.e. subject, informant, clinician), what they are being 
asked (e.g. item type), and how they are asked (e.g. question type).   
The patient group scored more highly on all three versions on the AES than healthy 
controls.  While subject and informant versions of the AES showed significant positive 
correlations amongst the control group this was not the case amongst the patients.  Despite 
significant correlations between patient and clinician assessment on the AES (AES-S and AES-C) 
and between clinician and carer (AES-C and AES-I) there appears to be differences between the 
patient reports and those of their carers (AES-S and AES-I) even when the cognitive measures 
(ACE-R) and measures of mood disturbance (BDI-II) are controlled for. This demonstrates that 
while apathetic symptoms are commonly reported amongst people with FTLD associated 
syndromes, irrespective of whether subject, informant, or clinician is asked, the nature of these 
reports varies between each source and do not correlate with each other. 
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I quantified the discrepancies between subject and informant scores on the AES and CBI-
R.  The terms ‘Overscore’ and ‘Underscore’ denote the subject’s (patient’s) scoring relative to the 
informant (carer), although in reality an ‘Overscore’ may indicate the patient truly over 
reporting their symptoms (overscoring) or the carer under reporting (underscoring) the 
patient’s symptoms.  Similarly a high ‘Underscore’ may reflect low scoring by the patient or high 
scoring by the carer.  While patient scores may be influenced by their own insight, mood, 
cognitive ability or distress, carer scores may also be affected by the carer’s own conceptions of 
the patient behaviour or their own psychological state.  For example, discrepancy between 
patient scores on the AES-S and carer scores on the AES-I due to a high Underscore (i.e. the 
patient scores lower than the carer) which may relate to lack of insight by the patient and hence 
underreporting of their symptoms or alternatively, by the carer’s own distress and over 
reporting. 
A significant correlation was observed between CBIOverscore and the BDI-II but this 
was not the case for Underscore on the CBI or AES and no significant correlations were observed 
between either of the discrepancy measures and performance on the ACE-R or FAB. These 
results suggest that subject mood and depression may influence how they report symptoms but 
changes in subject mood or general cognitive performance alone are insufficient to explain the 
full discrepancy between patient reporting and that of their carers.  
  Taken together these results suggest that:   
1. Using a questionnaire or structured interview based approach to assess apathy, 
respondents report high levels of apathetic symptoms amongst subjects with syndromes 
associated with FTLD.   
2. Reporting varies amongst respondent with subjects with syndromes associated with 
FTLD reporting differently to their carers/other informants.   
3. These differences cannot be solely attributed subject emotional state or overall cognitive 
performance.   
4. Variation in reporting appears to be multifactorial and may be classified at least in part, 
by the questions asked and also the manner in which they are presented. 
Accepting that responses to questionnaire-based assessment of neuropsychiatric syndromes 
vary with respect multiple factors is not necessarily a limitation of this approach.  
Neuropsychiatric syndromes are complex multidimensional constructs with a wide range of 
neural, cognitive and psychological correlates.  By examining the factor structure and inter- and 
intra-correlation of the AES between different respondents and other assessments of mood and 
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cognition it is clear that responses to the items that make up the AES may vary with a variety of 
factors and that the AES when used in isolation cannot disentangle the underlying mechanisms 
by which apathetic syndromes are being reported.   
Behavioural testing is subject to different limitations than a questionnaire based approach 
and offers an alternative modality by which to examine behavioural and the underlying 
cognitive correlates.  While there are clear advantages to this approach it is also important to 
ensure that the behavioural test used does relate to the reported clinical syndrome. Splitting 
groups into those considered apathetic or disinhibited (or not) by their carers/informants and 
comparing mean scores for a range of fourteen behavioural measures (selected to test aspects of 
decision making and response inhibition) resulted in only one measure reaching statistical 
significance.  This was the probability of being correct at the point of decision-making on the 
Information Sampling Task (IST).  Interestingly subjects rated as disinhibited opened more 
boxes before reaching a decision than those who did not on the decreasing condition (where 
reward decreases as more boxes are opened).  The same pattern was observed for the fixed 
condition (where possible reward is unchanged regardless of how many boxes are opened) but 
did not reach significance. When considering the IST, one could have expected more impulsive 
and disinhibited patients to make a decision quicker with less sampling and the probability of 
being correct lower (as was the case when patients were compared to healthy controls in 
Chapter Four).  This does not appear to be the case between patients who were rated impulsive 
or not.  There are several possible interpretations of this result.  It may be that disinhibited 
subjects are less sensitive to the perceived reward so decreasing reward is of reduced 
significance to them (analogous to social disinhibition where subjects make inappropriate or 
tactless remarks and appear indifferent to the consequences).  Alternatively the IST requires 
subjects to sample a number of boxes then make the conscious effort to stop and evaluate the 
information they have obtained.  In may be that more impulsive subjects are more likely to 
simply continue with the first aspect of the task (sampling) and not stop to evaluate and make a 
decision.  Finally the results may be chance. One statistically significant result at the p<0.05 level 
from twenty-eight comparisons to reach significances at is within the expected rate for type one 
errors and this individual result does not survive correction for multiple comparisons.  
Regardless of a single statistically significant result the most notable results is that in all other 
comparisons of behavioural tests there was no significant difference between subjects when 
separated on the presence of apathy or disinhibition by their carers.  
A similar dichotomy arises between questionnaire based and behavioural assessments when 
Principal  Component Analyses are performed across testing modalities.   For both analyses 
(subjects and healthy controls and subjects alone) with the exception of factor seven (where the 
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difference in K loads strongly in the opposite direction to the BIS) behavioural and questionnaire 
based assessments load onto different components suggesting distinct mechanisms for variation 
in performance on behavioural tasks compared with questionnaire based assessments 
(regardless of whether subject or carer is the completing the questionnaire).   
The component structure for PCA of multiple testing modalities for patients alone for and 
patients and controls combined, appear very similar (Tables 5.9 and 5.11).  For the first analysis 
(subjects with FTLD associated syndromes and controls) Bartlett’s test of sphericity was 
significant and KMO of 0.615 implies mediocre factorial simplicity(236).  However, the lack of 
significance for Bartlett’s test and lower KMO when the analysis is repeated for subjects with 
FTLD alone suggests sampling is inadequate and that these data are insufficient for PCA.  Hence  
these results should be interpreted with caution. The similarity between component structure 
for both analyses suggests that while sample size may be inadequate to robustly support PCA 
analysis of subjects with FTLD associated syndromes in isolation the component structure for 
PCA of results from subjects with FTLD associated syndromes and controls is likely to be 
applicable to the FTLD group alone.  
By considering the weighting of individual variables included in the PCA for all subjects and 
the correlation between the extracted components and other measures not included in the 
analysis (e.g. ACE-R, BDI-II) it is possible to make some inferences as to what the extracted 
components may represent.  The PCA resulted an eight-factor component structure with an 
additional ninth component for the patient only analysis.  The first two components seem 
strongly influenced by patient reports of mood (Component One, which correlated strongly with 
the BDI-II) and motivation (Two, which did not).  Note the informant version of the AES did not 
make a large contribution to these.  The patient’s ability to attend to, and maintain, consistent 
performance on behavioural tasks seems core to component Three and is further emphasised by 
significant correlation with the ACE-R.  Other components such as Four and Six are heavily 
influenced by a single testing modality (saccadometer or joysticks tests) which raises the 
possibility these components relate to the methodology rather than cognitive target of these 
assessments.   
While the tasks and variables included in the PCA have an a priori rationale for being 
relevant to apathy and impulsivity it does not necessarily follow that variance in performance on 
these tasks is related to disruption of cognitive process that result in apathy or impulsivity. It 
may be that rather than being related to dissociable components of clinical apathy/impulsivity, 
these components simply reflect the subjects’ ability to make accurate voluntary saccades or 
physically handle and manipulate a joystick. It is possible that (for example) Component Six 
    146
reflects physical disability e.g. limb apraxia which could also account for the correlation with 
higher carer distress and hence the correlation with patient underscore (carers reporting higher 
symptom frequency relative to the patient because of their distress).  While I attempted to make 
inferences as to the nature of structure of individual components this approach is ultimately 
subjective and confounding influences not directly related to apathy/impulsivity remain 
possible.   
These results demonstrate that using a wide range of different methods subjects with 
syndromes associated with FTLD have higher levels of apathetic and impulsive behaviour than 
healthy controls.  While at a group level, subjects and their carers both report high levels of 
apathy and impulsivity, their reports do not correlate with each other.  Discrepancies between 
their reports cannot be easily explained by a single factor and in some subjects may be under- or 
over- reporting symptoms, as may be their carers.   Furthermore, subjects with FTLD perform 
differently to healthy controls on a range of tests of apathy and impulsivity.  There appears to be 
some underlying common factors to performance across different tasks but variance in 
performance does appear to be multifactorial.  Emotional and general cognitive factors appear 
to be relevant to some factors but less clearly so for others.  Some variance may not relate 
directly to apathy or impulsivity and the manner in which a task is presented and how the 
subject is able to interact and respond also appear to be relevant. 
These data support the hypothesis that in FTLD apathy and impulsivity are common and 
that they are complex multidimensional constructs with more than one underlying factor.  
Subjects with FTLD associated syndromes and their carers differ in reporting symptom 
frequency and severity.  The underlying causes of these discrepancies also appear to be 
multifactorial.  While objective behavioural tasks overcome some of the limitations of more 
subjective reporting methods, performance on these tasks does not correspond to symptoms of 
apathy and impulsivity reported by other methods.  When results of multiple testing modalities 
are considered together, variance appears multifactorial with physical, emotional and cognitive 
performance contributing differently to different factors.  Despite overlap between some tasks, 
dissociation between behavioural and questionnaire based assessments remain. 
 
5.6 Conclusions 
In this chapter I have shown amongst subjects with syndromes associated with FTLD 
apathetic and impulsive symptomatology may be measured in a variety of ways but different 
methods do not correlate well with each other.  While these data support the hypothesis that 
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apathy and impulsivity are multidimensional constructs I have also demonstrated that a 
statistical, data driven approach to dissociating these is subject to variation as the sample from 
which the data are derived changes.     Behavioural surrogates of apathy and impulsivity appear 
to measure relatively distinct processes compared with questionnaire based assessment. The 
results of behavioural testing can be dissociated in a number of ways but variation amongst 
subjects seems at least in part to relate to the physical process of testing (e.g. through a joystick, 
button or eye tracker) in addition to variation in goal directed cognition.  Similarly questionnaire 
based assessments of apathy and impulsivity vary with who is being asked and how they are 
asked.  Because of the multidimensional nature of apathy and impulsivity and these limitations 
of each individual form of testing I suggest these results support a multidimensional approach to 
apathy and impulsivity. 
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Chapter Six  
General Discussion 
6.1 Summary 
I studied a regional epidemiological cohort of patients with clinical syndromes associated with 
FTLD to describe the clinical features, lifetime risk, prevalence and incidence of these conditions.  
Using a range of assessment techniques I explored the symptoms of apathy and impulsivity in 
this cohort.  In this final chapter I discuss my key findings with reference to the following 
hypotheses: 
1. The clinical syndromes associated with FTLD overlap and form a dynamic spectrum of 
recognisable symptomatology.  
2. The revised diagnostic criteria for FTLD associated syndromes can be applied jointly to 
estimate their epidemiology. 
3. Apathy and impulsivity are commonly reported across the entire spectrum of syndromes 
associated with FTLD. 
4. Reports of apathy and impulsivity depend on who is asked, what they are asked and how 
they are asked. 
5. Subjects with FTLD perform differently to healthy controls on behavioural assessments of 
apathy and impulsivity. 
6. Reports of apathy or impulsivity do not predict performance on behavioural assessments 
of these syndromes. 
7. Apathy and impulsivity are overlapping and multidimensional constructs. 
8. No single testing modality used in isolation represents these constructs completely, or 
overcomes motor or language confounds that arise in some of the FTLD associated 
syndromes. 
6.2 The Clinical Syndromes Associated With FTLD Overlap and Form a Dynamic Spectrum 
of Recognisable Symptomatology. 
The clinical syndromes associated with frontotemporal degeneration have been described for 
centuries.  In Chapter One I re-presented a historical case of behavioural change associated with 
atrophy of frontal and temporal lobes.  While the underlying aetiology is debateable, the clinical 
syndrome of progressive behavioural change, disinhibition and apathy is extremely recognisable 
and remarkably similar to that seen in modern cases of behavioural variant FTD.  The patient 
    149 
described by Pinel also had a movement disorder (‘a paralytic numbness’) and changes in 
language function similar to later historical descriptions attributed to ‘senile’ frontotemporal 
atrophy (such as Arnold Pick and William Bevan-Lewis’ case reports).   
These early descriptions of FTLD were not restricted to isolated disorders of behaviour, 
language or motor function but all three coexisted in a single subject.  Similarly in the PiPPIN 
cohort while individuals have been given diagnostic labels of particular syndromes (and met 
criteria for such) in a cross sectional study it is clear that clinical features overlap between 
syndromes.  Movement disorders, language deficits and behavioural changes were commonly 
observed amongst all clinical syndromes, similarly apathy and impulsivity were frequently 
reported.  In Chapter Two I present the clinical features of 200 of the 204 cases of FTLD 
associated syndromes identified in the PiPPIN study (Table 2.4).  Through assessment in person 
and careful review of clinical records I have shown that while behavioural and language 
disorders are prevalent in the syndromes of FTD they are also common in PSP and CBS.  
Agrammatism (for example) was seen in over half of cases of CBS and nearly a fifth of those with 
PSP.  Apraxia and akinesia was noted in 8.7 and 13% of cases of svPPA respectively and 
semantic deficits noted in more than half of cases of bvFTD.  
This overlap is not unexpected and does not undermine diagnostic distinctions between 
clinical syndromes: over the course of their illness patients will deteriorate, acquire further 
disability and new clinical features.  Some initially prominent features will become masked as 
others emerge and individuals may move between diagnostic categories.  For example, a patient 
with prominent behavioural changes may be diagnosed as having bvFTD before later motor 
features of PSP-RS emerge.  This movement disorder and bulbar dysfunction may prevent the 
disinhibited actions by which behavioural change were exhibited.   Similarly a patient may first 
develop features of nfvPPA before limb dystonia and dyspraxia emerge to suggest an alternative 
diagnosis of CBS.  
In Chapter One I outlined the criteria that have been developed to diagnose the 
syndromes associated with FTLD.  Over time these criteria and also the associated nosology 
have evolved and fragmented.  For example, while Arnold Pick did not describe the first case of 
progressive language impairment associated with ‘senile’ frontotemporal atrophy(18), his name 
became has become associated with ‘Pick’s Disease’(237).  Initially the term was used to 
describe a clinical syndrome accompanied by frontotemporal atrophy characterised by the 
presence of ‘Pick bodies’(237), (histopathological inclusions first described by Alzheimer on the 
basis of their morphology and staining properties(238)) but it subsequently became clear that 
not all cases had Pick bodies at post mortem and ‘Pick’s Disease’ became the term reserved for 
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only those cases in which Pick bodies were identified (or presumed to be present).  Pick bodies 
are now further defined on their molecular basis by the predominance of three repeat 
microtubule binding repeat isoforms of Tau proteins(239)).  The result is that over the course of 
the last century ‘Pick’s Disease’ has been used to describe a variety of pathologically and 
clinically defined conditions.  Similar semantic shift is seen with other terms associated with 
FTLD.  At the same time, additional distinct clinical syndromes have recognised and defined. The 
term ‘Pick’s Disease’ was superseded by ‘FTD’ which was divided between bvFTD and PPA and 
all of the associated subtypes, each with their own set of criteria which have been subsequently 
revised and refined by further experience and pathological validation.   
Conversely pathological and genetic discoveries have also expanded the clinical 
phenotypes of some forms of FTLD.  For example, the dramatic expansion in the clinical 
associations with large expansions of C9ORF72 that I discussed in Chapter One.  A subset of the 
PiPPIN cohort were screened for genetic mutations associated with dementia.  One case with 
lvPPA (more typically associated with Alzheimer’s pathology) and one with svPPA (typically 
TDP-43 and not usually associated with genetic mutations) had mutations in their MAPT gene.  
Technology has improved speed and affordability of genetic testing and in turn access to genetic 
testing which in turn is increasing genotype-phenotype associations and shifting the boundaries 
of clinical syndromes they are used to investigate. 
One issue concerning diagnostic criteria is that they serve more than a single purpose.  
They may be used to define a clinical syndrome (such as PPA or PSP-RS) and offer a set of 
descriptive terms of particular clinical features or syndromes.  Alternatively they may be used to 
predict underlying pathology, prognosis or influence genetic testing.   
In a research setting there is a clear need for criteria to define clinical syndromes and 
relate them to underlying pathology. This facilitates biological and treatment studies aimed at 
the underlying pathological basis of neurodegeneration. There is also clear need for a common 
framework to describe the neuropsychiatric, behavioural and cognitive aspects of these 
diseases, regardless of their molecular basis.  Defining and subdividing cohorts on the basis of 
different aspects of their syndrome may also in turn lead to new criteria and expose new ways to 
differentiate pathology.  For example, while FTD is largely considered a cognitive disorder (even 
though movement disorders coexist in early descriptions) the presence of features of PSP-RS or 
MND may be more predictive of underlying pathology than cognitive features.  Similarly in CBS 
cognitive features may be better predictors of underlying pathology than the movement 
disorder. 
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Rather than considering individual syndromes separately I chose to consider them 
simultaneously thereby allowing analysis of variance across the spectrum, and inclusion of 
intermediate clinical phenotypes that fall between criteria or transitional cases that move 
between criteria as the clinical syndrome develops.   In doing so I have shown that cognitive and 
movement disorders are common across the entire spectrum of FTLD.  Furthermore by 
discussing FTLD associated syndromes from a historical perspective I have shown that while 
frontotemporal syndromes are highly recognisable distinct set of syndromes but the boundaries 
between syndromic subdivisions and their associated nosology are less clear and subject to shift 
over time -in a manner that is reminiscent of the evolution of an individual’s clinical syndrome 
over the course of symptomatic neurodegeneration.  
6.3 The Revised Diagnostic Criteria for FTLD Associated Syndromes Can Be Applied 
Jointly to Estimate Their Epidemiology 
I used point prevalence methods, an unrestricted age range and revised criteria for FTLD 
associated syndromes simultaneously to estimate their prevalence, incidence and lifetime risk.  
The prevalence of these disorders was 10.84/100,000, incidence 1.61/100,000 and lifetime risk 
1 in 742.  Prevalence rates were similar between the major syndromes associated with FTLD 
(PPA, PSP, CBS, bvFTD).  Incidence and mortality rates were similar suggesting short-medium 
stability of the FTLD rates.  While similar to previous epidemiological estimates of FTLD (see 
Tables 2.1.1-2.2.2) these estimates are not limited to individual syndromes, incorporate 
intermediate clinical syndromes and exclude non-progressive ‘phenocopy’ syndromes.   
By considering all age groups I have shown that rather than diseases of middle age, these 
FTLD syndromes are increasingly common with advancing age.  The youngest case identified in 
the PiPPIN study was 41 at diagnosis (with potentially 5-6 years of prior prodromal symptoms), 
the oldest 92 at diagnosis (with 4-5 years of prodromal symptoms).  In both cases the diagnosis 
of an FTLD associated syndrome was delayed because of their age.  In the younger case a 
psychiatric condition thought most likely but when a neurodegenerative condition was 
suspected FTLD was considered early.  In the older case, Alzheimer’s was considered most likely 
and delayed their final diagnosis of PSP (the subjects general physician wrote questioning 
whether further evaluation would be helpful given their age and pre-existing Alzheimer’s 
diagnosis). On further evaluation they did not have clinical features of typical Alzheimer’s 
dementia.    
Young onset dementia is rare but FTLD accounts for a significant proportion of cases and 
hence is a “common” cause of young onset dementia.  Conversely despite being more common as 
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age increases other pathologies (such as Alzheimer’s) dominate and the index of suspicion for 
FTLD and proportion of cases correctly diagnosed may decrease. 
Within the PiPPIN catchment area there are three cities, large rural areas and a total 
population of around 1.6m.  Demographics vary widely between areas.  For example North 
Norfolk has the second oldest median age by local authority in the UK, while Norwich has one of 
the youngest (Office for National Statistics mid 2015 census data (115)). The population of East 
Anglia is predominantly white and British including substantial historic Viking and Norman 
contributions while more recently the Universities (particularly Cambridge) have attracted 
more diverse immigration to the area and areas of very high education rates.  Such demographic 
environmental and genetic factors may well influence rates of FTLD pathology, and also rates of 
diagnosis.  The numbers of cases of FTLD in individual areas within the PiPPIN catchment area 
are too small to allow direct comparison between them.  However by using geographic 
boundaries that coincide with the output areas for the UK census data, detailed population 
demographics data for this population are freely available and may be compared with other 
studies of FTLD associated syndromes.  In order to facilitate such comparisons I have 
standardised these epidemiological estimates by age and sex to the European Standard 
Population.  
6.4 Apathy and Impulsivity Are Commonly Reported Across The Entire Spectrum of 
Syndromes Associated With FTLD. 
In the PiPPIN study behavioural changes were reported in all the FTLD associated syndromes, 
most commonly in bvFTD and svPPA (100 and 96% respectively) but also in nfvPPA and 
PPA(other) (46% for both).  Apathy was reported in more than half of subjects and impulsivity 
in 46% (Table 2.4).   Nearly 60% of carers of 106 subjects with FTLD reported apathy and a 
third of all carers reported disinhibition when asked to complete the NPI-Q (Figure 3.4).  
Similarly high rates of apathetic symptoms were self reported by subjects (Table 3.2) with FTLD 
(via the AES-S) and observed during clinical interview (e.g. the AES-C).  Subjects with FTLD also 
reported higher rates of impulsiveness compared to similarly aged healthy controls. 
6.5 Reports of Apathy and Impulsivity Depend on Who is Asked, What They Are Asked and 
How They Are Asked. 
Reports of apathetic and impulsive symptomatology are common regardless of whether the 
subject with FTLD is asked or a carer who knows them well.  However reports of 
symptomatology did not correlate well between patients and carers.  For example, patients with 
FTLD score significantly higher on the AES as a measure of apathetic symptomatology regardless 
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of whether the AES-S (subject rated), AES-I (informant rated) or AES-C (clinician rated) 
questionnaire is used.  While the AES-I and AES-S both correlated significantly with the AES-C 
(as would be expected as this version combines subject interview with observed behaviour) the 
AES-S and AES-I do not correlate significantly (Table 5.4). 
It is tempting to favour the cognitively unimpaired carer’s reports of symptomatology as 
more likely to be reliable than those of the patient with FTLD but despite having cognitive 
impairment, patients are still able to give meaningful insights into their own emotional states.  
When completing self rated visual analogue scales of mood and motivation subjects with FTLD 
reported higher levels of states with negative valence (e.g. sad, bored) and lower levels of 
positive valence states compared to healthy controls (Figure 3.7).  However their responses 
were not one-dimensional, instead PCA of responses on 14 different scales revealed a four 
component solution with significant and separate correlation with other assessments of mood, 
motivation, apathy and arousal (Table 3.5).   
I also compared subject and informant responses on the CBI-R.  Subjects were asked to 
self-rate frequency for a subset of symptoms that their carer had also rated.  Patients on 
occasion over- or underscored symptoms relative to their carer.  While overscoring correlated 
significantly with self reported depressive symptomatology (via the BDI-II) no significant 
correlation was observed for underscoring or between performance on the ACE-R or FAB and 
either under- or overscoring. These results suggest that the subject’s mood and coexisting 
depression may influence their reporting of symptoms but changes in their mood or general 
cognitive performance alone are insufficient to explain the all the discrepancies between patient 
reporting and that of their carers.  It is possible that at least some of these relate not directly to 
emotional or cognitive state in the patient but instead to carer factors, whereby their own 
insights, interpretations and emotional state influence their reporting. 
In Chapter Five I examined the components resulting from PCA of the each of the three 
versions of the AES performed separately for all subjects (patients and controls) and patients 
and controls separately. The extracted components vary in number and variance explained 
between the separate analyses.  From nine PCAs a total of 40 components were extracted.  Using 
a systematic approach I then sought to classify these components based on the original item 
structure within the AES.  A third of components could be classified by the item type (e.g. 
cognitive, behavioural etc.) while a further 15% could not, but could be classified by negative 
scoring alone (where the scale the respondent is asked to complete is reversed compared to 
other items on the questionnaire).  These together suggest that responses rating apathetic 
symptomatology for a single subject with FTLD (via the AES) vary depending on who is 
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completing the AES, the particular items that make up the AES and also the manner in which 
they are presented. 
6.6 Subjects With FTLD Perform Differently to Healthy Controls on Behavioural 
Assessments of Apathy and Impulsivity. 
Rather than rely solely on questionnaire-based assessments of behaviour and symptomatology I 
also used behavioural measures that seek to assess and measure specific aspects of behavioural 
and cognitive symptomatology in a more objective manner. Subjects with FTLD performed 
differently on a range of behavioural tasks designed to test goal directed behaviour, reward 
responsiveness, action selection, initiation and cancellation.  When compared to controls across 
a range of tasks patients respond more slowly and less accurately. When potential reward or 
negative feedback are introduced (such as the IST and CRRT), subjects with FTLD and controls 
are both sensitive to this change and adapt their response strategies however amongst subjects 
with FTLD associated syndromes (and in contrast to healthy volunteers who are able to improve 
reaction time) I was unable to demonstrate a change in reaction time in response to the 
introduction of feedback or reward, despite a reduction in accuracy.  For example, during the 
second half of trials for the CRRT task (where response time is explicitly related to reward) 
healthy controls respond more quickly, especially when there is a higher chance of reward, but 
subjects with FTLD do not.  
Speed accuracy trade offs are well recognised across a number of species and tasks(240).  
Most subjects are able to sacrifice accuracy in exchange for better response time.  It is therefore 
notable that during tasks where speed is related to reward, subjects with FTLD did not appear 
able to improve reaction time even when accuracy reduced.   Conversely when reaction time is 
not related to reward but accuracy and sampling rates are (such as the decreasing vs. fixed 
conditions of the IST) healthy controls respond more slowly while subjects with FTLD did not 
(their box opening latency was actually marginally quicker for the decreasing condition).   
During the IST subjects with FTLD opened fewer boxes across both conditions and made 
more errors, despite being substantially slower when completing the task.  They made a final 
decision based on less information and took longer reaching a decision point.  However, both 
healthy controls and subjects with FTLD adapted their strategies to the change in condition from 
fixed to decreasing reward, sampling less and making a final decision based on less information 
demonstrating that both groups were sensitive to the change in condition.  Amongst controls 
only, I observed an increase in box opening latency when the condition switched from fixed to 
decreasing reward suggesting that when the number of boxes sampled has an effect on potential 
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reward, healthy subjects spent more time deliberating whether to continue sampling boxes or to 
reach a final decision.  This was not the case for subjects with FTLD who in actual terms had a 
slightly shorter deliberation time (box latency) during the decreasing condition compared with 
the fixed.  
   Taken together these results suggest that subjects with FTLD are: 
1. Slower and less accurate in their responses compared to healthy controls. 
2. Sensitive to reward and change in condition. 
3. Less able to slow down to make decisions, in response to new reward contingencies. 
4. Inclined to make decisions based on less information than healthy controls. 
This failure to slow down under conditions of uncertainty, risk or high-stakes has been 
demonstrates in other disorders, for example in Parkinson’s disease (e.g.(223,241)).  In contrast 
to this problem gamblers appear to be able to detect changes in reward and risk and do adapt by 
slowing reaction time (for example in a computerised simulation of blackjack both problem 
gamblers and healthy controls slowed reaction times in response to higher risk situations(242)).  
In one study using the SSRT, regular poker players were compared to non-gamblers; as the 
probability of a stop signal was increased both groups detected this and slowed reaction 
times(243).  In a non time limited paradigm (the Matching Familiar Figures Test) Kertzman et 
al.(244) showed that pathological gamblers had higher error rates than healthy controls but 
were not significantly different in terms of response times, suggesting that mechanisms other 
than speed-accuracy trade-offs may underpin impulsivity in such subjects.  Interestingly, in one 
further study subjects with both Parkinson’s and a gambling disorder had significantly faster 
reaction times than subjects with Parkinson’s alone but only in high risk situations(245) 
suggesting perhaps that impulsivity underpinning pathological gambling in the context of 
Parkinson’s may differ from those with problem gambling outside of a neurodegenerative 
condition; that the former having a measurable surrogate in terms of the effect of risk 
contingency on reaction time, while the later does not.  Alternatively, it may be that the 
combination of Parkinson’s pathology modulates the effect of a gambling disorder and results in 
an observable effect of risk on reaction time.       
A number of models have proposed for simple decision making, most assume 
accumulation of noisy evidence to a decision threshold, such as the drift diffusion model (Figure 
6.1).  In this evidence from perception or memory accumulates from a starting point to a 
threshold e.g. a boundary to ‘go’ or an opposite boundary to ‘no go’(246).   Accumulation is noisy 
and at a particular moment in time may point towards either boundary (but more often the 
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correct than incorrect), average rates of accumulation are called drift(246).  Speed accuracy 
changes may be explained in this model by changes in the thresholds at which a decision is made 
(Figure 6.1C).  Alternatively the starting point off accumulation may be shifted towards one 
boundary, simultaneously adding a bias and increasing the likelihood of that response (Figure 
6.1D).  Bias may be introduced in the relative rates of accumulation between respective 
thresholds(246).  
It is remarkable that some subjects with FTLD, especially PSP-RS, take an inordinate 
amount of time to make a response and yet when they do it is frequently a poorly conceived one. 
Zhang et al(223) addressed this by applying a drift diffusion model to decisions in an 
oculomotor version of the Go/NoGo task by subjects with PSP-RS, Parkinson’s and healthy 
controls (including some of the data from the PiPPIN study). Comparing four variants of the drift 
diffusion model they showed best fit for a model in which starting point and rates of drift were 
variable and that using this model, subjects with PSP had higher response bias to Go but slower 
drift rates i.e. they were strongly biased towards making a response but severely impaired at 
accumulating the necessary evidence to commit to it (Figure 6.1E). This reconciles the 
counterintuitive observation that subjects with PSP exhibit marked akinesia with motor 
impulsivity(223).   Similarly in the larger PiPPIN cohort, impaired accumulation could explain 
the increased reaction time observed and a lowering of threshold for response accounting for 
decreased accuracy in patients vs. controls.  Interestingly in Zhang et al.’s model subjects with 
PSP had shorter non decision time (Ter in Figure 6.1E, thought to reflect latency of early sensory 
encoding external to the decision process) than controls which they compare to similar EEG 
findings in Parkinson’s and suggest of could imply a partial compensation for impaired cognition 
by additional processing(223).  
The drift diffusion model used in this context assumes that inaction (NoGo) is an active 
decision not to go (as opposed to no decision and no action).  A subject who is not attending to 
the task or unable to generate any response in time (from either cognitive or motor deficits) will 
have higher omission rates, as was the case for both joystick and oculomotor tasks in the PiPPIN 
study.  In studies of the Go/NoGo task amongst healthy undergraduate students a single 
boundary model (a single threshold for ‘Go’) does not fit well(247,248) however in the PiPPIN 
cohort the sensitivity index (d’) for patients was significantly lower than controls for both forms 
of the Go/NoGo task (especially the oculomotor task).  This suggests lower signal detection 
amongst patients i.e. that their responses were noisier with less detectible signal.   In Zhang et 
al.’s study response times amongst the patients groups with PD and PSP were not slower than 
controls study but they were in the PiPPIN study.  Subjects in the PiPPIN study did have 
significantly slower mean response times on all versions of the Go/NoGo task than controls.  
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This difference may reflect lack of power to detect such a difference in the smaller PSP cohort 
used by Zhang et al. or alternatively greater variance and noise in the larger and more diverse 
PiPPIN cohort.  
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Figure 6.1. A The Drift Diffusion Model. Evidence for either outcome is accumulated in a noisy 
fashion (irregular black lines) with the rate of accumulation (drift) represented by the red 
arrows.  Signal accumulates from starting point, Z, until it reaches a threshold level (a or 0) at 
which a decision (‘Go’ or ‘NoGo’) is made.  Three example trajectories are shown with three rates 
of drift (V1-3).  Response time may be varied by changing the rate of accumulation (from V1 to V2 
in B), or the threshold at which a decision is made (C). In D moving the starting point from Z1 to 
Z2 introduces bias and makes Go responses more likely and quicker for a constant rate of 
accumulation (V1=V2). Zhang et al.’s(249) model of drift diffusion is shown in E.  Subjects with 
PSP (red dashed lines) start with a bias towards the Go threshold (Z2) but signal accumulation 
(V2) is impaired compared to healthy controls (solid red arrows and V1).  Response rates were 
not significantly different between PSP and controls who had a longer non decision time (Ter). 
A 
B C 
D E 
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It is possible that subjects with FTLD are unable to make an appropriate speed-accuracy 
tradeoff when adapting to change in condition because their response time is already as short as 
they are able.  However subjects with FTLD do appear to have different levels of accuracy when 
conditions change (as in the IST).   
It may be that rather than slower signal accumulation, in FTLD the accumulation of 
information is more stochastic and unstable. As neurodegeneration occurs connectivity and 
efficiency of the brain is reduced(250). In contrast to a healthy brain where responses are the 
result of (comparatively) steady and stable accumulation of signal, in FTLD there may be greater 
entropy of signal, impaired (rather than slowed) accumulation of signal and quicker signal 
breakdown. The result being that reaching a given signal threshold occurs less frequently and 
for shorter periods.  Lowering a threshold for response would have little effect on reaction time 
and those responses that do occur would be less predictable, less accurate or consistent (Figure 
6.2).   
   
Figure 6.2. Models of Response Initiation. In the top panel slow accumulation of 
signal/information eventually reaches threshold A, at which point a response/action is initiated 
at time point 1.  Lowering the threshold to B improves response time (2) but as less information 
has been accumulated, accuracy is sacrificed.  In the lower panel signal accumulation is 
stochastic and noisy.  Responses occur less frequently and suddenly.  In this model lowering the 
threshold sacrifices accuracy but has little effect on response time. 
Average discounting rates during the Kirby were higher for patients than controls (i.e. 
the prefer immediate reward compared to higher reward after a delay).  As with the lower 
    160
sensitivity indices observed amongst patients in the Go/NoGo tasks, patient consistency when 
completing the Kirby temporal discounting task was significantly lower than controls (i.e. the 
point at which they chose to switch from higher delayed reward to smaller immediate reward 
was not consistent across all their responses).  The Kirby is designed to assess aspects of 
decision making and patients may deliberate for as long as they like.  Even outside of a time 
dependent test patient responses tend towards the more impulsive option than controls but 
their responses are also more erratic.  
A frequent and early feature of bvFTD is emotional lability i.e. rapid switching on and off, 
of emotions.  Despite this increase in emotionality they are also described apathetic with loss of 
warmth and empathy with a psychomotor slowing and dramatic reduction in spontaneity(251).  
This combination of hyper- and hypo-emotionality is reminiscent of the akinesia and motor 
impulsivity seen in PSP-RS. Compared to Alzheimer’s, subjects with bvFTD and PSP have 
impaired emotion recognition(252,253).     In Figure 3.6 I presented a dramatic example of 
impaired ability to differentiate between emotional states more subtle than simply positive or 
negative.  Across all the patients, within subject variance on visual analogue scales of emotional 
state was higher for patients than controls i.e. they reported more extreme variation in 
emotional state (Table 3.3.).  This was also seen on self reported questionnaires that did not rely 
on an analogue scale (e.g. the AES or BDI-II).  Subjects with FTLD appear less emotional most of 
the time(251), but when they do display (or report) emotion it is more rapid and intense.  I 
suggest subjects with FTLD are less able to generate and/or recognise an emotion in themselves.  
In a similar fashion to their impaired ability to accumulate signal and respond in tasks of 
decision making, when patients process their own emotional states, impaired ability to 
recognise emotion impairs their ability to accumulate evidence (signal) to support a particular 
response.  As a result there is a compensatory lowering of threshold, partly by simplifying the 
range of emotionality so that emotions become more dramatic e.g. ‘all or nothing’ and simpler 
e.g. ‘happy or sad’. 
6.7 Reports of Apathy or Impulsivity Do Not Predict Performance on Behavioural 
Assessments of These Syndromes. 
In Chapter Five I separated patients based on informant reports (via the NPI-Q) of whether they 
displayed apathetic behaviour or not and compared performance on a range of fourteen 
behavioural tasks that were selected to assess aspects of decision making and goal directed 
behaviour (Table 5.7).  There were no significant differences between groups.  Similarly splitting 
the patients into groups depending on whether informants reported impulsive/disinhibited 
behaviour and repeating the comparison yielded only one statistically significant difference (i.e. 
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within the frequency expected for type 1 errors at this level of significance).  It is possible that 
the items from the NPI-Q used to define apathetic or impulsive groups (Apathy: ‘Does the patient 
seem less interesting in his/her usual activities or in the activities and plans of others?’ and 
Impulsivity: ‘Does the patient seem to act impulsively, for example, talking to strangers as if 
he/she knows them, or saying things that may hurt people’s feelings?’) are insensitive or not 
sufficiently specific to these syndromes to accurately dissociate groups.  However behavioural 
measures and questionnaire based assessments of apathy/impulsivity reporting also loaded 
onto separate factors on Principal Component Analysis suggesting a similar dissociation of 
objective measures and a wide range of patient self assessments and informant reports. 
Performance on these particular behavioural tests of decision making and goal directed 
behaviour could therefore have limited relevance to apathetic or impulsive behaviours observed 
by carers, or self-reported by patients.  Against this argument is that the behavioural tasks used 
were selected because they directly related to models of response initiation, inhibition, decision 
making and goal directed cognition. They had previously been used in healthy subjects, subjects 
with other brain disease and in animals to assess these aspects of behaviour (e.g. 
(165,166,187,220,233)).  In addition in the PiPPIN study subjects with FTLD demonstrated a 
partially preserved ability to change behaviour in response to changes in task conditions.  When 
conditions for potential reward or perceived value change (e.g. in the IST and CRRT tasks), so do 
their response strategies, demonstrating that the subjects are interacting with these tasks in a 
manner that is dependent on, and varies with, their perceptions of the effects of their actions.  As 
such their performance on these behavioural task does appear to be homologous to carer 
observed changes in motivation and goal directed cognition. 
Another explanation for the dichotomy between behavioural tasks and questionnaire 
based assessments may be that instead of the behavioural tasks not measuring relevant aspects 
of apathy/impulsivity, the subject/informant reports of apathy/impulsivity are unreliable in this 
clinical population, and do not relate to true symptomatology.  The informant based assessment 
tools used here been used in a wide range of clinical and research settings including dementia.  
For example the CBI-R has been in use for over a decade to assess symptoms in dementia 
(including FTD) via informant reporting(254) while individual informants may in some 
circumstances be unreliable it seems implausible that this would be case for the majority of the 
107 informants who completed the CBI-R in PiPPIN.  Similarly while patient self-reporting may 
be challenged on the basis of accuracy or levels of insight, I have demonstrated that these 
patients reports correlate with each other (e.g. Table 3.5) and on multimodal PCA load onto the 
same factors in an appropriate directional fashion (i.e. those questionnaires where positive 
valence symptoms equal positive scoring loading in the opposite direction to those with 
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negative scoring for positive valence).  These patients are able to give some insights into their 
own symptomatology and emotional and motivational state, even if their responses do not 
significantly correlate with carers’ responses.  While behavioural tasks, patient self reports and 
informant reports do not correlate well with each other, they appear to provide complementary 
insights into apathetic and impulsive symptomatology in this patient group.  
6.8 Apathy and Impulsivity Are Overlapping and Multidimensional Constructs. 
The lack of correlation between different testing modalities when assessing apathy and 
impulsivity discussed above is perhaps unsurprising. As discussed in Chapter Three, goal 
directed behaviour is dependant on more than one cognitive process (e.g. see Figure 3.1) and 
disruption at any point in this process may result in reduced goal directed cognition and hence 
the syndrome of apathy.  In the PiPPIN cohort reports of apathetic and impulsive 
symptomatology frequently coexisted within a single subject.  This observation also supports a 
multidimensional approach to these symptoms.  As I argued in Chapter Three, while poorly 
conceived and reckless and disinhibited behaviour may appear the direct opposite of apathy, it 
may also be the result of an “apathetic approach to consequences”.  
In support of the multiplicity of factors in apathy/impulsivity was the result of the 
multimodal PCA.  Eight factors accounted for 70% of the variance (Table 5.8).  Significant but 
different patterns of correlation were seen between these factors and tests of global cognition, 
mood, carer distress and discrepancies between patient and informant symptom reports (Table 
5.12).  From these data it appears that performance on these assessments of apathetic and 
impulsive symptomatology is not related to disruption of single one-dimensional process. 
6.9 No Single Testing Modality Used in Isolation Represents These Constructs Completely, 
or Overcomes Motor or Language Confounds That Arise in Some of the FTLD Associated 
Syndromes 
If apathy and impulsivity are complex and multidimensional then a comprehensive assessment 
of them will need to be similarly complex.  Taking a multimodal approach to their assessment is 
very similar to the clinical approach to the diagnosis of dementia as a whole.  A diagnosis of 
dementia is very rarely made on the basis of the patient’s own self reported symptoms in 
isolation.  Instead this is combined with collateral history from informants and objective tests 
like cognitive assessments and neuroimaging.  Where over emphasis is placed on one modality 
there is greater risk of diagnostic error, for example the bvFTD phenocopy syndrome where 
collateral history of behavioural change was not accompanied by typical deterioration in 
cognitive testing or brain atrophy.   
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In the PiPPIN study I took a multimodal approach to the assessment of apathy and 
impulsivity.  Patient and informant reports were combined with behavioural measures using a 
range of tasks and input methods.  When the results of these assessments were combined into a 
single PCA different testing modalities loaded onto different components (Table 5.9). 
Behavioural assessments loaded onto different components than questionnaires.  Interestingly 
while carer reports of symptoms did not predict performance on behavioural tasks, significant 
correlation with carer distress and discrepancy measures on the CBI-R were seen with extracted 
components that predominantly comprised of behavioural (rather than questionnaire based) 
assessments (Table 5.12) suggesting that performance on these behavioural measures may also 
be relevant to elements of carer morbidity and reporting which were not captured by the other 
assessments.   Many previous studies have used individual assessment tools (such as the AES) 
that use a single testing modality (e.g. questionnaire based) and then extract multiple 
components of such a tool.  My data suggests that while this may be a useful approach to 
assessing some aspects of apathy/impulsivity but (at least in this cohort) it does not capture the 
full spectrum of symptomatology and other potentially clinically relevant aspects may be 
overlooked.  Rather than demonstrating one testing modality or assessment tool that is superior 
to others or more relevant, these results support a multidimensional and multimodal approach 
to the assessment of apathy and impulsivity. 
 
6.10 Limitations 
The PiPPIN study aimed to identify every subject with a diagnosis of a syndrome associated with 
FTLD within a geographically defined area.  Despite multisource referral and using a range of 
approaches to raise awareness of the study it is likely that some cases will have been missed.  
Some subjects with a diagnosis will not have been invited and some may have been invited but 
refused to participate.  Others with the relevant disease will not have been correctly diagnosed, 
or not presented for diagnosis at all.  
The majority of patients with a diagnosis of FTLD are seen in our regional referral centre 
for these conditions and hence are seen in a clinical capacity by physicians who both work in the 
PiPPIN study (such as myself) or work closely alongside us.  I am aware of only one subject with 
FTLD who initially refused participation in PiPPIN (and subsequently changed their mind to be 
included in the epidemiological aspects of the study) suggesting that the number of subjects 
with a diagnosis who refuse any participation is likely to be very small.   
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It is more difficult to estimate the number of patients with symptomatic FLTD who do 
not carry a diagnosis (or have it suspected) and hence would not have been invited to 
participate.  This group of patients may be split into those who have symptomatic FTLD but are 
in an early prodromal phase whereby they would not meet criteria for a diagnosis (‘pre-
diagnosable’), those who have symptomatic disease that is not typical for one of the syndromes 
of FTLD either because of comorbidities or because of an unrecognised syndromic variant 
(‘undiagnosable’) or those who have typical syndromic disease but have not been recognised as 
such (missed diagnosis).  While knowledge of the number of pre-diagnosable patients with 
prodromal disease has use from an epidemiological perspective and clear value in early 
intervention trials, expanding the inclusion criteria to capture such patients also limits the 
usefulness of such a study.  Moreover, expanding the inclusion criteria is likely to reduce their 
specificity and hence the cohort acquired may be less reflective of FTLD pathology.  Including 
patients with pre- or oligosymptomatic disease also reduces the level of current morbidity of the 
collected cohort. As a result inclusion of ‘prediagnosable’ subjects may both over represent the 
epidemiological impact of FTLD and simultaneously underrepresent its morbidity.    
Those ‘undiagnosable’ patients, who do not fulfil current criteria for FTLD associated 
syndromes and do not present in a fashion that may be recognised as associated with FTLD, 
represent a different challenge to epidemiological estimates of FTLD.  Some patients with FTLD 
will have additional comorbid neuro- and psychopathology that may not only serve as exclusion 
criteria for the diagnosis of FTLD but also change the clinical phenotype.  Mixed pathology is 
common in dementia especially with advancing age and may account for the some of the 
reduction in incidence and prevalence of FTLD seen in the most elderly groups in the PiPPIN 
study.  It is also possible that FLTD pathology may present as a syndrome not encompassed by 
current clinical criteria.  For example Pure Akinesia with Gait Freezing (PAGF) is a syndrome 
associated with PSP type pathology but not included in the NINDS-SPSP or NNIPPS criteria used 
in the PiPPIN study.  Other syndromes may exist that are not currently recognised as being 
associated with FTLD.  Epidemiological studies of this nature cannot encompass such cases, 
which can only be identified via clinico-pathological studies using other biomarkers, genetics 
and pathological validation. 
Since this study was designed and conducted, new criteria have been proposed for 
PSP(48).  Progressive Supranuclear Palsy was originally a clinically defined entity, this is now 
more commonly referred to as PSP-Richardson’s syndrome (formerly Steele-Richardson or 
Steele-Richardson-Olszewski syndrome)(255) while PSP is used to denote a particular pattern 
of neuronal atrophy and four repeat Tau aggregation(47).  The most recent criteria for PSP 
attempt to reconcile the wide variety of clinical syndromes associated with PSP pathology and 
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by using different thresholds of ocular motor dysfunction, postural instability, akinesia and 
cognitive impairment, seek to operationalize criteria by which different levels of diagnostic 
certainty may be attributed(48,256). The authors suggest different levels of certainty may be 
appropriate for different purposes.  Using a more inclusive and sensitive criteria for 
epidemiological research but restricting therapeutic and biological studies to those syndromes 
with the highest specificity(48).   
These new criteria have taken a similar approach to the current criteria for CBD(7,12).  
By taking a more inclusive approach syndromes that would previously have been classified as 
CBS or bvFTD may now be considered within the spectrum of PSP.  Patients with mutations in 
MAPT (who would previously have been excluded from criteria for PSP) may now be classified 
as PSP.  While subjects recruited in the PiPPIN study were not assessed with direct reference to 
these criteria I suspect use of these new criteria are unlikely to change the epidemiological 
estimates substantially for several reasons.  Firstly the new criteria broaden the clinical 
phenotype associated with probable or possible PSP mainly by inclusion of aspects of other 
FTLD associated syndromes (such as CBS or bvFTD).  These are already included in the PiPPIN 
criteria and clinical features of another FTLD associated syndrome were not considered 
exclusion criteria for PiPPIN or individual syndromes.  Second while some clinical syndromes 
that would not have been included in PiPPIN are now included in the criteria for PSP I think it is 
unlikely that many such cases would have been identified and referred to the PiPPIN study even 
if these criteria were used in the study assessments.  Examples of such cases include PSP-P 
(where slow vertical saccadic speed plus Parkinsonism with tremor, which may be dopamine 
responsive and asymmetric) or progressive gait freezing.  Under new criteria these would be 
considered possible or probable PSP pathology and the authors suggest inclusion in 
epidemiological studies(48).  Working within general neurology clinics for over seven years, and 
in specialist tertiary clinics for PSP, CBS and MSA for four years, I have seen three cases of pure 
akinesia with gait freezing.  While gait freezing in isolation is highly suggestive of PSP 
pathology(9) I suggest it is rare and would not necessarily be recognised as a presentation of 
PSP-pathology in general neurology clinics and hence would be unlikely to have been referred to 
a study such as PiPPIN or a tertiary service for PSP during the study. I do not anticipate that 
inclusion of such cases would have substantially changed the epidemiological estimates.  In 
contrast to this inclusion of subjects meeting criteria for PSP-P may have had a more dramatic 
effect on the epidemiological estimates.   The new criteria for PSP classify a case of typical 
Parkinsonism (dopa responsive asymmetric rigidity with tremor) with slowing of vertical 
saccades, as ‘PSP-P’ with probable underlying PSP pathology.  This is on the basis of a 
retrospective review of clinical features of 437 patients (206 with PSP pathology) recruited from 
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nine brain banks(48,256).  Accepting that subjects with a syndrome more typically associated 
with idiopathic Parkinson’s Disease may at post mortem have PSP pathology(60) the authors of 
the new criteria have used the high specificity of abnormal vertical saccades in this cohort to 
justify use of saccades as a sensitive and specific feature of PSP type pathology(48,256).  I 
suggest this may be open to misinterpretation.  Firstly as idiopathic Parkinson’s Disease is 
underrepresented in their brain bank cohort, and second as they consider a clinical feature that 
has not been recorded as one that is absent - this is not necessarily the case(256).  Abnormal 
saccades had a sensitivity of 7.5% for Parkinson’s pathology amongst a cohort of 53 
pathologically defined cases(256).  Hence abnormal saccades were documented in three cases of 
Parkinson’s and presence or absence of abnormal saccades in the rest unknown.    The new PSP 
criteria provide much better operationalized criteria for abnormal vertical saccades as a 
criterion for PSP but these have not been subjected to prospective pathological validation (48).  
Two studies have retrospectively addressed specificity and sensitivity of these new criteria: The 
first using subjects with Parkinsonism or pathologically confirmed PSP from the Society for 
Progressive Supranuclear Palsy brain bank(257) and the second by review of clinical features 
recorded from a brain bank cohort of subjects with FTLD(258).  Neither approach can assess the 
sensitivity or specificity of these criteria to detect PSP pathology from a cohort of (for example) 
incident Parkinsonism.  Recruitment into the Society for PSP brain bank is very likely to be 
biased towards rarer movement disorders and where PSP was already suspected (and with 
reference to older criteria). Cases with Parkinsonism within this cohort will therefore not be 
representative of all cases of incident Parkinsonism.  Validation of these criteria amongst cases 
of FTLD demonstrates that they are useful for this purpose but does not overcome the issue of 
non-FTLD type pathology (such as Parkinson’s disease).  It has been demonstrated that subjects 
with Parkinson’s disease may have impaired vertical saccades; even if this occurs in 7.5% of 
cases of Parkinson’s(256),  the higher prevalence of Parkinson’s compared to PSP mean that 
Parkinson’s would still be the commonest cause of PSP-P as defined by the new criteria. It may 
be that with further validation of these criteria, or subsequent refinement, it will become 
possible to include subjects with syndromes more traditionally associated with Parkinson’s 
Disease into epidemiological studies of PSP. However given the substantially higher prevalence 
of Parkinson’s compared to FTLD, inclusion of PSP-P into epidemiological studies may lead to 
substantial over estimates of PSP pathology.  I suspect that (at present) even if PSP-P had been 
included in the PiPPIN criteria many subjects meeting the criteria for PSP-P would not have 
been recognised and referred, as many clinicians would diagnose idiopathic Parkinson’s disease. 
This issue speaks to a more fundamental one, how a disease is defined and to what 
purpose. Many recent classification systems have recognised that the purpose of classification 
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varies(11,48).  Some clinicians use criteria to reflect diagnostic certainty and relate diagnosis to 
prognosis or treatment options, biological studies of pathogenesis or of disease modifying 
therapeutics require high-level clinico-pathological specificity while studies of the epidemiology 
of disease or of disease burden may prioritise sensitivity or specific aspects of the clinical 
syndrome.  Other studies may not require firm pathological validation but instead a common 
framework to describe clinical aspects of the condition and uniformity between 
groups/centres(11).  In some circumstances the molecular or histopathological basis of a 
particular syndrome may be less relevant that the syndrome itself and its neuropsychological, 
cognitive and functional neural basis.  The syndromes of PSP-RS or bvFTD (for example) cause 
similar morbidity irrespective of whether they are caused by a 4 repeat tauopathy, TDP-43 or 
some other process and as such should be considered together in (for example) some 
epidemiological studies, descriptive studies of symptomatology or morbidity and some 
interventional trials.    
Even using current criteria that have been subjected to pathological validation some of 
the subjects included in the PiPPIN study will not have an FLTD pathology.  The specificity for 
these criteria is not 100% and other pathologies may mimic FTLD.  Limitations of 
clinicopathological correlation and disease identification are common in epidemiological 
research.   Some of this may be ameliorated by reference to cohorts with pathological correlation 
(e.g. (129,259)) however such ‘Brain Bank’ studies are also subject to their own limitations and 
bias(260).   It is also possible to use additional biomarkers (e.g. CSF Tau and β-Amyloid or PET 
imaging) to increase specificity to FLTD but, as with post mortem validation, this more invasive 
approach would limit recruitment those who chose to participate in such a study may not be 
representative of the cohort as a whole. 
Pathological validation may not always be necessary and in some circumstances could be 
unhelpful.  I have shown that the syndromes of frontotemporal degeneration are well 
documented and recognisable across two centuries of scientific literature. The progressive 
destruction of personality, interpersonal relationships and motivation that are associated with 
these syndromes have unique effects and morbidity irrespective of whether they are caused by 
Tau, TDP-43 or another non-FTLD type pathology and there is merit in studying the 
epidemiology of these syndromes in their own right.  This work aims to investigate the 
epidemiology of these highly recognisable syndromes, not necessarily their associated 
pathology. While studies directed at the pathogenesis of neurodegeneration in FLTD may 
require high levels of molecular and pathological validation, studies such as this that examine 
the pathogenesis of the syndromic aspects (such as this study of apathy and impulsivity) and 
associated morbidity do not necessarily require these additional molecular restrictions. 
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Not every subject recruited was able to complete every aspect of the protocol.  I had 
expected this to be the case, by attempting to recruit a representative cohort I chose to include 
subjects whose illness was advanced to the point where they were unable to attend clinic or 
complete assessments themselves, and could only complete the most basic aspects of clinical 
verification in the PiPPIN study. Amongst this cohort were subjects who (for example) had 
significant language deficits such that questionnaire based assessments were not possible but 
they had sufficient comprehension to be able to complete aspects of the behavioural testing.  
Others were able to complete most questionnaires but motor aspects of their condition 
significantly limited behavioural testing.  Within a heterogeneous spectrum of clinical 
syndromes it is very likely that some testing modalities will be better to suited to some subjects 
than others.  Rather than restrict testing to specific and narrowly defined clinical syndromes I 
chose a more inclusive approach.  Not only because this approach better represents the clinical 
syndromes associated with FTLD but also because it seems possible that those aspects that limit 
some aspects of testing may be directly relevant to the syndromes of apathy and impulsivity that 
I wished to study.  Also this inclusive approach exploits syndromic heterogeneity and allows 
identification of common factors that may run throughout the spectrum of FTLD associated 
syndromes. 
I have deliberately not separated results by clinical diagnosis because such distinctions, 
typically made at the point of diagnosis, often dissipate over the course of an individual’s 
illness(26).  As I have shown (in Chapter Two) and consistent with other reports of FTLD (e.g. 
(261) individual clinical features of each syndrome are not exclusive.  A supranuclear gaze 
paresis (for example) is not only seen in PSP and apraxia is not exclusive to CBS.  While some 
subjects may have met criteria for bvFTD at the diagnosis, by the time of testing in the PiPPIN 
study they may have acquired further features of CBS or PSP-RS.  It is not clear to me how such 
subjects would be classified if the results here were compared by diagnostic category, accepting 
that the point of diagnosis is to some extent arbitrary and dependent upon when a subject meets 
with a suitably experienced clinician.  One aspiration of this work was to set out methods by 
which behavioural syndromes may be quantified and operationalized within this cohort of 
subjects, with the eventual aim of facilitating further study of such syndromes and symptomatic 
treatment trials.  Subdividing results by clinical syndrome would limit the opportunities to do so 
and restrict sample size and usefulness of these data substantially. 
I have shown that performance on tasks selected to assess apathy and impulsivity may 
be separated into a number of distinct components, some of which relate to carer reports, others 
to patient or clinician assessments and others to performance on a range of behavioural tasks.  I 
have not however demonstrated that performance on each task directly relates to apathetic or 
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impulsive behaviour/cognition, or assessed which relate to patient or carer morbidity.  It is very 
likely that other factors including (for example) motor disabilities, carer distress and patient 
insight will all have had an effect on symptom reporting and performance on some aspects of the 
testing battery.  While this is a limitation when drawing conclusions on disruption of goal 
directed cognition, this is also a limitation of any behavioural testing or interview based 
psychology.  
By using a heterogeneous group of subjects and an array of different testing methods I 
have attempted to ameliorate the effects of any specific limitations in any particular syndromic 
group but I also suggest that some deficits may be directly relevant to a clinically based study of 
apathy and impulsivity.   For example in a study of stroke patients language disorders and motor 
dysfunction strongly correlated with assessments of apathy(262).    
Despite selecting a range of behavioural tasks aimed to assess aspects of decision making 
that have a clear relevance to apathy and impulsivity, there was very little significant difference 
between performance amongst those subjects with FTLD rated as apathetic or impulsive by 
their cares and those who were not.  Similarly combining ‘objective’ behavioural testing with ‘subjective’ patient and carer based questionnaires into a single Principal Component Analysis 
produced very little overlap between testing modalities.  Similar lack of association between 
questionnaire and task based assessments have been reported in other studies, for example, of 
inhibitory control(263)  
At least some of the extracted components appear to relate to the method by which 
testing is performed (for example by measuring saccades, use of a joystick etc.).  Motor 
components have previously been reported as confounding neuropsychological testing in some 
studies (e.g. in motor neurone disease(266)), others have suggested that associations between 
dysfunction of motor control and behavioural testing reflect common underlying mechanisms. 
One study(267) bradykinesia and chorea both had significant but opposite associations with 
apathy in Huntington’s disease.  The authors suggest this may support both motor dysfunction 
and apathy being manifestations of dysfunctional striatal gating in Huntington’s.   Hence while 
some extracted components in the PiPPIN study may be related to abnormal motor function 
they may still be relevant to the study of motivation and behaviour. 
Principal Component Analyses of the various versions of the AES demonstrated that 
extracted component structure varied depending on who was included in the analysis (patients, 
controls or both), who was asked (subject, informant, clinician) and that the extracted 
components could be classified not only by what was being asked (item type) but also the 
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manner in which was asked (question type).  Again while this suggests factors other than simply 
variation in the target symptoms may be contributory to the results.  Such factors are not simply 
confounders but may also be contributory to apathy and impulsivity.  Factors such as insight, 
perspective and emotional state of each interviewee are likely to be directly relevant to subject 
behaviour.  For example the characteristics of carers of people with dementia and their 
premorbid relationship can contribute to aggressiveness in dementia(268), how a carer 
responds to their situation and their own management strategies also influence patient 
behaviour(137).  Language considerations are also likely to be relevant to behavioural 
symptoms.  Aphasia is associated with post stroke apathy(264) but also distinct patterns of 
speech and language dysfunction in FTLD have been associated with different motivational 
changes in FTLD.  For example in one study patients with primary progressive apraxia of speech 
had higher rates of apathy but lower disinhibition rates than patients with other forms of 
primary progressive aphasia(269).  
 Throughout this thesis I have argued that apathetic and impulsive symptomatology is an 
important source of patient and carer morbidity and as such a valid subject of research.  This 
argument is largely based on clinical observation and carer reports which are subject to the 
same limitations as the reports and testing used here.  Rather than considering other factors 
such as motor disability, language disruption, patient insight and carer distress as potential 
confounding factors, I suggest they are directly relevant to the clinically observed syndromes of 
apathy and impulsivity in FTLD and as such equally valid and important.    
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6.11 Future Directions 
A single epidemiological study can only provide estimates of disease state in a defined 
population at a defined point in time.  There is a need to monitor the epidemiology of FTLD and 
its associated syndromes to track changes and important differences in disease rates between 
cohorts.  Such disease monitoring is vital to identify risk factors and barriers to diagnosis and 
care.  No single study is sufficient to do this and, as with other diseases, there is a need to 
periodically revisit the epidemiology using methods such as these to allow comparison between 
studies.  As diagnostic criteria continue to change future studies will also need to consider 
methods by which changes in criteria may affect diagnosis rates and allow for this when 
comparing with previous estimates.  We await the results of the second phase of PiPPIN, 
undertaken between 1st January 2017 and 31st December 2018.  
I studied apathy and impulsivity with syndromes associated with FTLD. I have shown 
that these subjects perform differently on tests of these symptoms and their performance relates 
not to a single process but to a multitude of different components that each relate to 
performance on different sets of assessment tools.  I have not attempted to show which of these 
are clinically important in terms of mortality risk – a point addressed by Lansdall et al(270). Nor 
have I undertaken a health-economics assessment, although others have shown the impact of 
apathy on healthcare cost(271,272). The anatomical, chemical and functional brain changes 
associated with the PiPPIN cohort have been addressed by Lansdall et al(255,256) and on going 
work in  second phase of PiPPIN that recruited 2017-2018 in conjunction with MR-spectroscopy 
(Murley et al in prep). 
A future treatment for apathy or impulsivity will seek to modulate these brain changes, if 
not by repair then by supplementing deficits.  One potential further development may be 
studying the functional and structural correlates of individual components of 
apathy/impulsivity and by doing so it may be possible to make inferences from previous 
research as to how these processes may modulated pharmacologically and select potential 
treatments for further evaluation. Targets include the noradrenergic(222,234,273,274), 
dopaminergic(275,276) and serotonergic (220,277,278) contributors to impulsivity; and the 
restoration of GABA-ergic and Noradrenergic systems that are abnormal in FTLD 
disorders(162,168,279). 
Before moving to treatment trials for apathy or impulsivity there is also a need to 
establish which components of these syndromes are clinically important and relate to mortality, 
co-morbidity and quality of life.  This is not straightforward.  It is not immediately clear how 
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they should be measured, in which patients and by whom.  The effects of different components 
of apathy/impulsivity may be felt differently by patient or those around them (and this may 
account for some differences between reports in the PiPPIN study).  Reports of distress or 
morbidity are subjective and limited by the same factors as the questionnaire based 
assessments of apathy/impulsivity used(280–283).  More ‘objective’ assessments of morbidity 
may include assessments of financial or social cost, for example hospital admission rates or care 
costs, but these are influenced by a much wider range of factors than just apathy or impulsivity.  
 
6.12 Conclusion 
In conclusion I have shown that the syndromes associated with frontotemporal lobar 
degeneration have been described over centuries.  The nosology and criteria used to describe 
them have evolved and changed over time but within this entire spectrum of disease there are 
recognisable and important syndromes such as apathy and impulsivity.  The basis of these and 
how they relate to associated morbidity is complex and they reflect multifaceted and 
multidimensional constructs.  They may be assessed by a variety of different methods but I have 
argued that a multidimensional approach with respect to the underlying cognitive constructs 
and their effects on patients and those around them has the best chance of accurate and useful 
results. 
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